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Abstract 
Current methods of clinical guideline development have two large challenges: 1) 
there is often a long time-lag between the key results and publication into 
recommended best practice and 2) the measurement of adherence to those 
guidelines is often qualitative and difficult to standardise into measurable impact. 
In an age of ever-increasing volumes of accurate data captured at the bedside in 
specialist intensive care units, this thesis explores the possibility of constructing a 
technology that can interpret that data and present the results as a quantitative 
and immediate measure of guideline adherence. 
Applied to the Traumatic Brain Injury (TBI) domain, and specifically to the 
management of ICP and CPP, a framework is developed that makes use of process 
models to measure the adherence of clinicians to three specific TBI guidelines. By 
combining models constructed from physiological and treatment ICU data, and 
those constructed from guideline text, a distance is calculated between the two, 
and patterns of guideline adherence are inferred from this distance. 
The framework has been developed into an online application capable of producing 
adherence output on most standardised ICU datasets. This application has been 
applied to the Brain-IT and MIMIC III repositories and evaluated on the Philips ICCA 
bedside monitoring system. Patterns of guideline adherence are presented in a 
variety of ways including minute-by-minute windowing, tables of non-adherence 
instances, statistical distribution of instances, and a severity chart summarising 
the impact of non-adherence in a single number. 
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Application 
The following application was created in support of this thesis and is available at 
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credentials below. A PDF user guide is available for download at the home page of 
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Code repository 
The code written to support the work performed in this thesis is available at the 
following repository link. A “Readme” guide is provided detailing the language and 
environment requirements for download and execution. 
www.github.com/astell/tbi_guidelineadherence 
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Summary 
Current methods of clinical guideline development have two large challenges: 1) 
there is often a long time-lag between the key results and publication into 
recommended best practice and 2) the measurement of adherence to those 
guidelines is often qualitative and difficult to standardise into measurable impact. 
In an age of ever-increasing volumes of accurate data captured at the bedside in 
specialist intensive care units, this thesis explores the possibility of constructing a 
technology that can interpret that data and present the results as a quantitative 
and immediate measure of guideline adherence.  
Clinical scope 
Though with potentially general application, the domain chosen was traumatic 
brain injury (TBI), specifically the threshold monitoring guidelines of ICP, CPP, and 
BP management. They were chosen due to the complexity and uncertainty 
inherent in TBI guidelines, combined with the availability of high-volume ICU data 
in the field. 
Hypotheses 
1) In high-resolution time-series clinical data, one can extract clinically-valid 
treatment processes for ICP/CPP management in TBI patients 
2) Having extracted treatment processes, one is able to develop a method to 
compare those against other treatment processes to establish the degree of 
similarity between them 
3) One can develop a computerised tool that readily quantifies and displays to 
clinical staff a metric of actual ICP/CPP management protocol adherence 
 
Methodology 
The main technological concept in this thesis is that of process models – a 
construct used in corporate and business domains to model time-varying processes 
and identify efficiencies. The process models were used to measure the adherence 
of clinicians to three TBI guidelines (ICP/CPP/BP monitoring thresholds) using 
physiological and treatment data from bedside machines in neurological ICUs.  
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Similarly, the relevant guideline texts from the Brain Trauma Foundation (BTF) 
were represented using Business Process Model Notation (BPMN) so that a 
comparable process model could be constructed. Building on previous comparison 
work between process models (Dijkman, Dumas and García-Bañuelos, 2009), a 
“distance” between the two models was then calculated and applied as a metric of 
guideline adherence, along with the qualitative components of that metric.  
This model was developed into a web-enabled application that can readily feed-
back the non-adherence measurements in a clinical environment for any given 
cohort of patients with standard physiological and treatment output. 
Evaluation of the system included: 
 Individual unit tests of general adherence cases (e.g. treatment not 
present), and cases specific to the individual BTF guidelines (e.g. presence 
of mass lesion/diffuse injury when following the ICP guideline).  
 Processing of guideline adherence output on three patients in the Philips 
ICCA system at the Queen Elizabeth University Hospital, Glasgow, and 
compared against the patient notes provided by the supervising neuro-
intensivists. 
 Accuracy of treatment annotation timing – a key component of the system – 
was evaluated by running a comparison of timing in a “live annotated” ICU 
dataset, against one produced in a regular ward shift. 
 A relationship between guideline adherence and patient outcome was 
investigated using logistic regression between the instances of non-
adherence and the 6-month Extended Glasgow Outcome Score (GOSe). 
The system was then applied to large-scale ICU datasets to further explore 
individual and aggregate information. One was a neurological specialist dataset 
(Brain-IT) and one a general non-specialist ICU dataset (MIMIC III). 
Non-adherence “distance” and duration was presented in a variety of ways to 
communicate as efficiently as possible how patient management is affected by 
guideline adherence. These included minute-by-minute windowing output (single 
number each minute, with component reasons viewable if desired), list per-patient 
of all non-adherence instances (also with component reasons) and a summary view 
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using inter-quartile range tables and box-plots (to understand the spread of non-
adherence durations). 
Results 
The following results were obtained from the four evaluations: 
1) For the unit tests with artificial data, the framework produced adherence 
output conforming to expected outcome 
2) For the investigation of timing accuracy, on the “live observed” data, 24 
events out of 32 across four patients were closely matched, with a mean 
distance of 3 minutes and a median of 1 minute. The “non-live” timings had 
no events matched within the asserted time limit (15 minutes) 
3) On the patient data with domain expert notes, 80% of treatment 
annotations were associated with EUSIG events and adherence output could 
be reasonably matched to the patient notes on two patients out of three. 
4) No statistically significant correlation was found between the guideline 
adherence output and 6-month patient outcome. 
From the large-scale datasets: 
1) Brain-IT had 17% of treatment annotations associated with EUSIG events, 
with instances of non-adherence detected according to all cases listed in 
the unit tests (with the exception of CPP pressor/fluid balance). Severity 
was reported as “mid-range” for nearly all patients. 
2) MIMIC III had 7% of treatment annotations associated with EUSIG events. 
Some instances of non-adherence patterns were detected with severity also 
reported as “mid-range”. 
Conclusions 
The conclusions relating directly to the three original hypotheses were:  
1) A treatment process for the management of ICP and CPP can indeed be 
derived from the analysis of physiological and treatment data  
2) This process can be compared against other processes of similar nature (in 
this, the BTF guideline represented in BPMN) to produce adherence output  
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3) The output of this comparison can be constructed into a clinically accessible 
tool – in this case a web-enabled application 
The overall achievement has been to provide a quantitative and standardised 
structure for the measurement of guideline adherence, using data from the ICU 
bedside and the guideline texts. 
Original contributions to research 
Technical 
 The application of process models to neuro-intensive data 
 The expression of the Brain Trauma Foundation guidelines as process models 
 The application of process model distance calculations to neuro-intensive 
data (and their use as a guideline adherence measure) 
 A novel method of presentation of guideline adherence results 
 A novel technological framework: the conversion of text guidelines and 
clinical data into comparable objects, the implementation of distance 
calculations to run the comparisons, the implementation of novel 
presentation techniques 
Clinical 
 A technological solution to provide direct and detailed information on 
guideline adherence and clinical management processes of ICP and CPP in 
neurological ICU data 
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1. Introduction 
Chapter summary 
The rise of clinical guidelines from evidence-based medicine is briefly described 
along with the availability of ICU data, which is often under-utilised. The general 
clinical goal of this thesis – improvement of knowledge about guideline adherence 
and the guideline themselves – is described, as well as the key requirements for a 
technological solution, which are: 
 High resolution physiological data 
 Comprehensive treatment data 
 The ability to combine these into a formal process-based expression 
 The ability to compare this formal expression against other similar process-
based entities (e.g. study protocols or local best practices) 
 
From this, three hypotheses have been developed: 
1) In high-resolution time-series clinical data, one can extract clinically-valid 
treatment processes for ICP/CPP management in TBI patients 
2) Having extracted treatment processes, one is able to develop a method to 
compare those against other treatment processes to establish the degree of 
similarity between them 
3) One can develop a computerised tool that readily quantifies and displays a 
metric of actual ICP/CPP management protocol adherence 
 
The work conducted to address these hypotheses has the following original 
contributions to the field: 
Technical 
 The application of process models to neuro-intensive data 
 The expression of the Brain Trauma Foundation guidelines as process 
models 
 The application of process model distance calculations to neuro-intensive 
data (and their use as a guideline adherence measure) 
 A novel method of presentation of guideline adherence results 
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 A novel technological framework: the conversion of text guidelines and 
clinical data into comparable objects, the implementation of distance 
calculations to run the comparisons, and the implementation of novel 
presentation techniques 
Clinical 
 A technological solution to provide a direct and detailed link between 
guideline adherence and clinical management processes of ICP and CPP in 
neurological ICU data 
 
Finally, the methodology used to achieve these goals is described in summary 
along with a brief outline of the rest of the thesis. 
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1.1. Background and rationale 
Evidence-based medicine (EBM) can be defined as “the conscientious, explicit and 
judicious use of current best evidence in making decisions about the care of 
individual patients” (Sackett et al., 1996). Though it has been practised as a 
method of applying medicine throughout history, it has only been formally 
recognised as a specific methodology in the latter half of the 20th century and has 
helped progress many fields of medical research (Howick, 2011). An important 
component in the development of a clinical evidence-base is the creation of 
clinical guidelines, which provide a standardised description of the current best 
practice in a particular field. 
Across many fields of clinical medicine, guidelines are used to inform and develop 
best practice. In order to understand whether these guidelines are being followed 
effectively, there are a variety of methods to monitor compliance. Common 
current methods to do this include post-hoc surveys or regular meetings after a 
hospital shift (or similar) to discuss different cases where perhaps the guideline 
was not adhered to, or negative outcomes were potentially avoidable (Levy et al., 
2010). 
Nearly all current methods have two features: 1) they are a qualitative evaluation 
and 2) there is often a long time-lag between the publication of survey or 
discussion of results, and their submission into either local best practice or to 
multi-centre evaluations for the further development of the guidelines. Whilst 
useful, these methods often do not make full use of the data and technology that 
is now available to many fields of clinical medicine. A potential advantage of using 
such data and technology would be quantitative evaluations (i.e. understanding 
the degree to which a guideline has been adhered to) and rapid feedback of non-
adherence to guidelines. 
The work presented in this thesis attempts to exploit those advantages by 
providing an ability to monitor clinical guideline adherence, as well as providing 
measurable quantitative feedback. Using data and technology currently available, 
the goal of the research is to express the structure of physiological and treatment 
patient data in such a way that can be immediately compared against best-
practice clinical (text) guidelines. The output of the research is to observe 
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adherence to best-practice guidelines over a study group, with a view to providing 
additional information to the clinical bedside. 
1.2. Scope – clinical and technical 
In critical care medicine – traumatic brain injury (TBI) as an example – technology 
has advanced throughout the late 20th and early 21st centuries to the point where 
nearly every modern intensive care unit (ICU) in the developed world has a 
multitude of high frequency data streams available, which can closely capture the 
application of clinical interventions and the physiological response of patients.  
The technologies that enable this output of raw data are well established, and the 
economics of data storage make retention of large volumes for extended periods a 
feasible option. However, the key to establishing the integrity of that data for a 
specific purpose – whether it is a multi-centre randomised controlled trial (RCT) or 
an audit of local clinical practices – is to monitor that raw data and understand the 
relationships between clinical treatments and physiological output. 
This process involves understanding that relationship at a level above the raw data 
output from bedside monitors. This could also be considered as observing data at a 
higher “layer of abstraction”. The raw physiological output consists of a series of 
numbers, which on their own mean very little, but with clinical context can be 
formed into structures that do have clinical meaning (for example an “adverse 
event” such as a sudden spike in blood pressure). When this is combined with 
clinical treatment information (such as the time and dose of a bolus of 
Noradrenaline) then patterns of clinical behaviour and patient response can be 
formed. 
If the algorithms used to extract and infer these patterns are valid, then it is very 
likely that this representation will be a highly accurate description of what 
actually happens in an ICU, due to the proximity to the actual data source, rather 
than having gone through several layers of interpretation in a qualitative survey or 
statistical analysis. In theory, it would be possible for such a system to work out – 
empirically from source – whether a specific process in the ICU has been followed, 
and if not, by how far it had deviated. 
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For specific processes, significant secondary inferences can also be made, which 
would fall into two categories depending on whether the output or the input of the 
process is being studied. For instance: 
1) Does a particular guideline recommendation actually work (viewing 
adherence output against patient outcome)? 
2) Has a particular protocol or guideline been applied correctly (viewing 
adherence input against the mandated guideline)? 
In practical terms, a requirement of monitoring guideline compliance in real-world 
clinical processes would be for that activity to inhabit a clinical work-flow with 
minimal impact (i.e. its presence must require no input from a clinician or obstruct 
clinical treatment). To achieve this, the concept of deviation from a process (or 
expressed conversely: the similarity of two processes) would have to be 
measurable using only data that is currently available. It would also have to be 
measured, calculated and expressed in a manner that would make clinical sense, 
using an interface that clinicians would be comfortable using and confident of its 
clinical efficacy. 
From all of these considerations, it is suggested that the development of a tool at 
the patient’s bedside to establish actual clinical practice, would help establish the 
integrity of protocol adherence in general. This in turn would provide stronger 
validation for clinical recommendations and guidelines, and also provide strong 
support for current techniques of analysing treatment effectiveness. 
To this end, the research described in this thesis aims to build an automated 
procedure that will evaluate the physiological and treatment information in 
several ICU datasets, extract the required clinical processes, then compare these 
processes with others of a similar nature (such as the recommended guidelines 
from literature). A quantitative measure of similarity, and therefore adherence, 
will then be available that can provide information on guideline effectiveness and 
compliance. This will in turn be available as a measure of baseline information 
that can be incorporated into subsequent studies. 
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The technical requirements to achieve this are as follows: 
 High resolution physiological patient data 
 Accurate and comprehensive treatment data 
 The ability to combine these into a formalised process expression 
 The ability to compare this formalised expression with other similar entities 
(such as guidelines, study protocols, institutional procedure, etc) 
Although the approach presented is general, the methodology must first be applied 
to a specific clinical domain to test its validity. The chosen area for this evaluation 
is traumatic brain injury (TBI), and specifically the management of intracranial 
pressure (ICP) and cerebral perfusion pressure (CPP). TBI has many features that 
make it a good candidate for study: the condition is complex and certainty in the 
guideline compilation and compliance is variable (Bullock, Chesnut and Clifton, 
1996), it is an environment that heavily uses modern technology that provides 
high-resolution ICU physiological and clinical treatment data streams (Shaw et al., 
2009), and the seriousness and prevalence of the condition means that any 
advances in the field have the potential to make large and positive impact on the 
population. 
1.3. Hypotheses 
In support of the discussion above, the following hypotheses have been 
formulated: 
1. In high-resolution time-series clinical data, one can extract clinically-valid 
treatment processes for ICP/CPP management in TBI patients 
a) Treatment processes for ICP and CPP management in TBI can be expressed 
by a work-flow data structure, comprised of “primitive” objects (a simple 
point value and time stamp) and “complex” objects (many values with 
interacting sub-structures). 
 
b) The treatment processes that are extracted are clinically meaningful and 
accurately reflect clinical management in a neurological ICU environment.  
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2. Having extracted treatment processes, one is able to develop a method to 
compare those against other treatment processes to establish the degree of 
similarity between them 
a) Treatment processes and other types of relevant process (e.g. protocols, 
guidelines, institutional policies) can be expressed in a standard form. 
 
b) This standard form expression can be compared in a measurable way. 
 
c) This standard form expression can be written in a computer-interpretable 
format. 
 
3. One can develop a computerised tool that readily quantifies and displays to 
clinical staff a metric of actual ICP/CPP management protocol adherence 
a) The standard form can be implemented in an application that can be 
integrated into a modern neurological ICU. 
 
b) The implementation provides meaningful and clinically useful feedback to 
clinicians. 
By addressing these specific hypotheses, it is believed that the answers will inform 
and progress the knowledge contributing to the collection and analysis of ICU data 
to support evidence-based tools in critical care medicine. 
1.4. Methodology and contributions 
There are several technological steps that are involved in this work: 
 The classification of events in physiological output known as EUSIG events 
(Edinburgh University Secondary Insult Grade), and compilation of an event 
log from this 
 The expression of those event logs as process models 
 The extraction of clinical guideline texts into process models 
 The comparison of two process models using complex similarity/distance 
algorithms 
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Together, these steps form the framework through which the possibilities of 
quantitative, real-time guideline adherence monitoring can be explored. Other 
technological and computational methods have been explored throughout the 
course of the research, and they will be discussed in the appropriate sections of 
the thesis. However, though there are always merits and drawbacks in the use of 
different technologies, the overall goal remains the establishment of such a system 
in principle. 
Event detection and representation from time-series data are common methods of 
data analysis in medicine. However, the automated semantic analysis of textual 
guidelines is an approach that has largely, to date, stayed in the realm of medical 
informatics research. Process models, at a general level, are processes of the same 
nature classified together into one model: a single process can be considered as an 
instantiation of that model. The use of process models and comparison/similarity 
calculations are borrowed from the field of business process management – most 
commonly used to describe real-world problems of project management and 
corporate efficiency (Panagacos, 2012). It has been used in isolated instances of 
medical problems, but again mainly in the logistical administration of hospitals and 
other large-scale corporate structures (where the fact that these structures are 
medical in nature is incidental) (Perimal-lewis et al., 2012). 
Figure 1.1 shows a simplified schematic of how the proposed framework in this 
thesis is used to convert ICU data and guideline text into comparable datasets. 
Step 1 is the translation of ICU data to an event log; step 2 in the conversion of 
this to a process model; step 3 is the formulation of the clinical guideline (Brain 
Trauma Foundation – BTF Guidelines) into a process model of similar format; and 
step 4 is the comparison between the two process models. 
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Figure 1.1: simplified schematic of the architectural process underpinning the proposed research 
From the hypotheses and methodology described, the specific original 
contributions of this thesis are: 
Technical 
 The application of process models to neuro-intensive data 
 The expression of the Brain Trauma Foundation guidelines as process models 
 The application of process model distance calculations to neuro-intensive 
data (and their use as a guideline adherence measure) 
 A novel method of presentation of guideline adherence results 
 A novel technological framework: the conversion of text guidelines and 
clinical data into comparable objects, the implementation of distance 
calculations to run the comparisons, the implementation of novel 
presentation techniques 
Clinical 
 A technological solution to provide direct and detailed information on 
guideline adherence and clinical management processes of ICP and CPP in 
neurological ICU data 
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1.5. Chapter outline 
The rest of this thesis will be divided up as follows: 
 Chapter 2: Background – TBI, clinical technology and data 
 Chapter 3: Literature review 
 Chapters 4 – 7: Method 
o Chapter 4: Expression of clinical guidelines as process models 
o Chapter 5: Translation of ICU data to process models 
o Chapter 6: Calculating distance and similarity of process models 
o Chapter 7: Framework implementation 
 Chapters 8 – 10: Results 
o Chapters 8: Evaluation 
 Unit testing of general and individual guideline cases 
 Treatment annotation timing verification 
 Domain expert information from a real clinical setting 
 Logistic regression of guideline adherence against 6-month GOS 
o Chapter 9: Application of framework to the Brain-IT dataset 
o Chapter 10: Application of framework to the MIMIC III dataset 
 Chapter 11: Discussion and future work 
 Chapter 12: Conclusion 
Chapters 2 and 3 will provide a more in-depth background to the work in both the 
clinical and technological fields, providing background and literature on the broad 
clinical issue as well as the issues specific to the domain under study (TBI). 
Chapters 4, 5, 6 and 7 detail the specific technological methods developed and 
their implementation. Chapter 8 describes the evaluation work of the framework 
and its application against various benchmarks such as the accuracy of treatment 
annotations, statistical relationship to 6-month patient outcome, and the 
experience of domain experts in the field. Chapters 9 and 10 detail the results of 
the system when run against two different large-scale ICU datasets (Brain-IT and 
MIMIC III). Finally, chapters 11 and 12 outline the discussion, conclusions and 
avenues for potential future work. Each chapter is preceded with a small summary 
of the chapter contents. 
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2. Background 
Chapter summary 
The clinical mechanisms underpinning traumatic brain injury (TBI) – in particular 
intracranial pressure (ICP) and cerebral perfusion pressure (CPP) – are described, 
providing background to the necessary data required for collection in this domain.  
 
The methods of data collection and synthesis for the development of TBI 
guidelines by the recognised leader in the field – the brain trauma foundation 
(BTF) – are then described. These are arrived at through meta-analyses of 
qualifying studies and trials and ascribed a confidence level out of three 
categories: option (level 3), guideline (level 2), or standard (level 1). A notable 
feature of the TBI domain is the lack of level 1 and level 2 recommendations. 
 
The theme of addressing uncertainty is further developed with a discussion of 
studies and novel methods that have been attempted to improve confidence in TBI 
guidelines. Notable are contradictory findings in various studies, the negative 
results (i.e. unable to ascertain clinical significance) in Cochrane reviews, and a 
novel attempt to improve study power post-hoc by the TBI-IMPACT group. 
 
Finally the current state-of-the-art in TBI data representation is discussed, with a 
view to exploiting this data to improve certainty in the output of TBI studies and 
trials. EUSIG (Edinburgh University Secondary Insult Grade) events are described 
as a pattern of representing physiological patient events – particularly relevant to 
ICP and CPP. Systems to interpret this are described, such as ICM+ and CareScape, 
and data repositories to build on this further are introduced, such as Brain-IT and 
CENTER-TBI. 
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The research questions addressed in this work are issues which are believed to be 
applicable to many clinical fields. However, as previously mentioned, in order to 
test the validity of the proposed approach a specific domain has been chosen: 
traumatic brain injury (TBI).  
2.1. Traumatic brain injury and intracranial pressure 
Traumatic Brain Injury (TBI) is defined as the damage sustained by the brain 
resulting from an external mechanical force, and is one of the leading causes of 
hospitalization, with almost 349,000 admitted to hospital in the UK in 2013-14 
(Headway, 2018). 
When the brain or skull is damaged due to an external force, there are many 
primary injuries that can result, including (but not limited to): hydrocephalus, 
brain oedema, tearing of axons, tearing of blood vessels resulting in formation of 
“mass” lesions (in this case, collections of blood) such as extradural, intradural or 
parenchymal haematomas.  
The management of these primary conditions is often the immediate concern of 
the physician, but there are also secondary injuries that can result, which involve 
the more-subtle relationship between brain volume and brain pressure. This 
relationship comes about because of the equilibrium that exists between the 
various components of the skull, based mainly on the assumption that the skull is 
an incompressible structure filled with fluid and different types of neuronal and 
vascular tissue. The formal expression of this is known as the Monro-Kellie 
hypothesis: 
 “The sum of volumes of brain, CSF, and intracranial blood is constant. An 
increase in one should cause a decrease in one or both of the remaining two.” 
(Mokri, 2001) 
Part of the outcome of this doctrine can be shown graphically as the relationship 
between intracranial pressure and intracranial volume (figure 2.1). As can be seen 
there is a mainly linear relationship until a critical intracranial volume is reached – 
the volume where “compensatory craniospinal volume” becomes exhausted (i.e. 
most of the available space within the skull-spinal axis is filled). Above this point, 
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the intracranial pressure then increases dramatically to any further increase in 
added volume (Reilly & Bullock, 2005). 
  
Figure 2.1: graph of cranio-spinal volume vs pressure, exemplifying the Monro-Kellie doctrine 
(Trauma, 2014) 
Focusing on the cranial component and following from this equilibrium 
relationship, are a variety of pressures and pressure gradients that exist within the 
skull. The most important function of these is to maintain constant cerebral blood 
flow (CBF), providing oxygen and nutrients to the brain. The brain is – unusually 
amongst human organs – highly sensitive to critically low blood flow and can 
quickly become ischaemic if deprived of that flow. This flow is maintained by a net 
pressure gradient across the cerebral vasculature, known as cerebral perfusion 
pressure (CPP), which is dependent upon intracranial pressure (ICP) and mean 
arterial pressure (MAP): 
CPP = MAP – ICP 
This pressure is important when looking at the process of cerebral auto-regulation. 
This is the process where – to protect the brain from ischaemia – a physiological 
mechanism balances small perturbations in the pressure-volume interdependence, 
to maintain the optimum blood flow (Reilly & Bullock, 2005). Auto-regulation is 
achieved primarily by small arteries that expand or contract depending on the 
chemical messages received from other physiological control systems. These 
methods of physiological control include nitric oxide as a chemical messenger, 
which affects the proteins that control the blood vessel wall response (also known 
as endothelins). Recent work in (Payne, 2016) also suggest contributory 
mechanisms of capillaries via pericytes may be involved.  
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Figure 2.2 shows the relationship between blood flow and pressure, where the 
auto-regulation mechanism is active and most effective. Auto-regulation is a 
biological feedback mechanism that works to adjust a system’s response to stimuli. 
Cerebral auto-regulation aims to maintain an adequate and stable cerebral blood 
flow. The edges of this curve indicate where the pressure is either too high or too 
low for auto-regulation to work effectively and where the disruption of regular 
organ function begins to occur. 
 
Figure 2.2: a graph of perfusion pressure versus blood flow, illustrating the curve of auto-
regulation (CVPhysiology, 2017) 
Measurement of the forces acting across the cerebral vasculature such as the ICP 
and CPP can be, and often are, used as secondary measures to indicate the status 
of the CBF.  However, they can also indicate the presence of complicating 
secondary injury factors in themselves. For instance, hypotension – an abnormally 
low blood pressure – can be detected by monitoring an increase in ICP, which can 
indicate an impending potentially fatal drop in cerebral blood flow. 
In terms of general treatment approaches for brain injury, it has traditionally been 
the case that clinical management has focused solely on the primary insult (the 
initial impact and injury). As such, consensus tended towards the idea that patient 
outcome was closely tied to the severity of these initial injuries in isolation. 
However, research over the last two to three decades suggests that secondary 
insults – such as altered CBF, cerebral edema, ischemia, hypoxia or hypotension – 
which may result from either developing patho-physiology from the primary injury 
or as an iatrogenic consequence of therapy, also have a significant impact on 
patient outcome, more than was previously thought (Jones et al., 1994). 
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When the primary injury results in a space occupying lesion that can be removed 
surgically, the primary management is surgical. In terms of treatment for these 
secondary insults, general medical opinion appears to be that for the non-surgical 
management there is no first-line therapeutic approach, due to the complex 
interplay of factors. However, there are principles of treatment that can aid the 
management of a patient suffering from TBI as shown in table 2.1 (Reilly & 
Bullock, 2005). 
Aim Therapy 
Lower intracranial volume: maintain or 
lower ICP: 
Brain volume, CSF volume, Blood 
volume 
Mannitol, steroids, surgery, CSF 
drainage, diuretics, controlled 
ventilation 
Correct gases: 
Hypoxia, Hypercapnia 
 
Controlled ventilation 
Improve brain perfusion: 
Blood flow, Blood pressure, Blood 
viscosity 
Calcium antagonists, Maintain blood 
volume, Haemodilution 
Table 2.1: treatment therapy and the immediate physiological target 
An important principle in the case of TBI is the reduction of intracranial pressure 
(ICP), which would require a reduction of the intracranial volume, by various 
means (e.g. reduction of blood volume, management of autoregulation, reduction 
of CSF volumes). The understanding of this approach is the pursuit of many TBI 
research communities throughout the world – for instance the three-yearly ICP 
conference (ICP 2019 Congress) – and motivates the specific gathering and analysis 
of physiological and treatment information relating to ICP and CPP. 
With this overview of the physiological mechanisms of TBI and the main treatment 
principles, specifically for issues in ICP management, we now look at the 
formulation and maintenance of the leading guidelines in TBI hosted by the Brain 
Trauma Foundation (BTF). 
2.2. TBI guidelines 
Clinical treatment guidelines provide a method to bridge the gap between 
evidence and clinical practice, standardize treatment practices, and improve 
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patient care. The compilation of guidelines is based upon a review of existing 
literature which can range from multi-centre randomized controlled trials to small 
scale studies. To reflect the range in evidence base, guidelines are often 
accompanied by an associated level of confidence which reflects the quality of the 
literature that led to a particular recommendation. As medical literature is 
constantly being updated, a natural feature of medical guidelines are for them to 
be constantly developed and refined as medical research and science progresses; 
in essence they can be considered as a “living document” (Kaiser and Miksch, 
2009). 
There are various sources of guidelines for the treatment of TBI, but those 
endorsed by the national health services of many developed countries (e.g. 
Scottish Intercollegiate Guideline Network (SIGN) and National Institute Centre of 
Excellence (NICE), for Scotland and England respectively) very often focus upon 
the immediate emergency triage that must be administered to a brain-injured 
patient before they are admitted to the intensive care unit (Harbour and Miller, 
2014). The most comprehensive guidelines in the area of TBI are published by the 
Brain Trauma Foundation (BTF), which cover all types of situations including 
intensive care stays, emergency accident-scene care, specific situations such as 
trauma sustained whilst in military combat, and of particular interest: long-term 
treatment and outcome effects (Bratton and Chestnut, 2006). 
The guidelines published by the BTF provide a common benchmark against which 
an institution can compare their procedures for the treatment of TBI. They are 
generally accepted as providing the best “gold standard” in TBI care, and have 
been associated with the development of TBI care management over the last two 
decades (Faul et al., 2007) However, despite the advances in the standardisation 
of TBI treatment through this guideline development process, non-adherence is 
still relatively commonplace, for a variety of reasons such as lack of awareness, 
agreement and familiarity with the guidelines (Hesdorffer and Ghajar, 2007). 
In recognition of the varying evidence used to generate guidelines and the 
effectiveness of those guidelines, the BTF provide a tabulation of the confidence 
level behind a specific treatment or guideline. Three broad classifications of 
guidelines exist in the BTF (in decreasing order of certainty): Standards, Guidelines 
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and Options. These classifications of specific guidelines are based in turn, on the 
classification of the supporting evidence: level 1, 2 and 3 treatment 
recommendations, supported by class 1, 2 and 3 evidence respectively (and again 
in decreasing order of certainty of efficacy). 
Level 1 None 
Level 2 Intracranial pressure (ICP) should be monitored in all salvageable 
patients with a severe traumatic brain injury (TBI; Glasgow Coma 
Scale [GCS] score of 3-8 after resuscitation) and an abnormal 
computed tomography (CT) scan. An abnormal CT scan of the head is 
one that reveals hematomas, contusions, swelling, herniation, or 
compressed basal cisterns. 
Level 3 ICP monitoring is indicated in patients with severe TBI with a normal 
CT scan if two or more of the following features are noted at 
admission: age over 40 years, unilateral or bilateral motor posturing, 
or systolic blood pressure (BP) < 90 mm Hg. 
Table 2.2: BTF guideline recommendations for Indications for Intracranial Pressure Monitoring 
As a relevant example the recommendations for “Indications for Intracranial 
Pressure Monitoring” are detailed in table 2.2 (Braintrauma, 2018)1. 
As is standard throughout the BTF guidelines, the text supporting these 
recommendations include an overview of the medical issue being discussed, more 
in-depth information on the scientific foundation for arriving at the conclusions 
that they have, key issues for future investigation, and a summary. Of particular 
relevance to this work is the outline of the literature review process that sourced 
the evidence-base for this information, which in this case is: 
                                                     
1 The text for table 2 had been originally written in mid-2014. Between then and late 2017 the BTF had 
significantly updated their website, along with much of the latest evidence supporting current 
recommendations from the 3rd to the 4th editions. Next to the ICP monitoring example there is now the 
following qualifying text, which neatly exemplifies the exact issue discussed in this chapter – i.e. that even 
though their criteria had become more strict between editions, they still did not have enough information to 
make strong recommendations: 
 
“The Level II and III recommendations from the 3rd Edition of these guidelines are not supported by evidence 
meeting current standards because they were derived from descriptive studies, or from studies that do not 
meet the current inclusion criteria for this topic. While no evidence is available from comparative studies to 
support a formal recommendation, the Committee chose to re-state here the 3rd Edition recommendations. 
The rationale for doing so is to maintain sufficient recognition of the patient characteristics associated with risk 
of increased intracranial pressure.” 
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“For this update, Medline was searched from 1996 through July of 2004 (see 
Appendix B for search strategy), and results were supplemented with literature 
recommended by peers or identified from reference lists. Of 36 potentially 
relevant studies, 12 were added to the existing table and used as evidence for this 
question (Evidence Tables I, II, and III)” 
The evidence tables themselves are divided into three, one each to support the 
three questions posed about intracranial hypertension (ICH) in the scientific 
discussion section: 
1. Which patients are at risk for ICH? 
2. Are ICP data useful? 
3. Does ICP monitoring and treatment improve outcomes? 
As examples, table 2.3 shows the most recent contributing study for each question 
(all supporting level 3 recommendations only). 
Overall, this process is an example of a meta-analysis of all available information, 
one of the most effective tools available for building an evidence-base of 
knowledge from study information. But there are many areas where the procedure 
can be significantly improved which is discussed in more detail in the next section. 
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Question Reference Description Conclusion 
1 (Miller et al., 
2004) 
82 severe TBI 
patients were 
retrospectively 
analyzed regarding 
initial CT findings 
relative to ICP 
CT findings regarding 
gray/white differentiation, 
transfalcine herniation, size 
of ventricles, and basilar 
cistern sulci are associated 
with, but not predictive of, 
intracranial hypertension 
2 (Servadei et al., 
2002) 
ICP ranges assessed 
in patients with 
traumatic 
subarachnoid 
hemorrhage to 
determine if there 
were any identifiable 
changes predictive of 
worsening CT 
findings 
ICP monitoring was the first 
indicator of evolving lesions 
in 20% of patients. 
However, in 40% of 
patients, CT worsening was 
not associated with ICP 
elevations, thus ICP 
monitoring alone may be 
inadequate to follow CT 
abnormalities 
3 (Aarabi et al., 
2006) 
Prospective 
observational study 
of 50 severe TBI 
patients, 40 with 
intractable ICH 
whose ICP was 
measured before 
decompressive 
craniectomy 
Of the subgroup of 40 
whose ICP had been 
measured before 
decompression, the mean 
ICP decreased after 
decompression from 23.9 to 
14.4 mm Hg (p < 0.001). Of 
the 30-day survivors of the 
total original group of 50 (n 
= 39), 51.3% had a GOS 
score of 4 or 5 
Table 2.3: most recent studies contributing to evidence supporting recommendations for 
“Indications for Intracranial Pressure Monitoring” 
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2.3. TBI studies and trials addressing evidence-base uncertainty 
Clinical studies and trials are one of the most effective and well-known methods 
for compiling a clinical evidence-base, such as those used to support clinical 
guidelines. There are varying degrees of accuracy and knowledge that can be 
extracted depending on the methods used (e.g. a randomised-controlled trial is 
considered the “gold standard” but can be prohibitively expensive to conduct, so 
in some areas less accurate study methods are acceptable). In TBI there is a lack of 
strong evidence to support current treatment practices, the main indicator of 
which is the lack of level 1 recommendations (“standard”) in the BTF guidelines. 
Currently the only Level 1 recommendation in the “Inhospital Severe TBI 
Guidelines” is against the use of steroids as a treatment, and throughout the 
guidelines the overwhelming majority of recommendations are of level 3 certainty 
(“option”), rather than level 2 (“guideline”) (Haddad and Arabi, 2012). 
Throughout the literature – discussed further in section 3.2 – there are many 
studies that support and also contradict the individual recommendations of the 
BTF guidelines. Examples of support include treatment using hyperventilation 
(Neumann et al., 2008), treatment through patient cooling (Harris et al., 2012), or 
treatment through the administration of barbiturates (Morrow and Pearson, 2010)). 
Examples that contradict the BTF, include (Pascual et al., 2011) where 
oxygenation treatments are evaluated and suggest that the BTF guideline-
mandated method may not be ideal. These studies and papers do make 
contributions to the evidence base, but it is notable that they are often smaller 
longitudinal studies, with confidence not sufficient to significantly influence the 
guidelines (i.e. with level 1 confidence). 
The accuracy of studies to build the evidence base in TBI can also be confounded 
by ethical considerations, which are particularly significant due to the complexity 
and sensitivity of the brain. The CRASH trial (Edwards et al., 2005) discovered a 
marked negative treatment effect in the administration of corticosteroids for 
traumatic brain injury, and was therefore halted on ethical grounds (Czekajlo and 
Milbrandt, 2005). That the use of steroids was detrimental was a surprising result 
in itself, as it had been used for years as standard treatment without the overall 
knowledge that it was doing more harm than good. As such the CRASH trial can be 
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considered as a successful scientific outcome. However, the trial was also 
(appropriately) stopped before completion, so the data also stopped being 
collected. It is likely that further information would help inform the community, 
and the clinical evidence-base, in even greater detail. 
Another related example is that of ICP monitoring which is an important potential 
avenue of treatment study, as it provides near-direct clinical insight into a 
patient’s ICP/CPP status. This in turn informs the administration (or not) of 
remedial treatments to manage ICP/CPP-related secondary insults, which are 
increasingly shown to affect the long-term patient outcome.  
This tension between clinical importance and invasiveness was present in the 
BEST-TRIP trial, a study conducted in Ecuador and Bolivia directly investigating the 
importance of ICP monitoring (Chesnut et al., 2012). The investigators of this study 
concluded that the study indicated no treatment effect in ICP monitoring, which 
would require a new assessment of future ICP monitoring methods and the ethical 
implications of whether this intervention would be administered. However, these 
conclusions have been challenged in the expert community as an over-
interpretation of results, with questions about the strict adherence to TBI 
guidelines in the study – given the resourcing of the participating centres – and the 
lack of data on arterial hypotension. The particular issue of ICP monitoring appears 
to be far from settled (Härtl and Stieg, 2013) and uncertainty in the evidence-base 
remains. 
Another method of mitigating against random effects of statistical uncertainty – or 
put a different way, understanding the significance of a single result against the 
overall landscape – is to analyse groups of studies systematically. These systematic 
reviews (or meta-analyses) combine the results of a number of similar studies to 
increase the “power” of the analysis. These techniques are well regarded, but can 
still be subject to issues arising from their constituent RCT analyses; issues such as 
publication, selection and agenda bias (Eysenck et al, 1994). Therefore, if these 
methodology issues exist in the trials used for the meta-analysis, the results of the 
meta-analysis will have corresponding low certainties. 
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One of the most comprehensive contributors to the field of evidence-based 
medicine is the Cochrane Collaboration (Cochrane, 2018), which provides a 
database of well-conducted RCTs and systematic reviews. The entry criteria are 
strict and therefore the reputation of information from a “Cochrane Review” is 
considered highly reliable. If a trial or study has a methodology which is at odds 
with the requirements for inclusion, they will simply not be included. In terms of 
TBI, there are various entries in the Cochrane database, such as (Harris et al., 
2012) (patient cooling), (Sahuquillo et al, 2006) (decompressive craniectomies) or 
(Roberts and Sydenham, 2009) (barbiturate therapy), but nearly all produce 
negative results, indicating no ability to comment on a treatment’s effectiveness 
(in this regard the clear outcome of the CRASH trial is unusual). So, although TBI 
research is represented with trials that are well conducted and follow sound 
methodological principles, the statistical significance of the results are often low. 
Therefore, the baseline of clinical understanding remains undetermined and the 
uncertainty in TBI treatment guidelines remains. 
A leading research group in TBI based in Antwerp, Belgium have attempted to 
address these issues using post-hoc statistical analysis. This analysis is known as 
the IMPACT project (McHugh et al., 2007) and attempts to extract further 
information from the low-power TBI datasets already in existence by modifying the 
statistical analyses of these data. They include the use of broad enrolment 
criteria; changing the outcome analysis from dichotomous (“good” and “bad”) to a 
finer-grained five-ordinal state (three “good” and two “bad”, with varying degrees 
of severity); and a covariate adjustment to baseline patient characteristics. 
Results from this approach appear to be inconclusive, but the possibility of 
manipulating the analysis in this way has yet to be ruled out as unviable (Maas et 
al., 2010). 
In summary, despite the available tools and other novel attempts to establish 
greater certainty in the formulation of TBI guidelines, much uncertainty remains. 
However, a key avenue that shows promise in reducing this uncertainty is the 
advance of technology and data in TBI. In the next section, the nature and 
representation of that data and technology is described in more detail. 
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2.4. Physiological and treatment representation using TBI data  
A modern intensive care unit is very much a “data rich” environment. Signal 
processing technology and the advance of Moore’s Law (an approximate doubling 
of transistor capacity every two years) have resulted in the feasibility of data 
collection and storage at an unprecedented scale. This in turn has led to ICUs (and 
neurological ICUs) that have many machines monitoring patients and producing 
large amounts of clinical information to aid with healthcare delivery. 
There are many types of data that come from this environment covering a wide 
spectrum of information and clinical behaviours: physiological output, 
drug/intervention treatment information, surgeries, routine and exceptional 
clinical events, and more. Arguably the most important are those of patient 
physiological signals (indicating their status and health), and clinical treatment. 
With these two types, it is possible to monitor – either in real-time or 
retrospectively – the status of a patient and their reaction to those clinical 
drugs/interventions. 
In terms of data structure, an important piece of related work was the 
identification of a “physiological monitoring event” from routinely collected 
physiological data, which includes the Edinburgh University Secondary Insult Grade 
(EUSIG) (Jones et al., 1994), the standard outline of which can be seen in figure 
2.3. It shows various structural features such as the event/clear hold-down (length 
of time for an event to have officially started/finished) and the threshold crossing 
value. This model can be used for data represented as a continuous time-series, 
which in the neurological ICU would include (amongst others): intracranial pressure 
(ICP), cerebral perfusion pressure (CPP), blood pressures (BP), central venous 
pressure (CVP), heart rate (HRT), temperature (Temp), respiration rate (RR), pulse 
oxygenation (SpO2), end-tidal carbon dioxide (ETCO2). 
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Figure 2.3: schematic outline of a physiological monitoring event, with ICP used as an example 
When analysing physiological data using these structural definitions of events, one 
of the key clinical questions is the specific physiological values that should be used 
for threshold crossing (e.g. a value of greater than 100 beats per minute (bpm) for 
heart rate) and hold-down times (e.g. greater than 100 bpm for 10 minutes). This 
is often a source of debate within the expert community. For instance, the 
numerical definition of a hypotensive event – one defined (semantically) as an 
abnormal drop in blood pressure – can be many and varied, involving not only 
different values (e.g. diastolic BP drops below 40 mmHg), but different parameters 
(e.g. mean BP or in the neurological case, cerebral perfusion pressure) (Eastridge 
et al., 2007). 
In the case of ICP – which, as discussed in sections 2.2 and 2.3, is believed to be a 
useful indicator of brain status, but is difficult to monitor practically – the 
uncertainty is such that there is even debate not only on the value of thresholds, 
but also the nature of how the data has been summarised (minute-by-minute or 
averaged wave-form values) (Shaw et al., 2009), or whether patient-specific 
thresholds can be identified by charting individual information on pressure-
reactivity index (PRx) versus ICP (Lazaridis et al., 2014). 
Systems such as ICM+ (Smielewski et al., 2005), Philips CareVue (CareVue, 2018) 
and Carescape monitors (GEHealthCare, 2018) are built to detect events as defined 
above. To enable decision support for clinicians, the focus of these systems is to 
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use this information to trigger real-time predictive alarms over a useful timescale. 
They often have the sophisticated ability to vary a threshold warning (e.g. heart 
rate goes above 100 bpm) in response to whatever the favoured clinical event 
definition is at a particular centre (Donald et al., 2012). The level of detail of raw 
data captured is very high (e.g. millisecond wave-form data), and again this 
contributes to the discussion in the expert community about the benefits of what 
level of detail is optimal for informing clinical behaviour (Hemphill et al., 2005). 
Although patient monitoring systems routinely capture physiological parameters, 
treatment annotations are much harder to capture, partly due to their nature, 
which can often be both irregular and highly dependent on human intervention 
(e.g. a clinician making a judgement call to administer a drug). 
Systems such as Philips CareVue have only recently moved forward in this regard 
by connecting drug pumps directly to the integrated data system. If this option is 
not available, then an alternative is manual clinical entry. This is an example of 
where older clinical practice in an ICU is “playing catch-up” to the technological 
environment (i.e. the physiological data streams) that surrounds it. A discussion is 
required, similar to that of data resolution and beyond the scope of this work, to 
understand if the wealth of information in a certain ICU environment, is actually a 
help or a hindrance to clinicians. Some studies have been conducted looking at the 
rates of annotation within an ICU to aid neurological studies, such as (Enblad et 
al., 2004) and have found that the numbers of actual treatments recorded could 
still be greatly improved. In fact, a significant proportion of treatments are 
delivered by hand rather than through drug pump infusion and thus remain 
dependent upon accurate timing event annotation by medical staff. 
To utilise such data and technology more broadly, information platforms have been 
developed a layer “above” the data coming from bedside machines. The Brain-IT 
consortium documented a full specification of data parameters within a 
neurological ICU (Nilsson et al., 2005), with a view to supporting future 
neurological monitoring projects. As data collection and storage technologies have 
advanced over the course of the last two decades, the outline of these schemas 
would often act as a roadmap of the ideal data to collect, whilst the 
implementation of collection would itself take many years to become an 
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achievable goal - relating to the Brain-IT schema, this type of implementation has 
included in projects such as AVERT-IT (Stell, Sinnott and Jiang, 2009)2. A separate 
initiative, focusing more intensively on robust data collection in the TBI field, is 
CENTER-TBI (CENTER-TBI, 2018). The project comprises many work packages 
covering both clinical and technological areas of research. One of the main 
technological goals is to make sure that the quality and coverage of data collected 
is as great as possible given the abilities that are now available from bedside 
machines in many neurological ICUs. 
It should be noted that such platforms are often driven by domain experts, and 
hence a possible source of bias is the clinician’s particular field of expertise. A key 
point in improving the process of understanding patient response is to use data 
that represents a “real” ICU as closely as possible and the barrier to using this data 
is often due to the problems involved in the methods of data collection. A 
pioneering project that has recognised this and built a dataset to support the use 
of this in future studies, is MIMIC III (Saeed, 2007), a repository of over 30,000 
individual, anonymised patient data records collected since 2003 from a series of 
ICUs. The combination of physiological and irregular treatment information 
together in one uniformly accessible and generalised data store is highly unusual – 
this is based on their findings but is also corroborated by the survey of literature in 
this thesis (chapter 3). 
 
Finally, a note on the inherent uncertainty in measurements of the pressures 
involved. ICP monitoring is most often achieved using ventricular and parenchymal 
catheters, inserted into the cranium. There are various brands of these catheters, 
and some ongoing work on non-invasive methods of measuring ICP (Ragauskas, 
2012), though these methods are yet to be widely adopted, likely due to their 
lower accuracy than direct methods. There is a reported “zero drift” on the latest 
parenchymal catheters (Brattan, 2007), however this has been tested in (Citerio, 
2008) and found to be not necessarily true under demanding clinical conditions 
(the conclusion is that this brand of catheter – the Neurovent-P – is as good as but 
not better than other catheters). The reported uncertainty in using such catheters 
                                                     
2 Disclosure of interest: the author did a significant amount of work for the AVERT-IT project 
54 
 
is around +/- 1.1 mmHg (Citerio, 2008), which provides a context for 
understanding the reality of threshold crossing in the earlier discussion. 
2.5. Discussion 
This section has covered the mechanisms of TBI, TBI guideline formulation, 
relevant TBI trials and studies, and some of the predominant data representations 
in TBI.  
One important and recurring issue that is directly relevant to this work is that of 
the uncertainty in the findings of TBI studies. There are many possible reasons for 
this, such as resourcing, legal issues, or socio-economic factors. But these are not 
necessarily specific to TBI and often apply to all medical domains. Exceptional 
medical conditions can be hampered by the lack of patients and data to work with 
(for instance, in a rare but life-threatening condition such as adrenal cancer). 
However, with TBI, there appears to be an inter-play between the complexity of 
the condition, the life-threatening severity and the required invasiveness of 
treatments, all of which combine to confound the establishment of clear base-lines 
of information that further research can be built upon.  
There are other general issues in trial and study reporting, which also contribute to 
this lack of knowledge. These include the communication of results and their 
subsequent formulation into guidelines. As mentioned in section 2.2, guidelines 
and other evidence repository tools are “living documents” requiring constant 
maintenance and update, and periods of years can go past before the central 
evidence-base is updated in a meaningful way. This can have a cyclical negative 
effect if practices and treatments don’t reflect current research knowledge. 
Another general issue is that of access to the raw trial data which can often be 
very limited. The output of the analysis is what is published and fed back into the 
scientific/medical community, and there is little actively-enforced regulation on 
providing the raw data. Though the greater awareness of initiatives such as 
clinicaltrials.gov, demanding clarity and openness of study/trial data 
(ClinicalTrials, 2018), is having a progressive influence on the transparency of data 
used for trials and studies. With the limited certainty that is a theme of the 
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guidelines on brain trauma, it is likely that this is a source of issue with the 
analyses performed on TBI data, and one that is generally under-reported. 
Finally, we see that due to the advances in technology, increasing amounts of 
representative data can be gathered from the bedside, interpreted and sent to 
larger data platforms to give an increasingly accurate view of patient information. 
As more and more advanced repositories develop, pioneering efforts to understand 
that data and technology may aid in establishing greater certainty to the 
formulation of TBI guidelines. 
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3. Literature review 
Chapter summary 
Literature in the following areas were reviewed and discussed in order to present 
a fuller understanding of the background and rationale behind this thesis, to 
survey similar work conducted in the field, and to identify the most relevant 
technological solution: 
 Issues of adherence to clinical guidelines in general 
 Issues of adherence specific to clinical guidelines in TBI 
 Novel attempts to improve adherence in general without technology (in 
general and TBI) 
 Novel attempts to improve adherence using state-of-the-art technology 
In general, the main issues preventing adoption of clinical guidelines involved 
methods of dissemination, the authority of guideline publishers, and the rise of 
personalised medicine as a counter-point to population-wide guidelines. 
Specific to TBI, the issues raised were more numerous but essentially the same as 
those mentioned in chapter 2. Namely: the low power of studies leading to 
uncertainty about recommendations, and contradictory findings for specific 
treatments, despite large-scale attempts at well-conducted meta-analyses. 
Two examples of non-technological attempts to improve adherence were 
discussed: the Surviving Sepsis campaign and the CENTER-TBI project. Both 
projects curate data manually with the intention of constantly updating large-
scale information for the improvement of source information. 
The review of state-of-the-art technology included decision support systems, 
smart-phone apps, clinical guideline formalisms and process models. Decision 
support was reviewed as an end-point goal of the work of this thesis, whilst the 
review of smart-phone apps addressed innovations at the point of information 
delivery.  
Representations of the nature of clinical guideline information were covered by 
guideline formalisms and ontologies (providing comprehensive domain context). 
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Though the full feature-set required when adopting clinical guideline formalisms 
and ontologies was deemed unnecessary for the work of this thesis, a sub-set of 
the features was found to be uniquely useful: the process-oriented nature of 
guidelines. This feature is well represented by the concept of process models, a 
technology commonly applied to business processes and logistical administration. 
Throughout the review, analysis of guideline adherence at a detailed level of 
clinical management appeared to be missing in general, and in TBI in particular. 
Traditional studies have a “low resolution” view of the details of clinical 
management, and technology that leverages these studies lack the detailed 
combination of physiological and treatment data. 
A section describing the aims of this thesis is outlined at the end of this chapter. 
It presents a framework proposal based on the review of the clinical domain and 
the surveyed technologies, to address the gap between clinical management and 
guideline adherence. 
 
 
 
 
 
 
 
 
 
 
 
58 
 
3.1. Adherence to clinical guidelines 
Clinical guidelines have contributed to standardized clinical practice and have 
advanced the quality of patient treatment for many decades. In more recent 
years, their development has followed a more rigorous process, using evidence-
based techniques to avoid bias of either specialisation or agenda (Watters, 2008). 
However, despite these systematic attempts at improvement, guidelines are not 
always followed, and this can be for a variety of reasons.  
3.1.1. Dissemination of clinical guidelines 
The basic methods of communication of clinical guidelines can often be a barrier 
to the adoption of the guideline procedure. Even if the information contained in 
the guideline has consensus in the community of experts that it serves, sometimes 
a lack of awareness of the official guideline can adversely affect adherence. 
As an example, in the provision of care for osteoarthritis (Nelson et al., 2013) 
findings indicated that there was relative agreement between the centres 
involved, on what treatments should be provided. This was despite large variation 
in familiarity and adherence with the official guidelines (79% of those surveyed 
said they were aware of the management guidelines, whilst 54% adhered). The 
study concluded that guidelines in this area were effective, but the methods of 
dissemination required improvement. So participating centres were indeed 
following broadly the same principles, but this was only partially due to the 
influence of the official guideline.  
Issues of dissemination appear as a common thread when evaluating adherence. 
(Ansari et al., 2003) looked at beta-blocker use in heart failure and showed various 
methods and channels of disseminating the guideline information. These were to 
use a nurse facilitator (direct intervention by trained specialist), general education 
(documents, leaflets, etc) and clinical reminders (automated interventions). These 
all had different effects on adherence, with the nurse facilitator being the most 
successful. (Rood et al., 2005) indicated that a study of glucose measurement and 
regulation improves greatly when dissemination is provided through computer-
assisted, rather than through paper-based, means.  
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A systematic review of guideline dissemination strategies (Prior, Guerin and 
Grimmer-Somers, 2008) showed that the (non-) effectiveness of passive 
dissemination is a significant result. Similar to the (Ansari et al., 2003) study, 
where direct intervention is taken by a person or automated method, the 
adherence rate is markedly better than if the guideline document and information 
is published passively (e.g. using conferences, websites or didactic lectures).  
Other studies (Grol, 2001) and (Azocar et al., 2003) show that targeted and 
behaviourally “disruptive” methods are best for disseminating information and 
influencing clinical practice. Similarly (Grol and Grimshaw, 2003) and (Almatar et 
al., 2016) have shown that only comprehensive interventions on all levels of input 
and with specific targets and barriers identified stand a chance of influencing 
behaviour. Therefore, understanding the effectiveness of these different methods 
of dissemination is an important factor in developing tools to improve awareness 
and adherence (related to the third hypothesis of this thesis). 
3.1.2. Authority of guideline publisher 
An implicit assumption in the use of clinical guidelines is that they represent the 
most up-to-date knowledge in terms of clinical interventions, and the perceived 
quality and trustworthiness of the guideline itself can often go un-questioned. 
This authority is an important aspect when considering adherence and contributes 
to the many other human characteristics that mark whether a clinical guideline – 
which is not a legal mandate – should be followed. Examples of systematic reviews 
that have been conducted into the question of guideline authority in general 
health-care, includes: the evaluation of attitudes towards guidelines (Farquhar, 
Kofa and Slutsky, 2002), examination of bias in self-reporting and awareness of 
guidelines (Steinman et al., 2004), discussion of the positive and negative effects 
on clinical practice of guidelines (Grimshaw and Russell, 1993), and a more recent 
article that highlights the negative impact of the “evidence-based” movement, 
such as the volume of guideline evidence, and the mechanical implementation of 
the guideline in patient care (Greenhalgh et al., 2014). 
The results of these studies highlight issues that challenge conventional clinical 
wisdom – such as the large percentage of clinicians not meeting hypertension 
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guideline standards (medication prescription 67%, blood pressure management 
42%) despite these guidelines being largely unchanged for 30 years (Steinman et 
al., 2004). However, as highlighted in (Farquhar, Kofa and Slutsky, 2002), there is 
a general feeling that while clinical guidelines are a useful source of information, 
the associated administrative overhead that official compliance requires can cause 
institutions and clinicians to be tentative when considering full-scale adoption. 
(Grimshaw and Russell, 1993) conclude that, as a general rule, there is an 
unmistakeable improvement in clinical practice when clinical guidelines are 
adopted but their conclusions also showed vast variation in that improvement 
depending on other factors such as dissemination, education and resourcing 
(similar to the issues discussed in section 3.1.1). 
As discussed in (Watters, 2008) the move from general clinical practice guidelines 
to those underpinned by a systematic evidence base, does also vastly improve the 
quality of the guideline. This is due to the transparency of the guideline 
development process, along with the primary focus of removing systematic bias 
(compared to previous approaches which, with less transparency, often tended to 
reflect the treatment or economic goals of those developing the guideline). 
A final consideration on the authority of guideline developers is the possibility of 
competing sources of guideline publication, due to cultural, organisational or 
political reasons. One study looked into the nature of guideline development in 
general (Fervers et al., 2006). It concluded that there was a marked lack of trans-
contextual adaptation of guidelines – i.e. guidelines defined in one cultural and 
organisational setting were rarely, if ever, considered for other settings. This leads 
to an “organic” development of expert communities, the possibility of guidelines 
developing in parallel with – and isolation from – each development group and 
missing critical translational developments. Although this situation is not 
prevalent, where it does exist these factors undermine the systematic and 
evidence-based nature of clinical guidelines. Another study (Kearns, Moss and 
Kinsella, 2013) examined a specific case – management of patients with a 
fractured neck of femur – and found that the recommendations spanned many 
guidelines from across a spectrum of guideline-producing institutional bodies, with 
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some similarities but also conflicts that could lead to inconsistent patient care if 
followed to the letter.  
3.1.3. Personalized medicine 
A view-point that is gaining ground in general health-care and which can act as a 
counter-point to the use of medical guidelines is the notion of personalized 
medicine. This is where the priority is put on tailoring treatment for a patient’s 
specific case instead of abstracting the treatment process into something more 
general. (Goldberger and Buxton, 2013) provide a discussion about personalised 
medicine versus clinical guidelines, though they do not appear to provide strong 
arguments for evidence-based guidelines, choosing to hold guidelines as the 
authoritative position to be argued against, and provide counter arguments 
espousing the benefits of personalised medicine. Indeed, when reviewing this 
theme in literature, feelings on either side of the debate apparently run high, 
suggesting a level of “evangelism” when defending one of the two sides (Miles, 
Loughlin and Polychronis, 2008)3. 
However, more reasoned arguments have also been made, particularly involving 
the discussion of gene therapy, which is arguably where the link to individual 
personalisation is strongest. (Hamburg, 2010) discusses the potential for gene 
therapy as the field of translational research develops, where the identification of 
genetic markers in individuals will likely play a more prominent role in the 
development of clinical treatments at the phenotypic level. 
Despite the apparent “natural” opposition of personalised and evidence-based 
medicine, the overall argument made in papers such as (Goldberger and Buxton, 
2013), is one that this research work attempts to address: that there is a need for 
cautious interpretation of large-scale random controlled trials and studies. This is 
an over-arching problem that does not mean that the two approaches to treatment 
(guidelines vs personalized) necessarily have to be mutually exclusive. 
                                                     
3 For example, from the referenced paper: “… no author has been able to convincingly show the superiority of 
the Evidence-Based Medicine ‘approach’ [original quotation marks] and such assertions […] remain what they 
originally were: expressions of bald rhetoric and intellectually bankrupt hyperbole” 
62 
 
3.1.4. Summary 
From the areas covered in this section, we can see that a number of issues exist in 
general that are impediments to the successful adoption of clinical guidelines. 
Various methods are used to improve these adoption rates but with differing levels 
of success, and these issues are relevant to medicine in general. In the next 
section we look at the issues in adherence to guidelines specifically in the domain 
of TBI. 
3.2. TBI specific guidelines 
In 1994 the Brain Trauma Foundation (BTF) began an initiative to formulate 
treatments for brain injury into standardised, internationally-recognised 
guidelines. Since then studies have been conducted that show dropping mortality 
rates and improved long-term outcomes due to the adoption of these guidelines. 
One example is (Bratton and Chestnut, 2006), and another is (Tarapore et al., 
2016), both showing the continued trend of improvement through the last two 
decades. 
Evidence for this level of confidence in the guidelines is available: a survey of TBI 
management in 1995 (Ghajar et al, 1995), was one of the original studies that the 
BTF guidelines were formed in response to. When the numbers in that study are 
compared to those collected seven years later (Fakhry et al., 2004), an undoubted 
improvement in patient outcome is shown, largely attributed to the gradual 
adoption of BTF guidelines by many centres over this time period. 
However, adherence to the BTF guidelines is not universal – many studies outline 
their potential deficiency in various aspects such as hypothermia (Clifton et al., 
2001), intubation (Franschman et al., 2009) and the need for ICP monitoring 
(Chesnut et al., 2012). In one study (Lee et al., 2015), the investigation has 
focused on whether it is feasible, or even possible, to adhere to all 15 of the BTF 
guidelines when treating brain-injured patients. Their conclusions are that it is 
indeed a difficult objective to achieve and in many cases is also unnecessary. And 
in contradiction to (Tarapore et al., 2016), another study conducted by (Dawes et 
al., 2015) concludes that patient outcomes are in fact not statistically affected by 
strict adherence to the BTF guidelines. 
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However, whilst guideline non-adherence is a common issue across medicine for 
reasons of lack of awareness, familiarity, agreement, or outcome expectancy 
(Cabana et al., 1999), it is the case that studies investigating non-adherence to 
BTF guidelines are very focused in their rejection of the specific guideline. The 
NICE guidelines concerning treatment of TBI treatment in the UK (NICE, 2014) 
suggested that the key recommendation of “transfer the TBI patient to a hospital 
with a specialist neuro-trauma centre” is a grey area that causes many clinicians 
to reject the mandated guideline (though this is an issue affected by resourcing as 
well – if every hospital had a specialist neuro-trauma centre, the problem would 
not occur, a finding also supported by (Ghajar, 2000)). In another example, 
(Pascual et al., 2011) discusses the interventions mandated by the BTF guidelines 
when oxygenating the brain blood flow and conclude that those recommended 
actually worsen survival rates. ICP monitoring in particular, is an area that 
highlights the divided opinion of the expert community about the most appropriate 
treatment, demonstrating that much more work is required to underpin this 
particular BTF guideline. For instance, (Dawes et al., 2015) conclude that 
compliance with the BTF guideline on ICP monitoring and craniotomy has “minimal 
association with risk-adjusted outcomes in patients with severe TBI” whereas 
(Talving et al., 2013) conducting a very similar study conclude that “Patients 
managed according to the BTF ICP guidelines experienced significantly improved 
survival”. Evidently, uncertainty and disagreement surrounding the validity of 
many of the BTF guidelines still exists. 
Various studies have been conducted that investigate the adherence to BTF 
guidelines in regard to particular treatments. (Neumann et al., 2008) look at the 
administration of hyperventilation;  (Griesdale et al., 2010) quantified the 
adherence when applying an external ventricular drain to TBI patients; and 
(Griesdale et al., 2015) examined the association of CPP being maintained within 
the guideline range, with patient outcome. All report overall adherence to the BTF 
guidelines – associated with positive outcomes - but with notable exceptions 
largely delimited by geographical areas (e.g. in Europe, recommendations on early 
prophylactic hyperventilation and cerebral oxygenation monitoring are not 
followed in the majority of TBI centres (Neumann et al., 2008)). It is proposed that 
the overall adherence of specialist centres could be improved, but a critical point 
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is that all of these studies accept a priori that the BTF guidelines should be 
adhered to. 
Finally, the issue of regional and national differences is one that has received 
attention from studies in TBI, especially as the search for significant findings push 
clinicians to collaborate over wider areas, with potentially greater differences in 
treatment patterns. On one hand (Lingsma et al., 2011) conclude that differences 
in outcome between centres do not affect the treatment effect in TBI RCTs, as is 
commonly considered to be the case. On the other (Hukkelhoven et al., 2002) run 
a comparison of two RCTs for the same drug, Tirilizad (a drug to treat acute 
ischaemic stroke) and conclude that the differences in treatment patterns 
between centres, countries and continents are significant and do affect RCT 
outcomes. 
As already noted in chapter 2, there is large scope for uncertainty in the 
development of TBI guidelines, and this inevitably brings an unwillingness to fully 
adhere to a guideline. However, when discussing with a clinician (Dr Chris 
Hawthorne, University of Glasgow, 31st July 2018, pers. comm) in terms of specific 
parameter targets, they made the following two points when considering 
adherence, illustrating the pragmatic relationship developed with guidelines in the 
course of day-to-day routine: 
1. “There may become a point in patient care when the likelihood of survival is 
minimal and further aggressive treatment is felt to be futile. In these cases, 
non-adherence with guidelines may represent a decision to focus on palliative 
care rather than on targeting physiological parameters such as ICP and CPP.” 
2. “The BTF Guidelines are a very balanced and pragmatic set of guidelines that 
are extremely helpful to clinicians. However, little (if any) of the evidence is 
"level 1" and the guidelines themselves allow (indeed encourage) clinicians to 
consider the individual patient. This means that non-adherence in terms of 
targeting a specific CPP parameter may be common but may be acceptable 
within the scope of the guidelines.” 
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With this is mind, we now survey the areas where clinical guideline adherence has 
been improved using novel techniques, in a non-technological capacity and 
specifically for TBI. 
3.3. Novel attempts to improve adherence 
Evident from this review so far is that guideline adherence is subject to great 
variation. When considering how to improve adherence, the reasons outlined above 
can be broadly categorised into the result of one of two prime causes: being 
unwilling to adhere to a guideline and being unable to adhere. Whilst techniques 
to address the first category include improved dissemination, communication and 
various long-term social methods, improvements in the second category, which is 
usually functional in nature (e.g. lack of resources/time), can be approached using 
“behaviourally disruptive” methods. 
3.3.1. Data collection approaches 
Most attempts to improve adherence to guidelines in the medical domain involve a 
direct change or implementation of a care procedure. In these cases, the 
evidence-base for a guideline comes from a panel of experts in the field that have 
reached a consensus for various treatments. The novel attempts then concern the 
implementation of that guideline in patient care in a standardised and accountable 
way. 
A campaign that exemplifies this approach is “Surviving sepsis”, which targeted 
improvement of patient care by specifically supporting guideline adherence 
through the identification of resuscitation and management “bundles”. Part of this 
was an intensive data collection arm, which – in real-time – forced clinicians to 
systematically add data as part of clinical routine (Levy et al. 2010). The results of 
this work have shown a marked improvement in adherence to the guidelines, but 
an emergent complication was the lack of ability to stay current with the latest 
guidelines and update procedures to reflect this over a feasible timescale. 
Feedback from the first four years of this project into the re-development and 
improvement of sepsis guidelines has been cautiously optimistic (Dellinger et al., 
2013). And whilst not specifically providing a new type of analysis, a side-effect of 
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the rigorous collection is that it does provide a large repository of sepsis data that 
is potentially useful for future studies4,5. 
3.3.2. TBI-specific 
As mentioned in section 2.4, CENTER-TBI comprises many work packages covering 
both clinical and technological areas of research in TBI. Much of the work 
conducted by this group has established beyond doubt that large variation exists in 
the implementation and adherence rate to the TBI guidelines, even in large-
volume studies conducted in well-resourced specialist centres (Cnossen et al., 
2016a). A sub-set of this group, as part of the TBI-IMPACT project – also mentioned 
in section 2.3 – had attempted to address variation using post-hoc statistical 
techniques, but the results had been inconclusive (Maas et al., 2010).  
A central component of the CENTER-TBI initiative, extending on work begun in the 
TBI-IMPACT project, is the use of competitive effectiveness research (CER), which 
is a broad definition of various analytical tools. One of the main facets of CER is 
the use of “Living Systematic Reviews” (LSRs) – systematic reviews which are 
conducted with the express purpose of being updated at regular intervals, as 
opposed to being done “once and never again”. The cost of conducting such a 
review can be high, so keeping the study as a constantly updated document is a 
good way to maintain constancy without having the initial set-up costs of the study 
each time. As the CENTER-TBI project progresses, individual LSRs have yet to be 
developed, but evidence of their use and requirement are now starting to be 
published (Cnossen et al., 2016b), (Synnot et al., 2016). 
The use of the CENTER-TBI repository in this way, does leverage technology and 
data but still largely involves the manual collection and curation of that data. In 
the next section we now discuss direct technological (i.e. automated and semi-
automated) attempts to improve guideline adherence in general medicine. 
                                                     
4 The author of this thesis also witnessed a ward review meeting at the Glasgow Royal Infirmary, which was 
one of a set of regular sessions that are now in place due to the Surviving Sepsis campaign. The process was 
well established and made a comprehensive and detailed review of outcomes that week in the ward (death or 
discharge), how they related to the mandated guideline, and noted for feedback into the appropriate 
administration where any deviations had occurred. 
5 Since submission of this thesis, an app related to the Surviving Sepsis campaign has been released which 
neatly combines the output from this section (data collection) and 3.4.2 (apps) (Surviving Sepsis, 2019). 
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3.4. Technology – state-of-the-art 
When surveying the state-of-the-art in the context of improving clinical guideline 
adherence, there is a large landscape of technology to consider. However, to focus 
the work to the most relevant areas the review has been constrained to: a general 
(and brief) consideration of the role of decision support technology; the use of 
smart-phones and apps; clinical guideline formalisms and representations; and 
process models. 
3.4.1. Decision support 
Central to understanding the availability and utility of data in the ICU is being 
aware of the advances of ICU technology, particularly in the past four decades. 
One paper written in 1987 (Shortliffe, 1987) describes the concerns within the 
medical community that computerized support technology would outgrow its 
supporting role and end up replacing clinical decision-making. Nearly three 
decades on, this outcome has yet come to pass, and familiarity with techniques of 
artificial intelligence have eased these concerns6, with clinical judgement by a 
trained human still a required part of the interface with technology. However, the 
focus of research still remains upon understanding expert medical knowledge and 
problem-solving skills, and attempting to reproduce them with technology, in order 
to free resources for pursuing more advanced medicine. The pursuit of accuracy in 
this latter point of judgement is one of the main goals of the science underpinning 
decision support. 
As the mechanics of decision support strive for accurate automation, one way to 
measure progress is to look for metrics of efficiency. Hospital administrators may 
look at cost-benefits within a particular hospital, government health policy-makers 
will be concerned about cost-benefit to society as a whole, or the individual 
clinicians may look at overall patient outcome improvement. Whatever the 
targeted improvement is, there will be some metric associated with it, such as a 
protocol refinement of adult respiratory distress syndrome (ARDS) (East et al., 
1992) or enforcing adherence to diabetes guidelines (Lobach and Hammond, 1997).  
                                                     
6 More accurately: the concerns have eased “somewhat”. Debate in the area is still controversial. 
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Studies in other areas as diverse as chronic kidney disease (Ennis et al., 2015) and 
thyroid cancer management (Likhterov et al., 2016) support the conclusion that 
improvements in guideline adherence in these respective areas, improve similar 
metrics and – by extension – patient outcomes. It is in studies like these latter two 
that the connection between guideline adherence and decision support is made 
most explicit: in both, the concept of a retrospective assessment of protocol 
adherence helps understand why decisions in an ICU are taken, and the output 
allows later prospective decisions to be guided by understanding the effectiveness 
of the given protocol (also related to the third hypothesis of this thesis). 
3.4.2. Smart-phones and apps 
One method that has increased in step with the utility of personal smart-phones is 
the electronic application (or “app”). The physical proximity to a clinical 
professional and the increasingly-reliable connection to other digital assets over 
the Internet make this one of the most convenient technological interventions.  
This shift towards the use of smart-phones can be immediately seen in their 
adoption by major guideline developers in national health-services (e.g. the NICE 
guidelines for the NHS in England (NICE, 2014)). These provisions allow quick and 
easy access to guidelines for immediate consultation – useful in the clinical 
environment – but have yet to provide reliable dynamic interactivity in the update 
of the guidelines involved (the app is largely “broadcast only”). 
However, as fast-moving app development continues, various studies and pilot 
tests are now being carried out to include greater functionality that would allow 
more interactive access to a knowledge-base of clinical expertise. Some are 
specifically designed – similar to the NICE apps – to provide guideline expertise to 
professionals at the point-of-care, such as the “Sidelines Guidelines” app (Lee, 
Struik and Ahmed, 2016) which helps medical practitioners administer first-aid 
correctly during high-contact sports. Others focus on point-of-care help for a 
specific condition, such as a fitness and health app designed to provide aid in the 
case of seizure (Pandher and Bhullar, 2014). In this latter study, the focus was 
often on the development of the app and its ability to disrupt the behaviour of an 
epilepsy sufferer by providing immediate seizure management advice. 
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A further addition to this provision of clinical information at the point-of-care, is 
the integration of clinical guideline software into smart-phone apps, which is 
currently being conducted by the European MobiGuide project (MobiGuide, 2014). 
The anticipated outcome of this project is a direct stream of standardised 
guidelines, combined with personal digital health records, which interacts directly 
with patients (Peleg, Shahar and Quaglini, 2013). The interactions take the form of 
alerts and notifications with suggested corrective actions, so that adherence to the 
relevant protocol is maintained as closely as possible. Measurements of adherence 
improvement through this system can be seen at (Peleg, Shahar, Quaglini, Broens, 
et al., 2017a). 
Finally, another useful feature of apps is their ability to directly connect to 
medical registries, which focuses the input of information (usually in the form of a 
daily electronic diary) directly from the patient and synchronises with the central 
registry to allow accurate communication with their consulting clinician. Example 
apps of this type have been developed for rare diseases such as Niemann-Pick 
(Sinnott et al., 2015) or for public health challenges such as alcohol consumption 
(Zheng, Z, Bruns, L, Jr, Li, J, Sinnott, 2017). The improvement of adherence 
occurs as a third-party (the consulting clinician) can immediately see if the patient 
is non-adherent and take correcting action if appropriate 7.  
3.4.3. Clinical guideline formalisms and representations 
The behavioural disruption that the smart-phone app provides is almost always due 
to the convenient proximity of the knowledge base (the guideline data repository) 
to the end-point of information delivery (e.g. the patient or clinician). In this 
thesis however, the focus of the work is not only upon delivery but on the 
representation and processing of that information. The area relevant to this thesis 
is the use of electronic clinical guidelines, their formal specification as (realistic) 
medical processes, and their ability to be interpreted by both humans and 
computers. 
To illustrate clinical guideline formalisms, an example is the ProForma technology, 
a project developed by the COSSAC group (Fox, 2017). ProForma is a language 
                                                     
7 Disclosure of interest: the author works for the Melbourne eResearch Group, developing the registries that 
the apps referenced in this paragraph upload to. 
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specification designed to “support decision making and plan execution” for the 
authoring and execution of clinical guidelines. In order to build applications around 
this specification, the TALLIS software is required (COSSAC, 2014), around which 
various tools and tutorials are offered to build a complex clinical guideline object, 
which can then be “enacted”, and output received as to what a specific clinical 
decision should be, given the context of the guideline. 
 
Figure 3.1: illustration taken from (Fox, 2017) the ProForma application development tool (TALLIS) 
Similar language specifications and tools have been developed in this area. One of 
the most comprehensive comparison of these formalisms is (de Clercq et al., 
2004), which covers representations such as the Arden Syntax, GLIF, ProForma, 
Asbru and EON. This survey does not provide a “like-for-like” summary but does 
discuss the benefits and drawbacks of each representation (e.g. ProForma provides 
a low-level syntax; Asbru provides a rich set of temporal constructs though lacks an 
implementation engine; etc). It does note that as of the time of writing (2004), no 
single implementation had been created to enable these representations in the 
real world. However, the MobiGuide project – mentioned in section 3.4.2 – has 
aimed to implement these representations more robustly and has had moderate 
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success in introducing computer-interpretable guidelines into a clinical setting 
(Peleg, Shahar, Quaglini, Broens, et al., 2017b). 
Another application in this field is the use of ontology technologies. An ontology 
“encompasses a representation, formal naming, and definition of the categories, 
properties, and relations of the concepts, data, and entities that substantiate 
one, many, or all domains” (Ontology, 2018). Similar in theme to the descriptive 
and representative nature of formalisms described above, many groups developing 
clinical guideline formalisms have attempted to incorporate ontologies into their 
work, with the goal of introducing comprehensive context into the decision-making 
process, necessary for following clinical guidelines. 
An earlier paper by the same team that had compared clinical guideline formalisms 
(de Clercq et al., 2001) looked at the combination of ontologies with those 
formalisms. The primary argument was that the simple action-task descriptions of 
clinical guideline formalisms does not sufficiently capture enough information to 
represent and enact a guideline in the real world. Other research groups have 
approached this method of representation as well: two examples outlining the 
contemporary state-of-the-art were (Lezcano, Sicilia and Rodríguez-Solano, 2011), 
which discussed the integration of OWL (Web Ontology Language) and SWRL 
(Semantic Web Rule Language) frameworks in a clinical environment specifically 
for guidelines, and (Heymans, McKennirey and Phillips, 2011) which surveys the use 
of the SNOMED-CT – a computer-interpretable clinical terminology – and how it can 
be translated into an OWL standard ontology. 
After review of these technologies, amongst various criticisms, two stand out as 
the most relevant to this thesis. First, and most importantly, is the requirement to 
add information to imbue meaning to the data. Whilst the goal is laudable – to set 
up a uniform and interchangeable map of meaning between all entities on the 
Internet – the result often requires work by the end user (dealing with notations 
and languages, which are not their domain of expertise), or the same work by the 
informatics scientist (who is not a domain expert in whatever field of research 
they are requiring the input – e.g. clinical guidelines). This tends to result in an 
over-specification of functional requirements – e.g. the requirement for a large 
“enactment engine” in ProForma – and a requirement for extra work from both 
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parties. Second – in the case of ontologies – is the bias that can often creep into 
the specification. This is true of all descriptions (e.g. a database schema) but due 
to its comprehensive nature (the desire to “describe everything”), this bias can 
have a large negative impact on the data processing, which would be minimised if 
the descriptive part of the model is more constrained. 
An example paper describes the state-of-the-art in this area as of 2017 (Fox, 
2017), which summarises the use of the ProForma language, as part of the CREDO  
“cognitive computing” stack, after 20 years of development. Similar issues as 
those described above can be seen with this technology - there are still no agreed 
standards at a high-level (of use to the clinical community), the use of the 
technology requires tight integration with an over-specified language and 
implementation (the screenshots, such as figure 3.1, show interfaces that closely 
resemble technically-oriented development environments), and the reported study 
applications of the technology did not provide enough evidence of the formalism 
being reliable enough. Some were small, such as N=144 in (Bury et al., 2005),  
others had isolated statements of positive results (“Radiographers… performed 
better when using advice from the system”) without supporting numbers) (Taylor, 
Fox and Pokropek, 1999), whilst further had positive results based on general high-
level criteria (61% increase in recruitment based on main criteria only) (Patkar et 
al., 2012). 
Although there is substantial work in the field of guideline formalisms, it is felt 
that for the purposes of building a technology framework to address the particular 
challenges in this thesis, many of the characteristics that these digital guideline 
technologies – such as flow-control representation – appeared to be well 
represented by the more general concept of processes, and their classification as 
process models. 
3.4.4. Process models in a clinical context 
Process models are processes of the same nature that are classified together into a 
model (Process modelling, 2018). As the name suggests, they incorporate a 
process-based model, which is the most useful characteristic of the guideline 
formalisms discussed in section 3.4.3. This general feature is something relatable 
from many aspects of professional life, such as the development and use of flow-
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charts (states, actions, transitions between each, and decision points requiring 
contextual input) in many business and administrative contexts. 
The idea of layers of abstraction is pertinent to introduce here – these can be 
thought of as different layers of representation of data, which have, from the 
lowest level to the highest, increasing levels of sophistication and complexity. An 
example would be the raw physiological data from a bedside ICU machine at the 
lowest level (one number measuring a single parameter at a single time-point), 
leading to a clinical diagnosis from a clinician at the highest (a complex 
representation of data, based on inputs and context from many sources). 
 
Figure 3.2: visual abstraction of the layers involved in process modelling (Kless, 1993) 
The use of a process model allows a specific level in these layers of abstraction to 
be chosen, which is an important flexibility that the over-prescription of the 
guideline formalisms prohibits. (Perimal-lewis et al. 2012) claims that the 
fundamental element required for the construction of a process model is the 
historical event log of a process, and this lends itself to the description of actions 
and reactions that occur in a medical context. This research area is referred to as 
“process mining” and is usually applied to the higher-level patient care work-flows 
within a hospital, such as transport of patients and allocation of resources such as 
bed-spaces. An example study like this would be (Mans, et al. 2009), which 
investigate the different management processes using various process mining views 
on flow-control structures, and how these can improve the organisation and 
performance within a hospital, by identifying redundant clinical pathways. 
This area is related to the more general domain of business process management 
(BPM) not usually realized as medical processes, but critical in the use of 
event/reaction flow-diagrams to formally describe processes that occur within 
complex organisations. An example of this is (van der Werf, Verbeek and van der 
Aalst, 2012), which looks at tools to automate the compliance of a business to 
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specific guidelines, typically referred to as an “audit”. The idea behind this work is 
to develop an awareness of the context of a process, which can often impact the 
perceived compliance to a guideline, without being evident in the audit itself. 
At one level, the process mining work referred to above nearly always focuses on 
the clinician behaviour as part of a corporate body, with a view to improving those 
corporate processes such as (Perimal-lewis et al. 2012). Pattern extraction science 
– at a lower level – focuses on mathematical techniques to detect individual 
events. The connection between these two levels, which is where the work of this 
thesis is focused, is rare, though does exist. (Huang, Lu and Duan, 2012) looks at 
the “clinical pathway” area, where a clinical event log is analysed, and common 
remedial medical behaviours are extracted. The work was validated by clinical 
experts as a true representation of some of their behaviours, but it did conclude 
that the general nature of the conclusions meant that more specific work was 
required, and that some critical behaviours were missed. This is an example of 
where the focus on a specific condition – in this case TBI – would help in identifying 
processes more exactly and in a way that is immediately useful to clinicians 
working in the ICU. 
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Aims of the thesis 
In general, there is much work that attempts to improve adherence to clinical 
guidelines, or to improve the quality of information that can be extracted from 
studies, in order to refine guidelines more effectively. Many use non-technological 
methods, whilst those using technology often either provide intervention at the 
point of care-delivery, such as apps, or require a large input of knowledge in order 
to model a clinical process, such as guideline formalisms. What appears to be 
missing is the ability to provide new information on a clinical management process 
to a clinician, with a minimal requirement for knowledge (i.e. the information is 
extracted using only what exists at the bedside already). With the abundance of 
data available from modern ICUs, and the particular problems facing the output of 
TBI studies, this would seem to be an avenue that may provide worthwhile results 
and it is this gap that this thesis intends to address. 
Throughout the course of the literature review, several pieces of technological 
work were encountered that appeared relevant to this goal. The first was work 
which combined the technologies of process mining and ontological descriptions of 
a medical environment in order to measure similarities between medical processes 
(Montani et al., 2014). At the time of publication (2014), this work appeared to 
share similar issues to those described in section 3.4.3, namely an over-
specification of the descriptive entities (in this case a use of “taxonomic distance” 
with a descriptive ontology, requiring large amounts of knowledge to be input) and 
the limited access to a practical implementation, which made testing the claims of 
the work difficult.  
However, the broader theory of calculating a distance between two process 
models, appeared to be a viable avenue of investigation. At the start of 2014, the 
work of  (Perimal-lewis, Vries and Thompson, 2014) had been published describing 
the application of process models to the administrative maintenance of medical 
domains, such as hospitals, and was already showing promise as a possible 
representation to use in this thesis. The shared elements of these two works 
provide a base theory to use when describing a generalised approach to 
representing guidelines and understanding differences between two time-varying 
protocols. 
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Further investigation into process models to represent guidelines generally, led to 
the use of Business Process Management Notation (BPMN) as a representation of 
the BTF guidelines. Authoritative work by a research group in Eindhoven, which 
had been used for comparison by the (Montani et al., 2014) team, appeared to be 
highly relevant, though not specifically tailored to the medical domain. Their use 
of BPMN in process models was documented in (Dijkman, Dumas and Ouyang, 2008) 
but the work that proved most useful had been published a year later in (Dijkman, 
Dumas and Garcia-Banuelos, 2009), where they robustly calculated the similarity 
“distance” between two process models using different algorithmic approaches. 
With these component technologies identified, it was possible to collate these 
approaches into a framework and return to the original clinical problem of 
representing and comparing two sets of clinical protocols – one from text 
guidelines, the other from actual clinical data. The final requirement was that 
there needed to be an understanding of the “level” at which the interpretation of 
guideline adherence can occur. To illustrate what this means, the following four 
levels of data interpretation were identified: 
1. Raw data from the bedside 
2. Clinical management processes 
3. Statistical analysis of studies 
4. Meta-analyses of grouped trials and studies 
From the review conducted, it was noted that the second level in this list was one 
that typically received less attention than the others - most often raw data would 
directly contribute to a statistical analysis, with no analysis or interpretation of 
what the grouped information means in a live ICU context (e.g. a coarse-grained 
binary classification of say, patients that have received steroids during a patient 
stay against those that haven’t).  
Therefore, two broad conclusions were drawn: 
1. There is a desire for improved guideline adherence through novel methods 
in general, and in the area of TBI in particular. 
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2. No single or group of technologies is sufficiently established to perform an 
analysis of clinical management processes for the purpose of understanding 
guideline adherence. 
Informed by this final discussion, the original hypotheses of this thesis were 
formulated: 
1. In high-resolution time-series clinical data, one can extract clinically-valid 
treatment processes for ICP/CPP management in TBI patients 
 
2. Having extracted treatment processes, one is able to develop a method to 
compare those against other treatment processes to establish the degree of 
similarity between them 
 
3. One can develop a computerised tool that readily quantifies and displays to 
clinical staff a metric of actual ICP/CPP management protocol adherence 
And using the technological components identified, a research plan was drawn up. 
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4. Expression of clinical guidelines as process models 
Chapter summary 
This chapter describes the process of expressing the BTF guidelines in a format 
that represents them as process models, and which can be later compared to a 
similar format derived from the real ICU data. 
The method used is a design language known as Business Process Modelling 
Notation (BPMN). The key features are introduced alongside a brief discussion of 
alternatives. 
The template BPMN diagram is shown with key activities described (such as event 
start, and clinical management reaction). Temporal event and activity 
annotations are briefly described (such as time-window size and time to 
treatment administration). 
The three threshold monitoring guidelines are described in text, then shown in 
BPMN representation. Finally, there is a brief discussion about validation in terms 
of the relationship of these guidelines to others in the BTF, the location of the 
implementation data for these models in the database, and the feedback from a 
domain expert presented with these diagrams (which, in brief, was: “reasonable, 
but beware of the wider clinical context”). 
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There are 18 TBI guidelines for severe in-hospital treatment, in the 4th edition of 
the official Brain Trauma Foundation TBI management document. These cover 
various types of injury and treatment (BrainTrauma, 2018) – three more than in the 
3rd edition8. Of these, the three guidelines that were specifically investigated were 
the monitoring thresholds for: 
 Systolic blood pressure (SBP) 
 Intracranial pressure (ICP) 
 Cerebral perfusion pressure (CPP) 
Clinically relevant thresholds for SBP, ICP and CPP are routinely debated and 
feedback from monitoring adherence to these guidelines in clinical environments 
would be of particular interest to the research community. 
The conversion of BTF guidelines to a process model takes the form of expression 
in a format known as Business Process Model Notation (BPMN) (Camunda, 2018). 
BPMN is a representation that expresses processes in a graphical format with basic 
features such as flow objects (e.g. events and activities), connecting objects (e.g. 
sequence and message flow) and artefacts (e.g. annotations). It shares features 
with other software design languages, such as activity diagrams in the more 
commonly used Unified Modelling Language (UML), but has a primary focus on 
processes rather than objects. The flow-charting features of UML were considered 
for the expression of the BTF guidelines but were rejected due to the 
characteristics of BPMN being directly relevant to process models.  
Another possibility for capturing the BTF guidelines was to use a domain ontology. 
This would be similar in implementation to the work that was originally conducted 
in this thesis for physiological event detection (see Appendix B). Greater context 
could potentially be captured using an ontology, but BPMN was still considered an 
better choice due to its ability to model combined temporal and spatial processes 
more readily. 
                                                     
8 During the course of this research work (2011 – 2018), the BTF guidelines underwent a major revision from 
their 3rd to the 4th edition. This highlighted many of the issues raised in chapters 2 and 3 about clinical 
guidelines, and is detailed in Appendix C. For the purposes of the main body of work, unless explicitly stated, 
the updated 4th edition guidelines are assumed. 
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For each guideline detailed in this chapter, the text is shown along with a BPMN 
diagram. The representation of all three guidelines follows a similar general 
structure, shown in figure 4.1, and can be considered as a template for all three 
guidelines. Starting at the top-left of the diagram: a pressure event occurs (with a 
trigger threshold value), and a treatment is applied (“clinical management 
reaction”). The level is checked again: if the pressure has returned to a “safe” 
level then the treatment cycle is stopped; if not, the process continues round the 
cycle again. Depending on the specific guideline there may be additional factors 
between the event start and the application of treatment.  
It is noted here that this template shows three event and activity “annotations”, 
additional to information derived from the BTF guidelines: 
 mandated time window size 
 nature of treatment (“repeat/single”) 
 time from treatment 
Though these annotations are not mentioned in the BTF guidelines, they were 
considered temporal requirements based on both feedback from a domain expert, 
and the application of common sense during evaluation of real datasets (e.g. 
specifying a time for a reaction to occur within). For clarity, and because they are 
constant across all guidelines, these annotations are omitted in figures 4.2-4.5. 
81 
 
 
Figure 4.1: a general BPMN “template” representation of the three threshold-monitoring BTF 
guidelines 
4.1. Systolic blood pressure 
There is a single, level 3, recommendation in the BTF guidelines for the monitoring 
of systolic blood pressure: 
 Level 3: “Maintaining SBP at >= 100 mm Hg for patients 50 to 69 years old 
or at >= 110 mm Hg or above for patients 15 to 49 or > 70 years old may be 
considered to decrease mortality and improve outcomes” 
This translates to the BPMN diagram shown in figure 4.2. An event occurs (systolic 
< 110 mmHg), the age is checked, and a treatment is applied. The SBP level is 
checked again – if the SBP has returned to a “safe” level (which varies depending 
on age – hence the BPMN “message” symbol) then the treatment cycle is stopped; 
or continues if not. 
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Figure 4.2: BPMN diagram of the systolic blood pressure monitoring process according to the BTF 
guidelines 
4.2. Intracranial pressure 
The BTF guidelines contains two recommendations for intracranial pressure 
monitoring (ICP): 
 Level 2b: “Treating ICP > 22 mm Hg is recommended because values above 
this level are associated with increased mortality” 
 Level 3: “A combination of ICP values and clinical and brain CT findings 
may be used to make management decisions” 
This translates to the BPMN diagram shown in figure 4.3. An event occurs (> 22 
mmHg), other evidence such as brain CT scans (diffuse injury II, III or IV) and other 
clinical findings (e.g. mass lesion), assigned and input by the treating clinician 
during the patient stay, are considered, and a treatment is applied. The ICP level 
is checked again – if the ICP has returned to a “safe” level then the treatment 
cycle is stopped; or continues if not. 
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Figure 4.3: BPMN diagram of the ICP monitoring process according to the BTF guidelines 
4.3. Cerebral perfusion pressure 
Two recommendations for the management of cerebral perfusion pressure (CPP) 
are contained in the BTF guidelines: 
 Level 2b: “The recommended target CPP value for survival and favourable 
outcomes is between 60 and 70 mm Hg. Whether 60 or 70 mm Hg is the 
minimum optimal CPP threshold is unclear and may depend upon the auto-
regulatory status of the patient” 
 Level 3: “Avoiding aggressive attempts to maintain CPP > 70 mm Hg with 
fluids and pressors may be considered because of the risk of adult 
respiratory failure” 
This translates to the BPMN diagram shown in figures 4.4 and 4.5. In figure 4.4, an 
event occurs (< 60 mmHg), auto-regulation is checked, and a treatment is applied. 
The nature of the treatment is checked in a feedback loop and the CPP level is 
checked again, depending on the optimised value, based on auto-regulatory status. 
If the CPP has returned to a “safe” level, then the treatment cycle is stopped; or 
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continues if not. Figure 4.5 shows the detail of the feedback loop between pressor 
and fluid management. 
 
Figure 4.4: BPMN diagram of the CPP monitoring process according to the BTF guidelines 
 
Figure 4.5: BPMN diagram of the detailed nature of the CPP treatment 
85 
 
4.4. Discussion 
Figures 4.1-4.5 represent a single instance of a reactive process to a trigger, which 
in each case, is a pressure-level threshold crossing. Therefore, continuous 
monitoring can be represented by repeating this individual cycle many times, 
creating a much larger process model. BPMN diagrams are usually written from left 
to right, but the choice of a looped display for these guidelines deliberately 
reflects this cyclical link between the conditional threshold values “guarding” the 
beginning and end of the process. 
Overlap from the other BTF guidelines can only be found in the guidelines referring 
to monitoring recommendations for ICP and CPP, and even here these only amount 
to stating that monitoring provides a general benefit to ICP/CPP management9. So 
there is no quantitative or structural impact on these BPMN process 
representations of the threshold guidelines. There are no contraindications in any 
of the other BTF guidelines, though the possibility exists that there may be wider 
clinical considerations that are not part of the BTF focus. 
In terms of the implementation of these models – in the datasets used to evaluate 
the work – SBP, ICP and CPP are available in the physiological data stream. 
Required corollary information such as age (SBP), CT/clinical findings (ICP), and 
ancillary monitoring, auto-regulation and pressor/water load (CPP) are available in 
the captured treatment data and clinical notes where available. All other 
contributing information is standardised into the treatment profile database 
(schema details are shown in chapter 5). This corresponds to the BPMN notion of a 
“rule engine” or the use of business rules to evaluate the steps in the process. 
Finally, the most complex of the manually extracted BPMN representations – 
cerebral perfusion pressure – was given to a domain expert for validation. As the 
                                                     
9 However, despite the lack of overlap, there were significant differences between the 3rd and 4th editions of 
the recommendations supporting ICP monitoring initiation. These do not bear directly on the work of this 
thesis but should be noted here. In particular the following two level 2b recommendations no longer meet the 
required level of evidence: 
 
“ICP should be monitored in all salvageable patients with a TBI (GCS 3-8 after resuscitation) and an abnormal 
CT scan. An abnormal CT scan of the head is one that reveals hematomas, contusions, swelling, herniation, or 
compressed basal cisterns.” 
 
“ICP monitoring is indicated in patients with severe TBI with a normal CT scan if >= 2 of the following features 
are noted at admission: age > 40 years, unilateral or bilateral motor posturing, or SBP < 90 mmHg.” 
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representations were structurally similar the feedback from this was considered 
applicable to all three. Though requiring an explanation of the notation, the 
expert confirmed that these were “reasonable” representations of the processes 
described, and that they were valid to follow in a neurological ICU context. 
However, it was suggested that as they represented a singular process they may 
lack surrounding contextual information which can be difficult to express in formal 
terms. As mentioned in the introduction to this chapter, the possibility of using an 
ontology to provide this context may be an avenue to explore in future work. 
From this work we now have three guidelines expressed in a common and 
comparable process model representation and can now construct a similar 
representation for the actual ICU data. 
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5. Translation of ICU data to process models 
Chapter summary 
This chapter outlines the conversion of the real ICU data into an event log – a 
sequential representation of EUSIG pressure events and treatment administration 
– and subsequently into a process model, comparable to the models generated in 
the last chapter from the BTF guidelines. 
The parameters of the EUSIG pressure events are described, which are a range of 
values for threshold and event/clear hold-down. The algorithm to extract this 
pattern from the physiological data is then described, along with the assumptions 
made in terms of associating treatment administration to events detected in the 
physiological output, and the association algorithm. 
The generation of process models from the event log is then described, along with 
the standardised database format that the event log is stored in, and also the 
BPMN template representation of the generated process model. Finally, a 
discussion of the attempts to generate the process model automatically, using a 
technique called “process mining”, is outlined, along with the advantages and 
disadvantages of manual versus automatic approaches, and why the manual one 
was finally settled upon. 
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5.1. Conversion of ICU data to event log 
To convert the ICU data into an event log, the word “event” is used to describe 
two separate entities and therefore requires clarification:  
 A pressure event – as defined by EUSIG (Jones et al., 1994) (see also section 
2.4) – is a pattern within time-varying physiological data, well established in 
clinical literature. Throughout the rest of this work this will be referred to 
as a “EUSIG-event”.  
 An event that constitutes the basic unit of an event log used to create a 
process model, is an object of higher order abstraction which consists of a 
“EUSIG-event” and an associated treatment annotation. 
5.1.1. EUSIG-event detection 
In order to detect EUSIG-events in time-varying physiological data, the following 
key structural characteristics are required: 
 
 Threshold – indicating when a EUSIG-event has started or finished by the 
physiological values crossing this value in one direction or the other 
 Hold-down – the minimum time for which consecutive physiological readings 
have remained above the threshold, indicating that a EUSIG-event has 
unambiguously occurred (i.e. confirmation of the EUSIG-event start) 
 Clear hold-down – the time for which consecutive physiological readings 
have remained below the threshold, indicating that a EUSIG-event has 
unambiguously finished (i.e. confirmation of the EUSIG-event end) 
 Duration – the length of time from the start of the hold-down to the start of 
the clear hold-down 
 Value range – the individual physiological readings during the EUSIG-event 
(sampled for this work at a rate of minute-by-minute) 
 
Therefore, the values input to a EUSIG-event pattern include the threshold 
crossing value, the direction of crossing, and the time definition of the event/clear 
hold-down. Table 5.1 shows the values that can be input for threshold, direction 
and hold-down, which will extract different overall pattern structures from the 
physiological data. 
89 
 
 
Parameter Threshold values 
(mmHg) 
Direction of 
threshold-
crossing 
Event/Clear Hold-Down 
(mins) 
ICP 15, 20, 25, 30, 35 Up 5, 10, 15, 20 
CPP 50, 60, 70 Down 5, 10, 15, 20 
SBP 90, 100, 110 Down 5, 10, 15, 20 
Table 5.1: list of physiological EUSIG parameters 
Figure 5.1 shows a schematic of a single physiological EUSIG-event, with a time-
window for treatment overlaid (the significance and use of time windows for 
association are discussed in sections 5.1.3 and 5.1.4.). A threshold is crossed and 
remains high for a specific period (the hold-down) indicating that a EUSIG-event 
has started. The clear hold-down indicates that the EUSIG-event has finished. Also 
shown are a treatment at a specific time-point and a time window overlaid for 
association of that treatment with the event. 
 
 
Figure 5.1: EUSIG-event definition for a given time-varying physiological data stream 
To borrow language commonly used in data science, this EUSIG-event pattern can 
be thought of as a complex “object” with various attributes. In the context of TBI, 
the structural details of this defined “object” are unlikely to change, as this is a 
generally accepted definition of a pressure event (Jones et al., 1994), (Donald et 
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al., 2012). This makes it a re-usable pattern, ideal for searching physiological 
time-series data. 
In terms of the variable values – intracranial pressure (ICP), cerebral perfusion 
pressure (CPP), and systolic blood pressure (SBP) – the optimum values 
recommended by the BTF guidelines of 22 mmHg (ICP), 60 mmHg (CPP), and 110 
mmHg (SBP), are supported by clinical literature. For instance, in studies outside 
those directly supporting the BTF threshold guidelines (e.g. class 2 studies (Berry 
et al., 2012), (Sorrentino et al., 2012), (Allen et al., 2014) for SBP, ICP and CPP 
respectively), the lowest grades of events listed in (Jones et al., 1994) are 20 
mmHg (ICP), 60 mmHg (CPP), and 90 mmHg (SBP). Similarly, in (Lazaridis et al., 
2014), a study is conducted into individualised ICP levels based on PRx (the 
pressure-reactivity index) and quotes the traditionally recommended levels of 
ideal ICP as 20-25 mmHg. 
With these key pieces of structural and numerical information about EUSIG-event 
definition in place, the program can be built that detects this pattern within the 
data-set and compiles the event log required to generate a process model. The 
algorithm driving the event detection is now described in section 5.1.2. 
5.1.2. Event-detection algorithm 
To detect the pattern described in section 5.1.1 from a physiological data stream, 
the following procedure is used. 
Step 1 – Create the list of parameter definitions in program memory ahead of 
processing the event-detection algorithm. A parameter in this context represents a 
physiological data stream – or a physical measurement of the patient’s brain (e.g. 
ICP). A representative parameter object is shown in figure 5.2. 
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Figure 5.2: ICU parameter object with event definition values 
Step 2 – Query the patient database for information10  
 For each patient, the data is read into an “n x n vector of vectors” (i.e. 
a matrix) 
 Each line in the “n x n vector of vectors” is a time-point (as the sampling 
rate is minute by minute, therefore each line increments by a minute) 
and each column is a particular parameter feed (see figure 5.3) 
 The header line is used to identify the column index for the parameter 
that is of particular interest (e.g. ICPm, CPP) 
 
Figure 5.3: example of one-line-per-timestamp structure (minute-by-minute sampling) 
Step 3 – For each parameter in the list, the event-detection algorithm detailed in 
figure 5.4 is executed. The algorithm uses the inputs from the patient parameter 
feeds, and for each definition of numerical variable (table 5.1) checks for event 
start (loop 2.4) or event clear (loop 2.3) to build the corresponding structure. 
Using this algorithm, the event structure can be extracted for all presented EUSIG-
event definitions. 
                                                     
10 Each line is processed in memory individually then written to persistent storage to make efficient use of 
memory heap space 
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Figure 5.4: the event detection algorithm, rendered in style recommended by (Zobel, 2014) 
5.1.3. Association of treatments with events 
Once the EUSIG-event pattern has been extracted from the physiological data, the 
next task is the association of treatment information with the EUSIG-events to 
create the event log. As described in section 2.4, features common to nearly all 
modern high-resolution ICU data-sets include the annotation of treatments 
administered to a patient during their stay in intensive care, for example a nurse 
administering analgesics to provide pain relief, or a ventilator machine being 
attached to a patient to allow steady assistance of breathing. 
Again, drawing on data science terminology, the structure of a treatment object 
varies depending on the nature of the treatment and can be simple or complex 
(see figure 5.5). In its simplest form a treatment would be represented by a 
timestamp, and a dosage of a certain amount of drug. A more complex 
representation would be, for instance, the attachment of the ventilator, which has 
start and end points, duration, and a range of values depending on the breathing 
assistance given. Other features could also be added to these lists (also increasing 
the complexity of the object structure). 
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Figure 5.5: schematic example of three treatment types – simple, complex, and time-varying 
Association between an event and an action can be calculated in many ways and to 
unambiguously establish causal association requires a lot of contextual 
information. Highly-targeted specification of the data-set would be the ideal 
method (e.g. a clinician directly highlighting for which event they are 
administering the treatment) but it is often the case that such specification is not 
available (Enblad et al., 2004). Therefore, any method that tries to establish this 
association can only do so to a limited degree of certainty. 
In the context of this thesis, the association being discussed is indeed causal (a 
treatment was applied in response to a particular event). If the treatment data is 
well annotated with contextual information, then a parameter target will have 
been explicitly noted. However, not all treatments will have annotations like this, 
and in any case, an independence of the treatment from the physiological events – 
at least in the mind of the clinician noting the treatment – does help achieve a 
truly independent representation of clinical management. 
Therefore, to account for these issues, the following assumptions have been made 
when it comes to treatment association with physiological events: 
 If multiple treatments fall within an event time window, then – subject to 
explicit contradictory information in all the multiple annotations – the first 
treatment is associated. 
 If multiple events of the same type occur in a short period, the associated 
time windows are conflated to one covering the full period (from the start 
of the first event to end of the time window after the last event) 
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 The treatment information has been reduced to the simplest point-like 
structure possible, consisting of: a timestamp, a value and a label. Where 
the treatments have more complex structures, the treatment information 
has been deconstructed to use the start and end points as the individual 
timestamps (as this state-change is the most significant part of the 
treatment). The start point is the information used for noting that an 
treatment annotation has occurred. 
These assumptions do add uncertainty to the process which is addressed in the 
discussion of this thesis (chapter 11). In the aggregate output of the Brain-IT 
dataset (section 9.4) the investigation of different values of thresholds sizes also 
attempts to mitigate this uncertainty by looking at the different range options. 
With these considerations in mind, the event detection algorithm is run against the 
physiological dataset and for each event detected, several time-windows differing 
in length (30, 60, 90 and 120 minutes) are overlaid, to identify associated 
treatments. 
5.1.4. Event/treatment association algorithm 
This association is implemented as follows: for each patient an “association 
object” is instantiated, shown in figure 5.6. It contains centre and patient 
identifiers, a list of EUSIG-events and treatment values (e.g. sedation), and a list 
of associated treatment times and association number counts. 
 
Figure 5.6: a patient association object 
To associate the events and treatments for each patient, all treatment information 
is retrieved, then for each parameter (defined in step (1) of event detection), 
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each hold-down definition, and each time-window definition, the association 
algorithm shown in figure 5.7 is run. 
 
Figure 5.7:  the treatment association algorithm, rendered in style recommended by (Zobel, 2014) 
Using this algorithm, treatment annotations are associated with the detected 
EUSIG-events, which are used in combination to create the event log, ready for 
process model generation. 
5.2. Process model creation from event log 
The output from the creation of the event log is the association of EUSIG-events 
with treatment information from TBI datasets. This data is then represented in a 
standardised format, so that future TBI datasets can be processed and compared in 
a similar way. Currently this standardised format is implemented in a MySQL 
database (known as the “treatment profile” database), and the entity-relationship 
diagram (the description of the database schema) is shown in figure 5.8. As noted 
in section 4.4, this corresponds to the BPMN notion of an “engine” database. 
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Figure 5.8: E-R diagram of the standardised “treatment profile” database. Strong key relations 
(where both entities can exist in their own right) between tables are denoted by an unbroken 
connecting line, with the foreign key in the table with the “tripod” arrow end. The single weak 
key relation (where one entity depends on the existence of another) is denoted by an broken line. 
As discussed in section 5.1, when considering the definition of an “event” whilst 
developing the process model, the event log actually encompasses both the EUSIG-
events and the application of treatments. This is the only abstraction that is made 
when constructing the standardised “treatment profile” database schema11. 
From this standardised format, it is now possible to create a process model that 
reflects what has occurred in the ICU. The general BPMN representation of this is 
shown in figure 5.9. This is the actual process model representing what has 
occurred in the ICU (c.f. the ideal process model, figures 4.2-4.5 in chapter 4, 
which represent what would occur if the guidelines were strictly adhered to). The 
main point of comparison between actual and ideal is the presence and nature of 
                                                     
11 Again, by making this abstraction, theoretically some information may be lost if the raw data fails to follow 
this structural definition of an event. However, dramatic differences in this structure are unlikely to be 
encountered. The most unusual difference found in the clinical literature was (Lazaridis et al., 2014), which 
used PRx values to calculate the optimum threshold-crossing value for ICP, and this still respected the basic 
structural definition of a EUSIG event. 
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the “clinical management reaction” activity (the dashed line representation in 
figure 5.9, which is added for clarity, and is not strict BPMN), though other 
attributes such as the time taken or single/repeat nature, also contribute to the 
comparison. Similar to the BPMN representations in the last chapter, the full 
process is constructed by concatenating each event represented together (similar 
to the “continuous monitoring” analogy, also in chapter 4). 
 
Figure 5.9: generic process model of reaction to a pressure event 
Whilst figure 5.9 shows a manually generated process model, another method of 
generating a process model is to do so automatically ("process mining"). For this 
thesis, this approach was initially attempted, and the output is detailed in 
Appendix D.  
In brief, repeated attempts to create process models automatically were highly 
susceptible to "noise" and produced output which bore no resemblance to real-
world processes within an ICU. During the development of the automated method, 
there were several steps of manual arbitration to modify the output which, when 
pursuing a realistic model, were occurring so frequently that a fully manual 
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generation was eventually considered acceptable. These arbitration points 
included the choice of miner program (e.g. the “simple heuristic miner”), the 
choice of algorithm (“alpha”), and the data range (e.g. selection and deselection 
of activity tags). 
When considering the impact of generating a process model manually versus one 
generated automatically, the following points for and against each approach were 
identified: 
 A manually generated process model is subject to similar assumptions and 
biases that would be present in the BTF guideline models (“ideal”) 
generated in chapter 4. Errors surrounding both these generation processes 
may therefore multiply. 
 An automatically generated process model was noisy and had relatively 
unrealistic output (i.e. diverged from the known real-world processes to an 
unrepresentative degree). Also, although subjective bias is less in 
automatically generated models, it is not removed completely, and often 
enters the calculation through the arbitration points mentioned above. 
With these arguments in mind, the construction of manually generated process 
models was considered a viable option and the work continued along this path. 
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6. Calculating distance and similarity of process models 
Chapter summary 
The two process models that have been derived in chapter 4 (the ideal guideline-
mandated process) and chapter 5 (the actual process that occurred in the ICU) – 
have been expressed in a common model notation (BPMN). This chapter now 
describes the calculation of a distance between those two models, which involves 
the evaluation of scalar and structural distances. 
The process model comparison work that this thesis references (Dijkman, Dumas 
and García-Bañuelos, 2009) is briefly discussed with emphasis on the comparison 
between a “pure” process model and an execution trace. 
The detailed method on how this comparison is applied in this thesis is then 
outlined, showing how the two process models (actual vs ideal) are evaluated on a 
minute-by-minute basis. The quantitative distances and weightings are then 
tabulated along with the qualitative reasons for non-adherence.  
Finally, a worked example is shown for illustration along with a brief discussion of 
the presentation of results: minute-by-minute windowing, interquartile range 
tables, and a grid providing a summary-measure estimate of the clinical severity 
as a result of the non-adherence. 
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As mentioned in chapter 3 (section 3.5), highly relevant research that looks 
explicitly at a calculation of distance between two process models, can be found in 
(Dijkman, Dumas and García-Bañuelos, 2009). Dijkman’s work proposes a method 
of comparing process models by converting the BPMN representation to a directed 
graph – a minor modification to a set of nodes (points on the model) and 
directional edges (connectors between those points) – then searching through a 
repository of process models and calculating a distance between each of those. 
The calculation itself is composed of three conversion steps: node label 
replacement (referred to as “string-edit similarity”), distance between two nodes 
(“graph-edit distance”), and a weighted description of that distance (“graph-edit 
similarity”). 
Other methods of calculating distances between complex, multi-dimensional 
objects exist. For the work of this thesis, two methods of comparison were 
considered: graph-based and document-based. These were chosen due to the 
process-oriented nature of guidelines and their communication in text documents. 
The latter of these methods primarily involves comparison of label strings with 
concepts such as a “bag of words”, where a distance between two texts is 
calculated based on the overall similarity of all the words in a document (similar in 
function to Google’s PageRank algorithm) (Xing and Ghorbani, 2004). Initially, this 
was considered the most appropriate technique, as the BTF guidelines were 
themselves text documents. However, a graph comparison approach was 
eventually settled on as the real ICU data processes had a flow-control structure, 
which could also be derived from the text of the BTF guidelines. This was 
considered to capture the processes more accurately that a document-based 
approach, and of the literature surveyed, the work by Dijkman appeared to be the 
most relevant. 
The final conversion step in (Dijkman, Dumas and García-Bañuelos, 2009) – the 
“graph-edit distance” – is a complex calculation, known as an “NP complete” 
problem as there are a vast (potentially infinite) number of distance solutions to 
find. Several algorithms to do these calculations were assessed within (Dijkman, 
Dumas and García-Bañuelos, 2009), each with different characteristics that trade-
off between completeness and efficiency: these are the “Greedy”, ”A-star”, 
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”Process heuristic”, and “Exhaustive” algorithms. Focusing on the algorithm’s 
performance in their paper, the conclusion was that the “Greedy” algorithm 
(searching for local optima) and “A-star” (a well-known shortest-distance 
algorithm) were the best performing in terms of speed versus acceptable 
completeness (“A-star” being slightly slower but more accurate). These algorithms 
do not play a significant role in the work of this thesis, as a relatively “simple” 
exhaustive algorithm was sufficient due to the constraints imposed by the problem 
addressed, such as the clear identification of start/end points in the EUSIG events, 
and the well-defined structure of the nodes being compared. However, a valid and 
likely avenue of future work would be to apply these algorithms to the problem 
space in this thesis for further efficiency gains, or to allow the expansion of the 
available categories to better reflect the detail of a neurological ICU. Therefore, 
the details of these algorithms are listed in Appendix E. 
To re-state for the work of this thesis: one process model – drawn from the BTF 
guideline – represents what the ideal clinical response would have been given the 
context of events, the patient situation, etc. The other process model is generated 
for the actual timeline from the treatment profiles database, which is a model 
representing what actually happened in the ICU for the same patient context. 
Therefore, an important point that should be emphasized is that the former is a 
“model”, in the purest sense of the word, whilst the latter is an execution trace – 
an “instantiation” of the process model using exact numerical input reported from 
the immediate situation12. In process model theory, it is considered acceptable to 
make interchangeable comparisons between these entities – a short discussion on 
this is available in (van der Aalst, de Medeiros and Weijters, 2006), describing the 
different levels of comparison available given local execution circumstances to a 
particular model. 
In summary, the distance between the actual and ideal processes is calculated 
using the main components of the conversion work established by Dijkman. The 
rest of this chapter now describes the detailed method for this implementation. 
                                                     
12 A useful analogy to consider for this concept is that the process model can be thought of as written code, 
whilst the execution trace can be thought of as the execution of that written code. 
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6.1. Process models for comparison 
The BPMN representations of both the guideline and the output from the ICU data 
have been constructed in chapter 4 (e.g. figures 4.4 and 4.5 for the CPP guideline) 
and chapter 5 (figure 5.9). To illustrate this more clearly, a time-varying 
comparison between the two has been drawn in figure 6.1, showing an 
“unwrapped” (left-to-right, rather than in a loop) version of the BPMN model and 
their points of comparison.  
When an event is triggered, for each minute of that event, a distance is calculated 
between the guideline process model (top) and the current state of the ICU output 
(bottom). This single evaluation is what is shown in figure 6.1. 
If a reaction is required by the guideline model (e.g. to administer hypertonic 
saline) and that reaction is not found in the ICU model at that time-point, then the 
distance between the two models will be greater than if it was found. The distance 
would also vary according to differing types of reactions. For instance, if 
hypertonic saline were required but vasopressors was found, the distance would be 
non-zero, but less than the maximum possible. If the reaction found is exactly the 
same as that required by the guideline, then the distance for that component 
would be zero. 
This evaluation occurs each minute that the event continues (figure 6.2) and 
therefore produces a distance number for each minute of that event. In this 
model, the greatest distance occurs if there is a mis-match between clinical 
management reactions. But smaller distances can also occur if there is a difference 
in the nature of the reaction (e.g. dosage) or the time taken to treatment. The 
size of these differences relative to each other is controlled by the assigned 
weightings (discussed in section 6.2). 
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Figure 6.1: Like-for-like comparison of the ideal and actual process models 
 
Figure 6.2: Implementation of the process model comparison conducted each minute 
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6.2. Quantitative and qualitative comparison detail 
Returning to the underlying theory, the three steps to calculate a distance 
between process models, are defined in Dijkman’s work as follows: 
 String-edit similarity – this is the direct similarity between two labelled 
nodes on the model. The primary attribute of a node is its label, and 
Dijkman approaches this with a view on the similarity of the literal strings 
themselves. In this situation however, the labels follow the assigned values 
relevant to the domain (in this case, an example is the categorisation of TBI 
treatments). A full list of the accepted node values is shown in table 6.1. 
 
 Graph distance – this is the number of steps that must be taken for one 
process model to become the equivalent of the other (including node 
substitutions, or string-edit similarity calculations). The steps involved can 
either be substitutions, insertions or deletions of either nodes or edges of 
the process model. 
 
 Graph-edit similarity – the final similarity calculation is produced by adding 
weighting “costs” to the steps achieved in the graph distance calculation. 
These weightings are outlined in table 6.2. 
The formal definition of node and edge substitutions in mathematical terms 
(according to Dijkman) is shown in figure 6.3. 
 
Figure 6.3: Mathematical expression of the weightings used in the graph-edit similarity calculation 
(Dijkman, Dumas and García-Bañuelos, 2009) 
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 wsubn – this co-efficient describes the weighting attached to the 
substitution of a node 
 wskipn – this co-efficient describes the weighting attached to the 
insertion/deletion of a node 
 wskipe – this co-efficient describes the weighting attached to the 
insertion/deletion of an edge 
 fsubn – the formula shown in figure 6.3 shows the graph-edit distance (itself 
made up of the string-edit distance (1.0 – Sim(n,m)) divided by the set of all 
nodes that have undergone substitution 
Table 6.1 outlines the possibilities for the labels in the nodes that make up the 
comparison (figure 6.1), represented as substitutions of the node. The options are 
categorical apart from the time taken, which is measured as continuous, but 
assigned to the node as a categorical full-minute number. 
Node Label options 
Treatment type Ventilation, Sedation, Analgesia, 
Paralysis, Volume expansion, Inotropes, 
Anti-hypertensives, Anti-pyretics, 
Hypothermia, Steroids, Cerebral 
vasoconstriction, Osmotic therapy, CSF 
drainage, Head elevation, Barbiturates, 
Other 
Nature of treatment Single, repeat 
Time taken Time between event and treatment 
Table 6.1: Node label possibilities for the different nodes in each process model 
The most likely structural change in the comparison of actual against ideal 
processes involves the treatment itself (the node labelled as “clinical management 
reaction” in figure 6.1). Therefore, the algorithm for calculating the structural 
difference between models is: 
 A node is deleted, which means that a corresponding edge is deleted as well 
 If the node is the “clinical management reaction” (i.e. a central node in the 
process): 
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o This deletes the entire group of nodes and associated edges (a major 
difference between the models) 
 Else (the node is peripheral in the process): 
o The node has either the “nature” or “time taken” label 
o The detailed specification of the structure is reduced (which is a 
relatively minor difference between the models) 
Considering the relative importance of the “clinical management reaction” node, 
and connecting edges, versus the other node types, table 6.2 outlines the 
weighting costs of each of the steps involved when comparing one model against 
the other (again with reference to figure 6.1).  
These weightings have been assigned as a measure of how important each 
difference is, relative to each other. For instance, the assignment of 0.99 to the 
central node being deleted, indicates this is the most important difference in the 
list (arrived at by adding the base cost of deleting a node, 0.75, and the node 
being central, which is 0.24). Correspondingly the lowest importance (“nature”) is 
assigned 0.25 as it is a relatively minor difference. These weightings have been 
chosen in attempt to model the importance of the different nodes as accurately as 
possible but require further calibration and consensus from clinical domain 
experts. 
Conversion step Normalised weighting (0 – 1) Variable 
Nature label switched 0.25 wsubn 
Time taken label switched 0.5 wsubn 
Treatment type label 
switched 
0.5 wsubn 
Node deleted (base cost) 0.75 wskipn (base) 
Edge deleted (base cost) 0.6 wskipe 
Deleted node is central 0.24 wskipn (additional) 
Deleted node is peripheral 0.08 wskipn (additional) 
Table 6.2: Weighting values of each step involved, when converting from one model to the other 
The calculations in figure 6.3 and the assigned weighting values from table 6.2 
provide quantitative information about guideline non-adherence. However, for 
multi-dimensional and interacting structures such as a guideline process, it is 
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important that the qualitative information supporting that numerical output is 
retained as well. For node deletion it is noted that there is a base and additional 
cost of deletion (so wskipn is repeated), the additional cost depending on whether 
the node deleted is central or peripheral. 
The qualitative reasons for non-adherence to a guideline are constructed by 
recording the individual steps taken to get from one model to the other. As the 
distance between one model and another is the shortest series of steps to convert 
one into the other (the “graph edit distance”), it follows that each documented 
step is being taken for “a reason”. The final (compound) list of these reasons 
provides the trace of qualitative information. In this way maximum information is 
retained throughout the evaluation of guideline adherence. Table 6.3 shows the 
one-to-one mapping of the qualitative reason for each step taken, when converting 
one model into another. 
Conversion step Qualitative reason for guideline deviation 
Nature label switched “Nature of treatment is different” 
Time taken label switched “Time taken to administer treatment is outside 
window” 
Treatment type label 
switched 
“Type of treatment is different” 
Node deleted “A component is missing: ” [component specified 
below] 
Edge deleted “A component is missing: ” [component specified 
below] 
Deleted node is central “Treatment” 
Deleted node is peripheral “Nature/Time taken” 
Table 6.3: Qualitative reasons for guideline deviation 
6.3. Worked example 
To give some practical context to the theory discussed in section 6.2, the following 
worked example demonstrates the calculation of guideline adherence. Figure 6.4 
shows the minute-by-minute output for the worked example described in this 
section. 
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Figure 6.4: Minute-by-minute output of guideline adherence of a single CPP EUSIG-event 
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6.3.1. Calculation template 
The following situation in an ICU provides the context: in response to a CPP event, 
a clinician has administered three doses of steroids within close proximity to each 
other and within 15 minutes of the event start. The guideline only recommends 
two doses within that time-frame. 
Therefore, the inputs to this calculation are:  
 A single CPP EUSIG event (< 50 mmHg) starting at 2004-05-28 05:17 
 Three steroid therapy treatments at 2004-05-28 05:22, 2004-05-28 05:24 
and 2004-05-28 05:26 (all within a 15-minute time-window since the 
EUSIG-event start). 
The anticipated outputs are: 
 The guideline adherence information will be composed of the following 
factors: 
o The incorrect type of treatment administered after a high-load of 
that treatment has been established (in this case the third instance of 
“steroid therapy”). 
o Time taken from the EUSIG-event start to treatment administration. 
o Default high non-adherence level once the time-window has expired 
and a further treatment has not been administered. 
For each time-point within the time-window, the calculation includes a 
measurement of distance for the five points of the model (with reference to figure 
6.1). Table 6.4 shows a template of how the distance weightings for this particular 
case are calculated. The five factors add together to create 100% of the single 
distance score (non-adherence), so the value of each contributes 20% of the overall 
score. The practical difference between guideline (ideal) and ICU (actual) is 
described in parentheses in the second column. Note that Type refers to the 
difference between actual administration and ideal, whereas Nature refers to any 
dose of a given drug. 
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Node Similarity weightings 
Event start 0.0 (no difference) 
Type 0.5 (load of treatment type is high) 
Time taken Time to treatment for each dose 
Nature 0.25 * number of doses over (+1) 
Check level 0.0 (no difference) 
Table 6.4: Template of values for each non-adherence instance 
6.3.2. Calculation instances 
In this calculation, the output shows four instances of non-adherence within the 
time-window 11.4%, 16%, 18.6% and a large distance of 36.2%13 outside it (figure 
6.4). 
The distance for the large “default” instance (36.2%) is calculated using the graph-
edit similarity formula as this is a comparison between two structurally different 
process models. Table 6.5 shows the contribution of each node to the overall 
guideline non-adherence distance. 
Node Similarity weightings (37.8% instance) 
Event start 0.0 
Type 0.56 
Time taken 0.54 
Nature 0.79 
Check level 0.0 
Table 6.5: Component contributions of each factor for the 37.8% instance 
These are arrived at using the weightings listed in table 6.2 and the following 
additional variable assignments: 
 fsubn = 1.0 (this is the substitution weighting, which in this case is a 
normalised value of 1.0 as it is at maximum with the missing node) 
 fskipn = fskipe = 0.6 (for Type – fraction of all nodes substituted = 3/5) 
 fskipn = fskipe = 0.2 (for Nature/Time taken – fraction of all nodes 
substituted = 1/5) 
                                                     
13 There is an issue with this figure, discovered post-submission, that leads it to be calculated as 37.8% 
(previously thought to be 36.2%). See Appendix F.3 for an explanation. Wherever the 36.2% figure is 
encountered with regard to the “default” distance, read 37.8%. 
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Using the similarity mapping shown in figure 6.3, the distance is calculated as 
follows: 
 ((wskipn * fskipn) + (wskipe * fskipe) + (wsubn * fsubn)) / (wskipn + wskipe + 
wsubn) 
Therefore, the similarity value of the “Type” component is (rounded to 2 decimal 
places): 
 ((0.6 * 0.99) + (0.6 * 0.6) + (0.5 * 1.0) / (0.99 + 0.6 + 1.0)) = 0.56 
The similarity values of the “Nature” component is: 
 ((0.2 * 0.83) + (0.2 * 0.6) + (0.25 * 1.0)) / (0.83 + 0.6 + 1.0)) = 0.54 
The similarity values of the “Time taken” component is: 
 ((0.2 * 0.83) + (0.2 * 0.6) + (0.5 * 1.0)) / (0.83 + 0.6 + 1.0)) = 0.79 
Add these five factors together to get the full contribution (normalised as a 
percentage): 
 ((0.0 + 0.56 + 0.54 + 0.79 + 0.0) / 5.0) = 0.378 = 37.8% 
For the distances within the time-window, the calculation follows the string-edit 
formula as the calculation between the two process models is structurally similar. 
Table 6.6 shows the contributing values. 
Node Similarity weightings (instances) 
16% 18.6% 11.4% 
Event start 0.0 0.0 0.0 
Type 0.5 0.5 0.0 
Time taken 0.3 0.43 0.56 
Nature 0.0 0.0 0.0 
Check level 0.0 0.0 0.0 
Table 6.6: Component contributions of each factor for the instances within the time-window (16%, 
18.6%, 11.4%) 
With the string-edit distance, the five factors are simply added up and normalised 
to a percentage, so the calculations and results are: 
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 ((0.5 + 0.3) / 5.0) * 100 = 16% 
 ((0.5 + 0.43) / 5.0) * 100 = 18.6% 
 ((0.56) / 5.0) * 100 = 11.4% 
6.3.3. Presentation 
Using these distance calculations, the final quantitative and qualitative 
expressions of guideline adherence are generated. The basic units of adherence 
are two – potentially interdependent – categories: degree of non-adherence 
(expressed as a percentage) and the duration of these levels of non-adherence (in 
minutes). The adherence levels detailed at each minute time-point of a patient’s 
stay are compiled into a set of contiguous “instances” of non-adherence. The blue 
line indicates the CPP level, whilst the red line indicates the corresponding level of 
guideline adherence. 
All non-adherence information for each patient can be viewed in the application 
referenced in the “Additional Resources” page at the front of this thesis. This 
particular (test) patient can be viewed by inputting the summary details shown in 
figure 6.5. 
 
Figure 6.5: Summary input information for the worked example 
Briefly, a more detailed description of the “default” distance, calculated at the 
beginning of this section, is merited here. This has been labelled as “default” due 
to its overwhelming prevalence in the datasets tested, and it being the value that 
the distance metric “defaults” to when the most common situation occurs: 
namely, when a treatment should have been administered in the time-window 
following an event (but hasn’t). The value is output at 36.2% in the cases reported, 
due to the choice of quantitative weightings (table 6.2). An intuitive assumption is 
that this case should have a distance score of 100%. However due to the fact that 
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the five components (figure 6.1) are evaluated semi-independently, each 
contributing 20% to the overall distance, and following the weightings applied, the 
common output – as worked through in this section – is 36.2%. Possible future work 
would be to calibrate this figure to have a more meaningful clinical analogue. The 
concept of this default distance is returned to in chapters 8, 9 and 10, in particular 
in section 9.3.2. 
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7. Framework implementation 
Chapter summary 
This chapter presents the implemented solution to the framework proposed in the 
thesis. The high-level design is introduced with a step-by-step description of each 
component, along with references back to the original hypotheses. 
The datasets to be used to evaluate the technology are then described including: 
Brain-IT (specialist neurological ICU data), MIMIC III (non-specialist ICU data), and 
ICCA (ICU data available from bedside machines, and accessible to a domain 
expert). 
The hardware and software implementations are described, with a brief 
description of the main code features implementing the key methods from 
chapters 4 to 6. 
The final section describes the presentation of the application. It is a web-
enabled system that provides adherence information on individual patients in a 
dataset, including minute-to-minute guideline adherence for a single patient stay, 
total duration and distance of non-adherence, and interquartile range spread to 
understand the significance of the different non-adherence instances. A novel 
method of presenting clinical severity of the combined output of guideline non-
adherence and duration using risk analysis charts is also described. 
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The overall goal of this framework is to represent both the BTF guidelines and the 
real ICU data as process models, then compare the distance between the two. 
Figure 7.1 shows a high-level schematic of the steps required to achieve this, 
reflecting the methodology outlined in chapters 4 to 6 (repeated from figure 1.1). 
 
Figure 7.1: Simple schematic of the architectural process underpinning the proposed research 
The steps involved in comparing two sets of process models in this context, are 
numbered in figure 7.1 and represent the following: 
1) Create an event log from the raw ICU data, using EUSIG event definitions 
2) Create a process model representation of the ICU data from that event log 
3) Create a process model representation of the BTF guidelines from their text 
4) Compare the two process models and evaluate how similar they are 
Recalling the hypotheses formulated for this thesis: 
1) In high-resolution time-series clinical data, one can extract clinically-valid 
treatment processes for ICP/CPP management in TBI patients 
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2) Having extracted treatment processes, one is able to develop a method to 
compare those against other treatment processes to establish the degree of 
similarity between them 
3) One can develop a computerised tool that readily quantifies and displays to 
clinical staff a metric of actual ICP/CPP management protocol adherence 
Steps 1 and 2 in figure 7.1 are directly related to the first hypothesis of this 
research work: a process model and event log generated from the raw data 
encapsulates a treatment process for ICP/CPP management. 
Step 4 in figure 7.1 relates to the second hypothesis: a comparison between 
treatment processes is performed between the process models generated from the 
raw ICU data and the BTF guidelines. Step 3 acts as an intermediate step for the 
second hypothesis: the process model is generated from the guidelines in order to 
perform the comparison. 
The third hypothesis is realised by the full implementation of the framework as a 
web-enabled application.  
7.1. Application to ICU datasets 
To apply the system to real TBI data, the following datasets have been sourced and 
have guided the development of this research: 
 Brain-IT (Piper et al., 2010) 
 MIMIC III (Saeed, 2007) 
 Philips ICCA (ICCA, 2018) 
These three datasets have been chosen as they represent common formats for the 
storage and processing of ICU data in a clinical and research setting. Brain-IT is a 
consortium that has developed a data schema specifically for the collection of TBI 
data, with a particular focus on the management of ICP/CPP. MIMIC III is a large-
scale repository of end-hour averaged data, chosen for its general focus on non-
specialist ICU data. The Philips ICCA system is a bedside data collection system 
that is used by many neurological ICUs in the developed world. 
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7.1.1. Specialist neurological ICU dataset (Brain-IT) 
The Brain-IT dataset is a collection of 262 TBI patients with clinical information 
collected from 22 specialist neurological ICUs across Europe. The data consists of 
physiological, treatment, lab results, surgeries, and other important clinical 
events, and was collected using a variety of technologies available at the time 
(2002 to 2007) such as interfacing with bedside monitoring machines to collect 
physiological data and using PDA Palm Pilots to collect treatment annotations. 
This dataset has been used as the primary one for implementation, due to its 
comprehensiveness, coverage and availability. The consortium focus on ICP/CPP 
management facilitates the identification of targeted treatments, but also 
represents a potential bias in treatment focus that must be considered when 
evaluating the final output. 
7.1.2. Non-specialist ICU dataset (MIMIC III) 
To provide a counterpoint to the specialist focus of the Brain-IT dataset, the MIMIC 
III dataset has been chosen specifically because its primary collection purpose is 
not TBI or ICP/CPP management. This allows the generality of the system to be 
evaluated and whether it can be transferred from one context to another using 
similar, but different, data structures.  
The MIMIC III dataset is a comprehensive collection of ICU data collected from 
wards across the United States from 2001 to 2012, with over 38,000 patient 
records. A sub-set of these patients are TBI and SAH (Sub-Arachnoid Haemorrhage) 
patients, which make them ideal candidates to standardise the output and run the 
guideline framework against. The structure is end-hour averaged physiological 
data, and the treatment data has a large coverage of the possible permutations of 
annotation labels strings (e.g. “CSF”, “cerebrospinal fluid”, “CS fluid”, etc). The 
challenge with this end-hour structure is viewing the output at a resolution that 
will give sufficient information to be useful in a clinical setting. 
7.1.3. ICU data collection system (ICCA) 
A set of annotated patient records were extracted from the Philips ICCA 
(IntelliSpace Critical Care and Anaesthesia) system. The intention of using this 
dataset was to make use of state-of-the-art ICU technology, in common use in 
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modern neurological ICUs. The physiological data structure is millisecond wave-
form, down-sampled to minute-by-minute for this work, whilst the treatment data 
is primarily ventilation support and drug administration. 
An additional feature of this dataset was that it was possible to use it to evaluate 
the guideline adherence system against patient context information provided by 
domain experts. To that end, a set of physiological and treatment data was 
compiled for three TBI patients, by two domain experts at the Queen Elizabeth 
University Hospital in Glasgow, UK. They were asked to provide notes on patient 
context and a brief rationale behind the clinical management of those patients. 
Some of the patients selected had contexts that specifically (and deliberately) 
provided circumstances where following the BTF guidelines was not the ideal 
clinical option. 
7.2. Implementation 
The guideline adherence application has two main modules. The first is a 
standalone program, written in the Java programming language, that translates 
the raw ICU patient data into an event log. The two main classes in this program 
are: 
 “TreatmentAnalysis” – this interfaces with the ICU patient data format (e.g. 
MS Access, MS SQL Server) and translates that format into a standardised 
representation of physiological and treatment information 
 “EventDetection” – which, based on input EUSIG definitions, converts the 
physiological data into higher level abstraction events and stores them in 
the treatment profile database (algorithm and database details are 
described in chapter 5). 
The second module is the guideline adherence calculation program, which is also 
coded in Java and in the web-enabled version, Java Server Page (JSP). It is an n-
tier web application, connected to the standardised treatment profile database 
and indexed on the unique patient IDs of each dataset. 
There are four components of the code that merit a brief description: 
119 
 
 The process model is represented as a complex object with component 
objects of nodes and edges. These nodes and edges are collection variables 
for each process model instance, with n-1 edges where there are n nodes. 
 The evaluation of the distance between process models is represented by 
composing the ideal process model, composing the corresponding actual 
process model for that time-point, and calculating the distance between the 
two. 
 The string-edit and graph-edit calculations include the specific, non-
abstracted information relevant to each guideline, with business logic rules 
to apply that information. 
 Contextual input from the guidelines (e.g. check age for SBP, check mass 
lesion presence for ICP, check fluid/pressor load for CPP) is present in two 
places: one on the original event detection algorithm, and one within the 
individual time-point distance calculation. 
The programs are run on a virtual machine hosted by the NeCTAR (“National 
eresearch Collaboration Tools And Resources”) cloud platform at the University of 
Melbourne, running the Ubuntu 16.04 (Xenial) amd64 operating system, on a 
machine with 1 VCPU, 4Gb of memory and 30Gb of storage, and the Java Virtual 
Machine (JVM) modified to make use of all of the available memory14. 
It is noted that the event information (EUSIG-event plus treatment annotation) is 
stored as formatted (re-usable) information in the treatment profiles database. 
Higher order information used in the process model creation (e.g. auto-regulatory 
status, brain/clinical CT findings, etc) are taken directly from the individual data 
repository (e.g. Brain-IT, MIMIC III, etc). 
A web-application was chosen for ease of communication of results and to provide 
general (but gated) access to the research community. If converted to a bedside 
application, to evaluate adherence in real-time, it would be better developed as a 
standalone program, for reasons of security (less exposed threat surface to general 
Internet) and speed (programmatic access to dedicated memory with local 
                                                     
14 The “JAVA_OPTS” runtime variable is set with the flag “-Xmx4096m” 
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response speeds, rather than communication across wider networks). However, for 
a non real-time audit application, a web application would still be appropriate. 
The code is available for download and execution at the repository referenced in 
the “Additional Resources” page at the front of this thesis. 
7.3. Presentation 
The guideline adherence output is obtained through the presentation pages of the 
web-enabled application. When selecting information, several choices are 
available, such as dataset, individual patient ID, and various options relating to 
event definition (e.g. threshold level, event hold-down size, etc) and options 
relating to display (e.g. “show default instance”, “select event ID”). 
7.3.1. Worked example 
Repeating the core concepts from section 6.3, the basic units of adherence are 
two – potentially interdependent – categories: degree of non-adherence (expressed 
as a percentage) and the duration of these levels of non-adherence (in minutes). 
The adherence levels detailed at each minute time-point of a patient’s stay are 
compiled into a set of contiguous “instances” of non-adherence. The final overall 
adherence information for a single patient stay is compiled from these instances of 
non-adherence and is presented in five sections. 
7.3.1.1. Minute-by-minute output 
Figure 7.2 (repeated from figure 6.4) shows the physiological read-out of a 
particular event in a patient’s stay. The guideline adherence level is overlaid on a 
separate series, detailing the quantitative level of non-adherence and listing the 
reasons contributing to that level at each time-point. The qualitative components 
of that non-adherence level can be viewed by clicking upon the individual time-
point on the non-adherence series. 
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Figure 7.2: Minute-by-minute output of guideline adherence of a single CPP EUSIG-event 
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7.3.1.2. Instances of non-adherence 
Figure 7.3 shows the total time spent at a particular (unique) level of non-
adherence in a patient’s stay, and the reasons contributing to that level.  
 
Figure 7.3: Aggregated instances of non-adherence (for worked example in section 6.3) 
7.3.1.3. Contributing reasons of non-adherence 
The reasons listed in the previous two sections are shown in a stacked bar-chart 
(figure 7.4) to visualise the contributing weight of each. 
 
Figure 7.4: Stacked bar chart visualising the relative contributions of each reason to each instance 
level (for worked example in section 6.3) 
7.3.1.4. Representative distribution of non-adherence instances 
The Interquartile range of each adherence aspect is measured and shown in figure 
7.5. The minimum, q1, mean/median, q3 and maximum quartiles are displayed 
(along with visualised box-plot in figure 7.6) of the levels of non-adherence, the 
durations of non-adherence, and two combinatorial metrics of the level and 
duration: “A” which equals (duration / level), and “B” which equals (duration * 
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level). Note that the large “default” instance has been removed from figures 7.5 
and 7.6 to show the variation in more detail. 
 
Figure 7.5: An interquartile range of non-adherence for worked example in section 6.3, with 
default instance removed 
 
Figure 7.6: Box-plot representation of the interquartile range of the “Duration” aspect shown in 
figure 7.5 
7.3.1.5. Severity chart 
In an attempt to apply real clinical interpretation to the guideline non-adherence 
output, the factors of non-adherence level and duration must be considered in 
combination. Therefore, as mentioned in section 7.3.1.4, two metrics are defined 
to indicate this relationship: 
 Duration / Non-adherence (A) 
 Duration * Non-adherence (B) 
To represent this relationship visually, a severity chart is presented that plots both 
metrics (the mean values of the metrics for all the non-adherence instances) 
against each other (figure 7.7 for the worked example in section 6.3).  
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Figure 7.7: Mean values of the two metrics (A and B) plotted against each other in the severity 
chart 
The clinical analogue of these combinations is that if A is very high or very low, the 
severity occupies either of the two mid-range quadrants. If A tends to 1, then it is 
either in the least or most significant quadrants. To ascertain which of these latter 
quadrants the output occupies, B indicates either high (most significant) or low 
(least significant). The axes are calculated by taking the maximum and minimum 
values from the set of non-adherence instances output by this patient’s stay (the A 
metric normalised to lie between 0 and 1). The thresholds are calculated by taking 
the mid-point of the maximum absolute range of the two contributing factors – 
duration and non-adherence distance – for that patient. Refining where these 
thresholds should be placed would be follow-up work (discussed further in chapter 
11). This method of presentation has been drawn from the domains of business 
process modelling and risk analysis (Magic Quadrant, 2018) and is hoped to provide 
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a single point of useful, clinical interpretation (i.e. in one representation, how 
severe has the impact of guideline non-adherence been – high, low or mid-range) 
over the distributed output.15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                     
15 Since the viva examination of this thesis, the rationale for the severity chart has changed to supporting a 
linear scale (measuring metric B only). See Appendix F.2 for further details. 
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8. Evaluation 
Chapter summary 
This chapter details the methods and results of four evaluations, which were 
conducted to assess the performance of the framework against key clinical 
aspects. These included:  
 A performance test of the framework’s primary functions 
 An evaluation of annotation timings on typical ICU datasets 
 An evaluation of the framework with contextual domain expert information 
 An investigation into the possible relationship between the adherence 
output and patient outcome 
Framework function performance – the individual components of the BTF 
guidelines that contribute to the overall adherence output were tested in this 
section. Two tests were run to confirm the contribution of two general aspects of 
the system:  
1) Whether the association of a treatment annotation with a EUSIG-event (within 
or outside a set time-window) can provide adherence information. 
2) Whether a breach of a limit on the number of drug administrations can provide 
adherence information. 
A further three tests were run to confirm the individual aspects of each separate 
monitoring-threshold guideline: 
1) Whether the effect of age on the BPs guideline can be detected. 
2) Whether the effect of mass-lesion/diffuse injury presence on the ICP guideline 
can be detected. 
3) Whether the effect of pressor/fluid load balance on the CPP guideline can be 
detected. 
The results of all the unit tests confirmed expected guideline adherence 
information. 
Evaluation of annotation timing - a study was conducted to investigate the 
accuracy of treatment annotation timing. A set of three Traumatic Brain Injury 
127 
 
(TBI) and five Sub-Arachnoid Haemhorrage (SAH) patients with annotation 
information recorded by a live observer were compared to the corresponding 
physiological information produced for them from the local bedside ICCA system. 
The distances from the “live” annotations to the corresponding marker in the 
physiological output were recorded. 
This was repeated for a second set of patients (x3 TBI), which had treatment 
annotations produced by regular “non-live” annotations (e.g. at the end of an ICU 
ward shift). Similarly, the timing distances from the recorded annotations to the 
corresponding marker in the physiological output were recorded. 
The live annotations provided highly accurate timing information: in four 
patients, 24 events out of 32 were closely matched, with a mean distance of 3 
minutes between events and a median of 1 minute. The non-live timings had no 
events matched within the asserted time limit (15 minutes), and timing distances 
of hours when that time limit was removed. 
Evaluation with domain expert information – guideline adherence was 
calculated for three TBI patient datasets extracted from the ICCA bedside system. 
These cases were presented alongside clinical notes that outlined the different 
patient contexts. The results from the adherence information showed that Patient 
#1 indicated non-adherence from the type of drug administered, with a spike in 
non-adherence due to high dosage; patient #2 indicated high severity of guideline 
non-adherence; patient #3 indicated a low number of associated events and 
treatment annotations, resulting in a mid-range severity output. When cross-
referenced with patient context, all patients indicate required refinements of the 
framework. 
Evaluation of relationship to patient outcome – a unique feature of the Brain-IT 
dataset is the capture of 6-month GOSe score indicating patient outcome post-
injury and discharge. Using this information a logistic regression was performed 
between the guideline adherence information and the patient 6-month GOSe. No 
statistically significant relationship was found. 
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8.1. Unit testing 
This section outlines the steps taken to make sure that each aspect of the 
guideline adherence calculation performed correctly given the appropriate 
situation. Two tests were performed which evaluated two general aspects common 
to all three guidelines (treatment presence and dosage level), and a further three 
were performed to test the unique aspects of the individual guidelines (age effect 
on SBP, mass lesion/diffuse injury effect on ICP and pressor/fluid load on CPP). As 
the aim of these tests was to identify issues with the performance of the 
adherence algorithm, test patient data had been created. Section 8.3 details 
performance of the system on real-world (unedited) datasets. 
8.1.1. General tests 
Two tests were run to confirm two general features of the adherence framework. 
The two cases are the presence of a treatment annotation within the specified 
time-window, and a treatment annotation either not present or outside the time-
window. The anticipated outcome was variation due to the presence of the 
associated treatment (lower than default output) and variation due to a dosage 
considered too high (higher than surrounding context). Table 8.1 outlines the 
short-hand notation used for reporting the results: there are four possible states of 
two features (output #1 – the dosage – can either be H (high) or L (low), and output 
#2 – the presence – can either be I (in) or O (out)). Therefore, to test all use-cases, 
contexts of HI, HO, LI or LO are constructed and tested. 
Feature Notation 
Treatment dosage too high (over x2 doses) H (high) 
Treatment dosage within range L (low) 
Treatment inside time-window I (in) 
Treatment outside time-window O (out) 
Table 8.1: Notation indicating the use-case being tested 
8.1.1.1. Testing presence of annotation within and outside time-window 
For this particular evaluation, treatments were artificially added to the dataset. 
Table 8.2 shows the base-line parameters used for most of these tests (general and 
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ICP). Different events were required for the BPs and CPP unit tests, which are 
shown in tables 8.3-8.5. 
Feature Value 
Patient 15026161 
EUSIG definition ICPm with threshold of 15 mmHg 
Hold-down 5 mins 
Time-window 15 mins 
Event index 0 
Event start 01:58 on 2004-05-28 
Event end 02:55 on 2004-05-28 
Table 8.2: Base-line features used for unit tests 
Using these features, the LI case (dosage within range, treatment within time-
window) was tested as follows: 
 Add a treatment (any type) inside the time-window at 02:08 on 2004-05-28 
The result – shown in figure 8.1 – indicated a guideline adherence value of 12.6% 
until the end of the time window was reached, when the adherence level goes 
back to a default value of 36.2%. The 12.6% value came from the time taken to 
treatment, with type and nature being fully adherent in this case (and therefore 
contributing zero to the distance value). 
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Figure 8.1: Unit test #1 – a treatment annotation occurs within the 15-minute time window since 
event start 
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The LO case (dosage within range, treatment outside time-window) was tested as 
follows: 
 Add a treatment (any type) outside the time-window at 02:18 on 2004-05-
28 
The result – shown in figure 8.2 – indicated a guideline adherence value of 36.2%, 
which dropped to 20% when the treatment was encountered and went back to 
36.2% once the time-window had expired (i.e. 15 minutes later). Note: the flag 
doesn’t show for this annotation, which is a deliberate user-interface choice. 
The initial high output was due to no treatment being found within the time-
window since the EUSIG-event start. The drop to 20% indicated a treatment now 
encountered, but outside this initial time-window, which resulted in a higher 
adherence level than before. This reverted back to the default value as the time-
window expired and no further treatment was found. 
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Figure 8.2: Unit test #2 – a treatment annotation (not shown) occurs outside the time window 
since the event start 
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8.1.1.2. Testing dosage administered 
The LI case (dosage within range, treatment within time-window) had been tested 
in section 8.1.1.1. with the result shown in figure 8.1. This served as a benchmark 
against which to test the dosage/nature component of the output. 
The HI case (dosage too high, treatment(s) within time-window) is tested as 
follows: 
 Three treatment annotations (same type – in this case steroid therapy) are 
added within the time-window at 02:04 on 2004-05-28, 02:06 on 2004-05-
28, and 02:08 on 2004-05-28 
The result – shown in figure 8.3 – showed a stepped output of adherence with 
contiguous instances of 7.4%, 10%, 12.6% and finally the default value of 36.2%. 
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Figure 8.3: Unit test #3 – three treatment annotations within a time-window since the event start 
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The HO case (dosage too high, treatment(s) outside time-window) was tested as 
follows: 
 Three treatment annotations (same type – in this case steroid therapy) are 
added, two within the time-window, one outside, at 02:08 on 2004-05-28, 
02:13 on 2004-05-28, and 02:18 on 2004-05-28 
The result – shown in figure 8.4 – showed a stepped output of adherence with 
contiguous instances of 12.6%, 19.4%, 20% and finally the default value of 36.2%. 
Note that the annotation flag at 02:18 does not show. 
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Figure 8.4: Unit test #4 – three treatment annotations, two within the time window, the third (not 
shown) outside the time window 
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The first two unit tests illustrated the difference in impact of a treatment 
annotation which occurred within the prescribed time window and one that did 
not. The latter reduced the adherence level from the default value of 36.2%, but 
only to 20%, whereas the former is considered more “adherent” and therefore had 
a level of 12%. 
A similar difference in pattern occurred between tests #3 and #4: several stepped 
levels of adherence occurred after the first measurement (15 minutes after the 
event start), which were separated by the time taken from the event start to the 
administration of the treatment. This same stepped output was present in test #4, 
but the distances were greater due to the fact of the final treatment annotation 
being outside the time window. 
8.1.2. Unit tests for individual guidelines 
Each individual BTF guideline has a component unique to that guideline only. 
These can manifest in two ways: either in the choice of EUSIG definition to render 
the physiological output (e.g. depending on the patient age, a BPs EUSIG definition 
of 100 or 110 mmHg is selected) or in the individual distance evaluation at a 
specific time-point (e.g. the presence of a mass lesion in an ICP adherence 
reading, causing the adherence value to be different to when the lesion is not 
present). The following three tests (with two expected outcomes each) verify 
these unique components. 
8.1.2.1. Systolic Blood Pressure (BPs) 
The recommendations from the BTF guidelines on BPs manifest in the two 
physiological patterns, which result from the two EUSIG threshold definitions (100 
and 110 mmHg respectively). This was tested as follows: 
 Add a treatment (any type) inside the time-window after a BPs event 
occurring (>110 mmHg) at 02:22 on 2004-05-29 (event 1). Event detail 
shown in table 8.3. 
 Add a treatment (any type) inside the time-window after a BPs event 
occurring (>100 mmHg) at 09:02 on 2004-05-29 (event 0). Event detail 
shown in table 8.4. 
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Feature Value 
Patient 15026161 
EUSIG definition BPs with threshold of 110 mmHg 
Hold-down 5 mins 
Time-window 15 mins 
Event index 1 
Event start 02:13 on 2004-05-29 
Event end 03:17 on 2004-05-29 
Table 8.3: BPs definitions used for first BPs unit test 
Feature Value 
Patient 15026161 
EUSIG definition BPs with threshold of 100 mmHg 
Hold-down 5 mins 
Time-window 15 mins 
Event index 0 
Event start 08:54 on 2004-05-29 
Event end 09:22 on 2004-05-29 
Table 8.4: BPs definitions used for the second BPs unit test 
The results of these tests – shown in figures 8.5 and 8.6 – indicated adherence 
relating to the time taken to treatment and the default values resulting outside 
the time window. The adherence values thus showed the impact that age has upon 
the guideline adherence output (albeit in temporal output only). 
139 
 
 
Figure 8.5: Unit test of BPs (110 mmHg threshold) guideline 
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Figure 8.6: Unit test of BPs (100 mmHg threshold) guideline 
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8.1.2.2. Intracranial Pressure (ICP) 
The unique feature of the ICP guideline from the BTF is the presence or not of a 
mass lesion or diffuse injury. This was tested as follows: 
 Add a treatment (any type) inside the time-window at 02:08 on 2004-05-28 
(event 0) on patient 15026161, which has a mass lesion/diffuse injury. 
 Add a treatment (any type) inside the time-window at 02:08 on 2004-05-28 
(event 0) on patient 15026161 (inputs artificially modified) which has no 
mass lesion/diffuse injury (therefore the treatment was not necessarily 
merited). 
The results of these tests – shown in figures 8.7 and 8.8 – indicated the standard 
12.6% distance defaulting to 36.2% outside the time window, when the mass 
lesion/diffuse injury was present, as the treatment was merited in this case (figure 
8.8). When the mass lesion/diffuse was not present, the distance within the time 
window was 22.6%, larger as a warning that the treatment was not necessarily 
merited. 
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Figure 8.7: Repeat of (general) unit test #1, which shows ICPm distance within time-window in the 
presence of a diffuse injury 
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Figure 8.8: Repeat of (general) unit test #1, which shows ICPm distance within time-window 
without the presence of a diffuse injury 
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8.1.2.3. Cerebral Perfusion Pressure (CPP) 
The unique feature of the CPP guideline in the BTF is the choice between 
administration of pressors and fluids depending on the context of patient history 
(the relationship is inverse, so if the pressor-load is high, fluid is recommended 
and vice versa). This was tested as follows: 
 Add three treatments inside the time-window after CPP event 1 on patient 
15026161, x2 inotropes at 05:22 and 05:24 on 2004-05-28, and x1 of 
osmotic therapy at 05:26 on 2004-05-28. 
 Add three treatments inside the time-window after CPP event 1 on patient 
15026161, all inotropes at 05:22, 05:24 and 05:26 on 2004-05-28. 
Feature Value 
Patient 15026161 
EUSIG definition CPP with threshold of 50 mmHg 
Hold-down 5 mins 
Time-window 15 mins 
Event index 1 
Event start 05:17 on 2004-05-28 
Event end 06:04 on 2004-05-28 
Table 8.5: CPP definitions used for all CPP unit tests 
Note that because the treatments were all within the time-window of this event 
and that the maximum dosage was three, then the other factors (time-taken and 
nature) were controlled and only the type difference was being tested. 
The results of these tests – shown in figures 8.9 and 8.10 – were contiguous 
instances of adherence at 16%, 8.6%, 11.4% and finally reverting to the default 
value of 36.2% in figure 8.9.  
In figure 8.10, where pressors were administered despite the pressor-load already 
being high, gave contiguous instances of 16%, 18.6%, 11.4% and the default value 
of 36.2%. The middle level was higher due to this extra (non-recommended) 
administration of pressors. 
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Figure 8.9: Unit test #6 – testing the pressor/fluid balance in the CPP guideline (x2 inotropes and 
x1 osmotic) 
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Figure 8.10: Unit test #7 – testing the pressor/fluid balance in the CPP guideline (x3 inotropes) 
147 
 
There is another component of the CPP guideline, not tested here, which is the 
value of CPPopt. This is dependent on the status of the patient’s cerebral 
autoregulation and has an impact on the EUSIG definition of the CPP physiological 
reading (similar to the difference in BPs threshold definition dependent on age). 
This will be future work for the refinement of this system16. 
8.1.3. Discussion 
These unit tests have shown the output that results when individual adherence 
circumstances are input to the system. Two output patterns predominate: small 
(but significant) variation when a treatment is encountered within the time-
window since the start of a EUSIG-event, and much larger periods of “default” 
adherence levels when a treatment is not encountered. This binary pattern is 
expected but underlines the importance of accurate and plentiful treatment 
annotations, both for the best performance of this system, and for accurate data 
capture in general. 
The variation that occurs within the time-window output should be the initial main 
focus of adherence measurement or guideline improvement. The adherence levels 
presented above indicate a “first cut” of the output given the assigned weightings 
attached to the reasons for non-adherence, and future work would include the 
refinement of these weightings in order to better understand the clinical priorities 
in a given moment (additional insight into this can be found in section 8.3 using 
the ICCA dataset). 
 
 
 
 
 
 
                                                     
16 The methods and API for this was implemented in the code but relied upon a moving calculation of the 
Pearson correlation coefficient, which was not providing suitable output by the time of thesis submission. 
148 
 
8.2. Evaluation of treatment annotations timings 
An early finding of this thesis was that the accuracy of treatment annotations, in 
particular the timing, was one of the most important aspects in obtaining reliable 
adherence output. This section describes a validation study that was conducted to 
establish how accurate clinical annotations are, in a real and representative 
clinical environment. 
8.2.1. Study description and method 
This validation study was conducted using a neuro-intensive ICU dataset that was 
compiled for a previous project, attempting to improve arterial hypotension in ICU 
patients by detecting and analysing artefacts in physiological data streams (Lal et 
al., 2015). In order to identify the artefacts, a live observer had been required to 
monitor the management of patients in the ICU and make annotations when a 
clinically relevant action or event occurred. This generated a unique neurological 
ICU dataset which included “live” treatment annotations. 
This set of “live” annotations was used to measure the difference in timing from 
the annotation (manually recorded) to the corresponding marker in the 
physiological data readouts for a given patient (e.g. ABP drops to near zero, or 
registers volatile output, when a blood sample is taken). The same process was 
repeated for a dataset that had been annotated in a “normal” ICU environment 
(“non-live”), to attempt to find an estimate of the difference between annotation 
timings in that ideal situation, and those in regular, resource-limited ones. 
Therefore, the two specific research questions that were considered for this study 
were: 
1. Given ideal conditions (a dedicated research nurse standing at the bed-space 
annotating events as they occur – “live”) - what is the average/range of timing 
differences between the event annotation time and the actual event as 
measured from the physiological data? 
2. Given “real-world” conditions where the normal bed-side nurse is annotating 
events when they can (“non-live”) - how does the difference in timing 
(average/range) compare against the “live” ideal conditions? 
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To investigate these questions, a list of annotations consisting of treatments that 
could be clearly identified on a physiological output (e.g. BP sampling, BP 
transducer goes to zero, patient is turned/moved, etc) was drawn up. The term 
used to describe these events is a ‘zero-drop event’. Both datasets (live and non-
live annotations) were then examined and occurrences of these treatment 
annotations in the physiological output identified and compared against the 
manually observed and recorded events. The average timings between both sets of 
events (annotation to physiological event) was noted. 
8.2.2. Results 
In the “live” dataset, there were 4 patients with a total of 32 “zero-drop” events. 
In the “non-live” dataset, there were 3 patients with a total of 27 “zero-drop” 
events. 
The time distance between the zero-drop in the physiological data and the 
treatment annotation was limited to 15 minutes (considered a reasonable time to 
assert that the two recordings are the same physical event). Table 8.6 shows the 
live dataset events in this group (24 out of 32). No matches were found in the non-
live dataset (0 out of 27). 
Patient ID Timestamp Annotation Zero-drop 
start 
Distance 
(mins) 
CSO_0083 30/10/2014 
21:25 
Blood sample 30/10/2014 
21:26 
1 
CSO_0083 31/10/2014 
00:08 
Blood sample 31/10/2014 
00:09 
1 
CSO_0083 31/10/2014 
06:04 
Blood sample 31/10/2014 
06:07 
3 
CSO_0083 31/10/2014 
06:37 
Zero ABP reading 31/10/2014 
06:51 
11 
CSO_0083 31/10/2014 
18:27 
Zero ABP reading 31/10/2014 
18:39 
12 
CSO_0083 31/10/2014 
18:37 
Blood sample 31/10/2014 
18:39 
2 
150 
 
CSO_0083 31/10/2014 
20:49 
Zero ABP reading 31/10/2014 
20:50 
1 
CSO_0083 01/11/2014 
06:25 
Blood sample 01/11/2014 
06:37 
12 
CSO_0083 01/11/2014 
06:37 
Zero ABP reading 01/11/2014 
06:38 
1 
CSO_0083 01/11/2014 
07:00 
Zero ABP reading 01/11/2014 
07:01 
1 
CSO_0086 04/11/2014 
07:46 
Zero ABP reading 04/11/2014 
07:47 
1 
CSO_0086 04/11/2014 
14:35 
Blood sample 04/11/2014 
14:36 
1 
CSO_0086 03/11/2014 
08:50 
Blood sample 03/11/2014 
08:51 
1 
CSO_0086 03/11/2014 
16:42 
Blood sample 03/11/2014 
16:43 
1 
CSO_0086 04/11/2014 
06:21 
Blood sample 04/11/2014 
06:22 
1 
CSO_0112 27/11/2014 
14:45 
Zero ABP reading 27/11/2014 
14:59 
14 
CSO_0112 27/11/2014 
14:57 
Blood sample 27/11/2014 
14:59 
2 
CSO_0115 01/12/2014 
19:01 
Blood sample 01/12/2014 
19:02 
1 
CSO_0115 02/12/2014 
02:09 
Blood sample 02/12/2014 
02:10 
1 
CSO_0115 02/12/2014 
06:22 
Blood sample 02/12/2014 
06:23 
1 
CSO_0115 02/12/2014 
20:53 
Blood sample 02/12/2014 
20:54 
1 
CSO_0115 03/12/2014 
00:02 
Blood sample 03/12/2014 
00:03 
1 
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CSO_0115 03/12/2014 
04:18 
Blood sample 03/12/2014 
04:19 
1 
CSO_0115 03/12/2014 
06:41 
Blood sample 03/12/2014 
06:43 
1 
Table 8.6: Live dataset events 
Total zero-drop events with no corresponding annotation found were: 27 (non-
live), 8 (live). 
Table 8.7 shows the average time distance (mean and median) for recorded 
annotation time to the nearest event detected in the live physiological dataset. 
Dataset Annotation 
number 
Mean distance 
(mins) 
Median distance 
(mins) 
Live 24 3 1 
Table 8.7: Live average time distance for all recorded zero-drop events to first-encountered 
annotation 
8.2.3. Discussion 
8.2.3.1. Data processing issues 
As the study concerned real-world data, there were several issues encountered 
during processing: 
 The “zero drops” were not always easy to identify. For instance, there had 
to be a robust definition of “zero”, as many machine outputs give readings 
of high volatility, rather than a simple disconnected value (e.g. high 
negative values, or “close to” zero). 
 Similar to the problem of association of events with treatments, it is not 
always clear which zero drop relates to which annotation. The 
correspondence in the live annotated dataset was so high that this problem 
was minimal in that dataset but became much more of an issue in the non-
live dataset (to the point where clinical sense of the output was effectively 
lost). A mitigation for this was to set the time-window cap mentioned 
previously (in this case 15 minutes). 
 The physiological data is provided in waveform format, thus gives readings 
per milliseconds. This was originally condensed to minute-by-minute (similar 
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to the resolution of the Brain-IT dataset) but it became obvious that zero-
drop events often have a duration lower than a minute, and the resolution 
was raised to second-by-second. This sampling frequency was deemed to be 
the most relevant to the problem space (e.g. blood sampling would never 
take less than 1 second), but the choice of resolution may still require 
future consideration. 
8.2.3.2. Interpretation 
The goal of this study was to use a unique feature of the CSO neuro-intensive 
dataset, to provide some additional insight into the timing accuracy of treatment 
annotations in a neurological ICU. 
The results show that when observed in real-time, the accuracy of timing does 
correspond well to the physical output of the physiological data at the bedside. 
However, the comparison against the non-live dataset was inconclusive. With no 
matching annotations at all, it is possible that the discrepancy between manual 
recording of annotations and the physiological output was so great, that none 
showed in this small analysis. To clarify, it should be noted that even though these 
annotations are performed at the end of a ward shift, the distance is from the 
time recorded in the annotation (at some point during the ward shift), and not the 
actual time of recording. Therefore, the discrepancies occur due to the mis-
remembering of times, rather than a systematic error. As this analysis should 
theoretically match between hours, it is unrealistic to think that these 
discrepancies are all due to this issue (or that shift nurses would get the timings so 
wrong), therefore the analysis should be performed again to verify this. 
Another possibility in this result is the approach to annotations in this particular 
sample set: it may be the case the events selected are recorded once per ward 
shift by agreement between staff. 
The high accuracy correspondence of the live observer is obviously very useful but 
also inefficient when considering the resources required (24 - high-skill - man-
hours per day). The more immediate benefits would be to pursue similar 
accuracies through automated means, such as the automated tracking of drug 
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infusions, ventilation application or thermal cooling through “smart” blankets and 
beds. 
A comparative timing measure was unable to be obtained in this study, so an 
understanding of the “average” timing errors was therefore not possible. However, 
if the study were repeated and a value obtained for the non-live dataset, this 
could be incorporated into the confidence with which an adherence pattern 
obtained from the framework can be interpreted. 
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8.3. Evaluation of framework with domain experts 
The purpose of this section was to verify the framework against contextual 
information from clinical domain experts, who work in neurological ICUs and would 
be the target users of the system in its production form. A dataset collected from 
the Philips ICCA (IntelliSpace Critical Care and Anaesthesia) system was chosen for 
this evaluation as it is a popular bedside patient management software commonly 
used in intensive care units in the UK and is familiar to the domain experts. 
8.3.1. Method 
Three TBI patients were selected for analysis by the domain experts, with the 
following data characteristics:  
 A prevalence of EUSIG events in the ICP output 
 Active management of ICP required 
 Two patients (#1 and #3) required non-intervention due to the nature of the 
ICP events 
 One patient (#2) had one large refractory event throughout the course of 
their stay 
Clinical management of the patients was carried out in accordance with a number 
of relevant treatment protocols and guidelines (not just BTF) which deliberately 
tested the ability of this system to provide useful guidance despite competing 
clinical priorities and possible co-morbidities. 
As already mentioned in section 7.1.3, the physiological data structure of the ICP 
data in the ICCA dataset was millisecond wave-form, down-sampled to minute-by-
minute for this evaluation. A code modification of the system was required in the 
“TreatmentAnalysis” module to perform this conversion. This was achieved by 
averaging the contributing millisecond readings across the corresponding minute, 
which would incur some loss of precision in the recorded variation across that 
minute (considered acceptable at this resolution). The treatment data was 
primarily ventilation support and drug administration, obtained by manual inputs 
to, and then drawn from, the integrated ICCA system. 
The results of guideline adherence output from these patients are presented in 
three sections: 
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1) An audit of overall counts of EUSIG-events and treatment annotations 
2) Overall adherence measures for all three patients, according to the 
presentation features described in section 7.3.1, including non-
adherence instance tables; a chart of contributing reasons; an 
interquartile range of instances; a severity chart 
3) Individual instances of non-adherence shown in a time-varying chart 
(section 7.3.1.1). 
The detailed clinical notes for the individual patients were as follows17: 
 Patient 1 - “Infusions of propofol, morphine, midazolam, nor-adrenaline; 
Repeat CT scan on 12/07/2017 - decision to stop sedation, disconnect ICP 
and assess; Repeat CT scan performed - no surgical options; Decision that as 
ICP not controlled by medical management - remove ICP monitor, stop 
sedation and assess” 
 Patient 2 - “ICP consistently >20, overall upward trajectory of ICP (despite 
infusions of Propofol 2% 400 mg/hr; Morphine 3 mg/hr; Midazolam 13 
mg/hr 11:00; Cisatracurium 30 mg/hr; Thiopentone 125 mg/hr 14:00; Nor-
adrenaline 0.1 mg/hr 13:34 - increased to 0.2 mg/hr at 14:00” 
 Patient 3 - “ICP > 20; Associated with rise in ETCO2; Optimisation of 
ventilation by increasing pressure support (documented at 0900 
15/12/2016); Decrease in CO2 leads to decrease in ICP” [Therefore non-
intervention was recommended as the ICP increase was expected to be 
transient] 
8.3.2. Audit: event and treatment counts 
The summary numbers in table 8.8 were compiled from the database once the 
ICCA sample dataset had been processed into the “treatment_profiles” database. 
Total EUSIG event number: 21 
 
 
                                                     
17 These are reproduced verbatim except the square brackets in patient 3, which were added as a separate 
note by one of the clinicians to provide added clarity. 
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Threshold value (mmHg) Hold-down value Count 
10 20 3 
15 20 10 
20 20 2 
25 20 3 
30 20 3 
Table 8.8: Count of individual ICPm EUSIG events from the ICCA sample dataset 
Total treatment annotation number: 1721 
Treatment Count 
Ventilation 406 
Propofol 119 
Noradrenaline 234 
Co-Amoxiclav 12 
Morphine 388 
Potassium Chloride 37 
Carbomer Ointment 13 
Hydrocortisone 1 
Salbutamol 28 
Magnesium Sulphate 11 
Calcium Gluconate 2 
Ranitidine 13 
Omeprazole 13 
Midazolam 55 
Mannitol 1 
Glycophos 75 
Metoclopramide 14 
Benzylpenicillin 25 
Temocillin 8 
Amoxicillin 12 
Paracetamol 54 
Lactulose 19 
Senna 19 
Phosphate-Sandoz 21 
Carbocisteine 27 
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Furosemide 1 
Metronidazole 27 
Clindamycin 27 
Laxido PO/NG 7 
Enoxaparin 3 
Ceftriaxone 5 
Sando-K 17 
Meropenem 18 
Clotrimazole 9 
Table 8.9: ICCA treatment counts 
For each time-window value, 8 EUSIG events were associated with treatments, 
which was 80% of the most numerous definition (an ICP threshold value of 15 
mmHg for a hold-down time of 20 minutes, which was the only hold-down 
definition available in this sample set – see discussion below). This suggests that 
the count of annotations was high relative to the physiological output (c.f. to the 
numbers presented for the older Brain-IT dataset in chapter 9). 
8.3.3. Overall adherence measures 
For the three patients the results are presented as: 
 Table of non-adherence instances 
 Charts of contributing reasons 
 Interquartile range table and box-plots (“duration with default state 
removed” as example) 
 Severity charts 
8.3.3.1. Patient #1 
Most instances for patient #1 are variation due to the time to treatment and a 
contributing factor of incorrect type. However, for two instances, the 
dosage/nature is a contributing factor as well. The majority of the non-adherence 
is spent in the default state (36.2%) and a lower, but similar value of 30%. The 
distribution appears to be spread evenly through all four factors 
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Figure 8.11: Instances of non-adherence for Patient #1 
 
Figure 8.12: Reasons contributing to the different instances of non-adherence for Patient #1 
 
Figure 8.13: Interquartile range table for instances of non-adherence for Patient #1 with the 
default state (36.2%) removed 
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Figure 8.14: Box-plot of the duration aspect of non-adherence 
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Figure 8.15: Severity chart of the non-adherence instances for Patient #1 
8.3.3.2. Patient #2 
In this case there is only one instance for the whole patient stay, which is the default 
instance (36.2%). 
 
Figure 8.16: Table of instances for patient #2 
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Figure 8.17: Contributing reason to non-adherence for Patient #2 
 
Figure 8.18: Interquartile range table for Patient #2 
 
Figure 8.19: Boxplot of interquartile range of Duration of patient #2 
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Figure 8.20: Severity chart for Patient #2 
8.3.3.3. Patient #3 
 
Figure 8.21: Table of instances for Patient #3, with the default instance (36.2%) removed 
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Figure 8.22: Contributing reasons for Patient #3 
 
Figure 8.23: Interquartile ranges for Patient #3 
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Figure 8.24: Boxplot visualisation of the Duration aspect of Patient #3 
 
Figure 8.25: Severity chart of Patient #3 
8.3.4. Individual charts of adherence 
 
Figure 8.26: Summary criteria for event 0 with patient #1 
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Figure 8.27: Timeline of event 0 ICPm 
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Figure 8.28: Summary criteria for event 0 in patient #3 
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Figure 8.29: Timeline of event 0, patient #3 
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8.3.5. Discussion 
Some general issues identified in this evaluation were the presence of EUSIG-
events that only had hold-down definitions of 20 minutes (i.e. no events were 
detected with hold-down values lower than 20 mins). It is uncertain whether this 
was an issue of data processing or if this was a clinician choice (no action unless 
event held-down for 20 minutes) that manifested in the data. It would be 
anticipated that at least some events would be detected that were sub-sets of that 
maximum value (e.g. 5, 10 and 15 minutes), therefore this needs to be further 
investigated and confirmed that these are in fact the only physiological events 
detected. 
Another issue was the categorisation of treatments. The direct drug name was 
listed in the treatment tables of the framework database, which can either be 
categorised according to the Brain-IT listing or can be individually incorporated 
into the framework (e.g. the drug name specifically listed in the code where 
pressors/fluids are captured to evaluate the type comparison in the CPP 
guideline). This categorisation would specify the measurement of adherence 
output more closely. 
Patient 1 – The guideline adherence value on patient 1, event 0 (figure 8.27), 
largely flips between 30% and 36.2% based on whether it has recently encountered 
a treatment or not. From the overall adherence information for patient 1 (figure 
8.11), it can be seen that the drug type contributes consistently to all non-
adherence instances with this patient – this is believed to be because the 
treatment data has been categorised under the individual drug names rather than 
into drug family types, resulting in the fact that the type is always returned as 
“not recommended”. Therefore, when a treatment is encountered the base level 
of adherence is generally 30% (composed of a type issue, plus the treatment being 
outside a given time window). This could be a reasonable representation of the 
contextual statement “ICP not controlled by medical management” for this patient 
(in the associated clinical notes). 
Patient 2 – this patient has no treatment associations. The output is believed to be 
due to the refractory nature of the ICP increase (mentioned in the patient notes). 
This failure to associate annotations with a single, large EUSIG-event comes back 
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to the issue of time-window definition (mentioned in section 8.1). In this case, as 
the physiological output never returns to a “sub-threshold” position, the pattern 
matching algorithm is never reset and no treatment is associated even though 
there are many recorded. This should obviously be refined as an edge-case of the 
system. 
The overall adherence output also reflects the lack of variation: one instance only 
(figure 8.16), one contributing reason (figure 8.17), and a highly skewed 
interquartile range output (figures 8.18 and 8.19). The severity chart (figure 8.20) 
shows the number being as severe as possible. This is indeed a severe case – 
however the severity is flagged by the (incorrect) reason of lack of treatments, 
rather than the escalating patient context (refractory ICP event) which is not 
addressed by the BTF guidelines therefore not captured in this system. 
Patient 3 – The number of treatments for patient 3 is much lower than the other 
two, and therefore the default instance of non-adherence is larger (figures 8.21 
and 8.22 from overall adherence information for patient 3). This leads to a severity 
value that occurs around the middle of the chart, an outcome which suggests that 
a small perturbation could have large effects on the considered severity (i.e. it 
would move it across the border between quadrants, though this measure is 
somewhat subjective). The main issue with the outputs from patient 3 is that when 
it is cross-referenced back to the original patient notes – which specified that the 
ICP EUSIG-events in this patient were occurring transiently and were apparently 
linked to the rise and fall of the patient’s ETCO2 – the consistent management 
position was to take no action. The guideline adherence framework fails to capture 
this nuance when presenting output, which again leads to an over-statement of the 
lack of annotations. However, the variation when a ventilation treatment is 
encountered captures at least part of this clinical management process. 
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8.4. Evaluation of framework against patient outcome (GOS) 
The Glasgow Outcome Score (GOS) provides an insight into the status of a patient 
six months after the initial brain injury and is on an 8-point scale (GOS-e or 
“extended” from the original 5-point GOS) as shown in table 8.10. 
Score / Label Description 
1 – Death Severe injury or death without recovery of 
consciousness 
2 – Persistent vegetative 
state 
Severe damage with prolonged state of 
unresponsiveness and a lack of higher mental functions 
3 – Lower severe 
disability 
4 – Upper severe 
disability 
Severe injury with permanent need for help with daily 
living 
5 – Lower moderate 
disability 
6 – Upper moderate 
disability 
No need for assistance in everyday life, employment is 
possible but may require special equipment 
7 – Lower good recovery 
8 – Upper good recovery 
Light damage with minor neurological and psychological 
deficits 
Table 8.10: Extended Glasgow Outcome Score (GOS-e) and label, with the associated description 
The ordinality of this score can be used in different ways, but for the purposes of 
understanding the relationship to guideline distance/duration, scores 1-4 are 
classified as “poor” (or value “1”), and scores 5-8 are classified as “good” (or 
value “0”). Therefore, given a set of guideline non-adherence instances for 
different time durations, we can assess whether there is any correlation with the 
outcome of a patient. Examples of similar “adjusted” assessments of other 
variables’ influence on patient outcome from traumatic brain injury can be found 
in (Edwards et al., 2005) and (Güiza et al., 2013). 
8.4.1. Materials and Method 
The Brain-IT core data-set is a repository of 262 patients drawn from specialist 
neurological centres around Europe, collected with a view to enabling post-hoc 
analyses (Shaw et al., 2009). A comprehensive collection of TBI data with 
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physiological, treatment, laboratory, surgery and other clinical events, with a 
particular focus on the management of ICP and CPP, it forms a detailed 
retrospective view of physiological and treatment data that is well suited to 
analyses such as the research work in this thesis. This is used for this statistical 
evaluation due to the presence of 6-month GOSe information for each patient in 
this cohort. 
The steps towards understanding the influence of guideline deviation and 
correcting for the influence of known TBI factors, are: 
 Create a “null” model – this is an “average” model, effectively a 50:50 
guess on what the GOS will be in 6 months. It is hoped that information 
about guideline deviations will be at least better than this. 
 Create a set of “unadjusted” models – these are univariate models that 
show the relationship between the GOS and the covariates (in this case 
guideline non-adherence distance and duration) and with the known factors 
influencing TBI outcomes (Edwards et al., 2005). These factors are: age, 
GCSm, pupil reactivity, major extra-cranial injury, and CT scan availability. 
 Create an “adjusted” model – this is a model including all the unadjusted 
co-variates that may have significance in explaining the model error (i.e. 
have a p-value less than 0.1).  
 Check the variance between the models – this is a method to test if a 
change has had a positive effect on the overall nature of the model, by 
comparing the change in variance between the models. 
To implement this, the output of all instances of guideline deviation (each 
instance containing a duration and a distance of deviation from the ideal 
guideline), are written to a spreadsheet. The first three models use a binomial 
logistic regression and the final comparison uses the “analysis of variance” 
(ANOVA) methodology. 
A further consideration is the possibility that the two covariates – distance and 
duration of guideline adherence – are related. Therefore, an analysis of variance 
between the two unadjusted models is run as well. 
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8.4.2. Results 
To run the logistic regression, the instance data is loaded, split between 
training/test (80/20 to optimise the variance between both performance and 
prediction), and fitted using the glm (generalized linear model) package in R, run 
on Ubuntu Xenial (16.04). 
The duration and distance measures were repeat measures so an average of both 
was used for each patient line. The following column headers were used, with 249 
instances (one line per patient, 13 removed due to lack of output, and Patient ID 
removed as it was an index only): 
 GOSe 
 Average duration of non-adherence 
 Average non-adherence level 
 Age 
 GCS motor 
 Left pupil reaction 
 Right pupil reaction 
 Facial injury 
The availability of CT scan was not individually identified in the Brain-IT dataset so 
was not included on the list. Facial injury was the closest single data point to 
capture “extra-cranial injury”, which is the actual indicator from the 
CRASH/IMPACT studies. 
8.4.2.1. Null model 
The null model was constructed by running a regression against the mean of the 
GOS alone. 
Model: GOS ~ 1 
Call: glm(formula = GOS ~ 1, family = binomial(link = "logit"),data = train) 
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Min 1Q Median 3Q Max 
-1.238 -1.238 1.118 1.118 1.118 
Table 8.11: Deviance residuals of the null model 
 
 Estimate Std. Error z value Pr (>|z|) 
(Intercept) 0.1402 0.1418 0.989 0.323 
Table 8.12: Coefficients of the null model 
8.4.2.2. Unadjusted models – guideline adherence 
The unadjusted model for adherence distance was created by running a regression 
against the GOS using the average of all instances for each patient. The intercept 
had a p-value < 0.1. 
Model: GOS ~ Avg.distance 
Call: glm(formula = GOS ~ Avg.distance, family = binomial(link = "logit"),data = train) 
Min 1Q Median 3Q Max 
-1.5656 -1.2091 0.8337 1.1488 1.1820 
Table 8.13: Deviance residuals of the unadjusted distance model 
 
 Estimate Std. Error z value Pr (>|z|) 
(Intercept) 0.87802 0.49460 1.775 0.0759 
Avg.distance -0.02455 0.01561 -1.572 0.1158 
Table 8.14: Coefficients of the unadjusted distance model 
The unadjusted model for adherence duration was created by running a regression 
against the GOS using the average of all instances for each patient. 
Model: GOS ~ Avg.duration 
Call: glm(formula = GOS ~ Avg.duration, family = binomial(link = "logit"),data = train) 
Min 1Q Median 3Q Max 
-1.4933 -1.2180 0.9905 1.1393 1.2020 
Table 8.15: Deviance residuals of the unadjusted duration model 
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 Estimate Std. Error z value Pr (>|z|) 
(Intercept) -0.057743 0.219086 -0.264 0.792 
Avg.duration 0.003917 0.003349 1.170 0.242 
Table 8.16: Coefficients of the unadjusted duration model 
8.4.2.3. Unadjusted models – known TBI predictors 
The unadjusted model for age was created by running a regression against the GOS 
of the patients. The intercept had a p-value < 0.05 and Age had a p-value < 0.01. 
Model: GOS ~ Age 
Call: glm(formula = GOS ~ Age, family = binomial(link = "logit"),data = train) 
Min 1Q Median 3Q Max 
-1.6202 -1.1608 0.8055 1.1335 1.4811 
Table 8.17: Deviance residuals of the unadjusted age model 
 
 Estimate Std. Error z value Pr (>|z|) 
(Intercept) -0.667656 0.315721 -2.115 0.03446 
Age 0.022767 0.008023 2.838 0.00454 
Table 8.18: Coefficients of the unadjusted age model 
The unadjusted model for GCSm was created by running a regression against the 
GOS of the patients. The intercept had a p-value < 0.05 and GCSm had a p-value < 
0.1. 
Model: GOS ~ GCSm 
Call: glm(formula = GOS ~ NSH_Adm_GCS_Motor, family = binomial(link = "logit"),data = train) 
Min 1Q Median 3Q Max 
-1.3974 -1.1559 0.9723 1.1094 1.3292 
Table 8.19: Deviance residuals of the unadjusted GCSm model 
 
 Estimate Std. Error z value Pr (>|z|) 
(Intercept) 0.67435 0.32989 2.044 0.0409 
NSH_Adm_GCS_Motor -0.17072 0.08922 -1.914 0.0557 
Table 8.20: Coefficients of the unadjusted GCSm model 
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The unadjusted model for left pupil reaction was created by running a regression 
against the GOS of the patients. Left pupil reactivity had a p-value < 0.01. 
Model: GOS ~ Left pupil reactivity 
Call: glm(formula = GOS ~ NSH_Adm_Left_Pupil_Reaction, family = binomial(link = "logit"),data = 
train) 
Min 1Q Median 3Q Max 
-1.6651 -1.1144 0.7585 1.2417 1.2417 
Table 8.21: Deviance residuals of the unadjusted left pupil reaction model 
 
 Estimate Std. Error z value Pr (>|z|) 
(Intercept) -0.1499 0.1654 -0.906 0.36472 
NSH_Adm_Left_Pupil_Reaction 1.2486 0.4189 2.980 0.00288 
Table 8.22: Coefficients of the unadjusted left pupil reaction model 
The unadjusted model for right pupil reaction was created by running a regression 
against the GOS of the patients. Right pupil reactivity had a p-value < 0.01. 
Model: GOS ~ Right pupil reactivity 
Call: glm(formula = GOS ~ NSH_Adm_Right_Pupil_Reaction, family = binomial(link = "logit"),data = 
train) 
Min 1Q Median 3Q Max 
-1.6459 -1.1272 0.7726 1.2285 1.2285 
Table 8.23: Deviance residuals of the unadjusted right pupil reaction model 
 
 Estimate Std. Error z value Pr (>|z|) 
(Intercept) -0.1193 0.1630 -0.732 0.46418 
NSH_Adm_Right_Pupil_Reaction 1.1754 0.4417 2.661 0.00778 
Table 8.24: Coefficients of the unadjusted right pupil reaction model 
The unadjusted model for facial injury was created by running a regression against 
the GOS of the patients. The intercept had a p-value < 0.1. 
Model: GOS ~ Facial injury 
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Call: glm(formula = GOS ~ Injury_Facial, family = binomial(link = "logit"),data = train) 
Min 1Q Median 3Q Max 
-1.6006 -1.2055 0.8067 1.1495 1.1495 
Table 8.25: Deviance residuals of the unadjusted facial injury model 
 Estimate Std. Error z value Pr (>|z|) 
(Intercept) 0.95551 0.52623 1.816 0.0694 
Injury_Facial -0.01779 0.01093 -1.627 0.1037 
Table 8.26: Coefficients of the unadjusted facial injury model 
8.4.2.4. Adjusted models 
The model for adherence duration and distance (combined) was created by running 
a regression against the GOS using the average of all instances for each patient and 
testing for the relationship between the two parameters. The intercept had a p-
value < 0.1 and the Avg.distance contribution had a p-value < 0.05. 
Model: GOS ~ Avg.duration * Avg.distance 
Call: glm(formula = GOS ~ Avg.duration * Avg.distance, family = binomial(link = "logit"),data = 
train) 
Min 1Q Median 3Q Max 
-1.7507 -1.1708 0.7915 1.1707 1.3059 
Table 8.27: Deviance residuals of the distance/duration model 
 Estimate Std. Error z value Pr (>|z|) 
(Intercept) 1.0001521 0.5224688 1.914 0.0556 
Avg.distance -0.0397791 0.0176229 -2.257 0.0240 
Avg.duration -0.0178465 0.0311498 -0.573 0.5667 
Avg.distance:Avg.duration 0.0007396 0.0009062 0.816 0.4144 
Table 8.28: Coefficients of the distance/duration model 
The model for all known TBI indicators (referred to here as the CRASH/IMPACT 
model) was created by running a regression against the GOS using all five 
covariates listed above. GCSm and left pupil reaction had a p-value < 0.05 and Age 
had a p-value < 0.01. 
Model: GOS ~ CRASH/IMPACT model (known TBI indicators) 
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Call: glm(formula = GOS ~ Age + NSH_Adm_GCS_Motor + NSH_Adm_Left_Pupil_Reaction +   
NSH_Adm_Right_Pupil_Reaction + Injury_Facial, family = binomial(link = "logit"), data = train) 
in 1Q Median 3Q Max 
-1.98821 -1.02000 0.00016 1.05666 1.75047 
Table 8.29: Deviance residuals of the CRASH/IMPACT model 
 Estimate Std. Error z value Pr (>|z|) 
(Intercept) 16.65411 1400.33243 0.012 0.99051 
Age 0.03226 0.01113 2.898 0.00376 
NSH_Adm_GCS_Motor -0.25987 0.10644 -2.441 0.01463 
NSH_Adm_Left_Pupil_Reaction 1.47781 0.75293 1.963 0.04968 
NSH_Adm_Right_Pupil_Reaction -0.41107 0.80073 -0.513 0.60770 
Injury_Facial -0.34513 28.00665 -0.012 0.99017 
Table 8.30: Coefficients of the CRASH/IMPACT model 
The model for the CRASH/IMPACT model with guideline adherence information 
added was created by running a regression against the GOS using all five covariates 
listed above and the duration/distance covariates. Age and GCSm had p-values < 
0.01, distance/duration had p-values < 0.05 and left pupil reaction and distance * 
duration had p-values < 0.1. 
Model: GOS ~ CRASH/IMPACT model with guideline adherence 
Call: glm(formula = GOS ~ Age + NSH_Adm_GCS_Motor + NSH_Adm_Left_Pupil_Reaction + 
NSH_Adm_Right_Pupil_Reaction + Injury_Facial + Avg.distance * Avg.duration, family = 
binomial(link = "logit"), data = train) 
Min 1Q Median 3Q Max 
-1.72050 -0.93226 0.00015 0.93286 1.98057 
Table 8.31: Deviance residuals of the CRASH/IMPACT model 
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 Estimate Std. Error z value Pr (>|z|) 
(Intercept) 1.641e+01 1.397e+03 0.012 0.99063 
Age 4.017e-02 1.225e-02 3.280 0.00104 
NSH_Adm_GCS_Motor -3.090e-01 1.129e-01 -2.737 0.00620 
NSH_Adm_Left_Pupil_Reaction 1.384e+00 8.039e-01 1.722 0.08506 
NSH_Adm_Right_Pupil_Reaction -1.441e-01 8.473e-01 -0.170 0.86495 
Injury_Facial -5.748e-01 2.795e+01 -0.021 0.98359 
Avg.distance 3.195e-01 1.336e-01 2.390 0.01683 
Avg.duration 1.691e-01 8.296e-02 2.038 0.04150 
Avg.distance:Avg.duration -4.475e-03 2.389e-03 -1.873 0.06111 
Table 8.32: Coefficients of the CRASH/IMPACT model 
8.4.2.5. Analysis of variance 
The deviance between the duration and null models was not high and without 
statistical significance. 
Model 1: GOS ~ Avg.duration 
Model 2: GOS ~ 1 
 Resid. Df Resid. Dev Df Deviance Pr (>Chi) 
1 198 274.83    
2 199 276.28 -1 -1.451 0.2284 
Table 8.33: Analysis of variance between duration and null models 
Similarly, the deviance between the distance and null models was not high and 
without statistical significance. 
Model 1: GOS ~ Avg.distance 
Model 2: GOS ~ 1 
 Resid. Df Resid. Dev Df Deviance Pr (>Chi) 
1 198 273.63    
2 199 276.28 -1 -2.6503 0.1035 
Table 8.34: Analysis of variance between distance and null models 
Between each other, the relationship did not appear to correlate in a statistically 
significant way (low deviance and no significant p-value). 
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Model: Avg.distance ~ Avg.duration 
 Df Deviance Resid. Df Resid. 
Dev 
Pr (>Chi) 
NULL   199 276.28  
Avg.distance 1 2.6503 198 273.63 0.10353 
Avg.duration 1 4.1174 197 269.51 0.04244 
Avg.distance:Avg.duration 1 0.6706 196 268.84 0.41284 
Table 8.35: Analysis of variance between distance and duration models 
When the adjusted models were compared, the explanatory power of the model to 
patient GOS was largely explained by the CRASH/IMPACT model (large deviance 
with significant p-value). 
Model 1: GOS ~ CRASH/IMPACT model * Duration/Distance 
Model 2: GOS ~ CRASH/IMPACT model 
 Resid. Df Resid. Dev Df Deviance Pr (>Chi) 
1 135 153.25    
2 138 168.22 -3 -14.969 0.001843 
Table 8.36: Analysis of variance between CRASH/IMPACT model with adherence and 
CRASH/IMPACT model without 
8.4.3. Discussion 
Through the creation of the regression models in this section, the possible 
relationship between the guideline adherence output and patient outcome was 
investigated. When combined with the known indicators in the CRASH/IMPACT 
studies, the instances of guideline adherence failed to have a statistically 
significant bearing on the explanatory power of the models. 
This is not unexpected, partly due to the weightings used in numerically evaluating 
the adherence instances, and the low treatment associations in the Brain-IT 
dataset (see chapter 9). It is possible that with calibration of the weightings and 
applied to a dataset with a higher density of treatment annotations it may have 
some relationship. 
8.5. Evaluation summary 
The evaluations performed in this chapter indicated satisfactory performance in 
capturing guideline adherence information at a clinical management level (section 
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8.1) and successfully provided representation against contextual information from 
real patient notes in an ICU setting (section 8.3). Accurate timing of treatment 
annotations was identified as a key requirement in section 8.1, and an attempt 
was made to quantify this timing difference in section 8.2. Unfortunately, the 
results of section 8.2 only provided information in the ideal “live” situation, but 
this in itself was an indicator of the required improvement in annotation timings 
(ideally by automated means). Section 8.4 failed to find a statistical relationship 
between the adherence output and patient outcome though it is hoped with more 
refinement of the weightings involved, this may improve. 
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9. Application of framework to neurological ICU dataset: Brain-IT 
Chapter summary 
In this chapter, the process model guideline adherence framework is applied to 
the Brain-IT dataset to evaluate its performance on real-world data. 
The information extracted from the Brain-IT dataset is presented in five sections: 
1. The number of identified events based on the EUSIG definitions 
2. Generation of the event log showing the association of treatment 
annotations with EUSIG-events and the distribution of treatment categories 
3. The individual patient output of the comparison of the resulting process 
models for selected patients: 
a. Minute-by-minute adherence 
b. Total duration and levels of non-adherence 
c. Interquartile ranges showing statistical spread (impact and 
relevance) of non-adherence 
d. “Default” vs “non-default” non-adherence instances 
e. Interquartile ranges with default instances removed (highlighting 
different sources of non-adherence variety) 
f. Contribution of non-adherence reasons 
g. Clinical severity charts 
4. Additional insights from applying the guideline adherence framework on 
the Brain-IT dataset, including the impact of overlaying a clinical response 
time-window, and the treatment category distribution 
Overall, the physiological data is comprehensive and the EUSIG event pattern 
easily extracted. However, the annotation frequency and density in the dataset 
overall is low, leading to low association numbers with EUSIG. Despite this low 
resolution, clear indications of guideline adherence were found within the 
dataset, suggesting that the framework does provide viable output for measuring 
guideline adherence. 
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The Brain-IT core data-set is a repository of 262 patients drawn from specialist 
neurological centres around Europe, collected with a view to enabling post-hoc 
analyses (Shaw et al., 2009). A comprehensive collection of TBI data with 
physiological, treatment, laboratory, surgery and other clinical events, with a 
particular focus on the management of ICP and CPP, it forms a detailed 
retrospective view of physiological and treatment data that is well suited to 
analyses such as the research work in this thesis. 
9.1. EUSIG-event detection 
The first stage of evaluation of this dataset is to detect physiological EUSIG 
(Edinburgh University Secondary Insult Grade) events. 
9.1.1. Coverage 
The coverage of physiological parameters in the database is summarised in table 
9.1. “Coverage” is defined by dividing the number of data points that are not 
“null” or blank by the overall number of data points for that physiological stream 
and calculating the resulting percentage. Parameters with coverage less than 10% 
are omitted as contributing negligible information to the analysis. 
ICU Parameter Coverage 
RR 26% 
HRT 87% 
BPs 84% 
BPd 84% 
BPm 96% 
ICPm 84% 
CVPm 20% 
CPP 82% 
TC 70% 
SaO2 82% 
SaO2pls 23% 
ETCO2 19% 
Table 9.1: Physiological parameter coverage in Brain-IT 
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By inspecting the coverage for the data points used, a level of initial confidence 
can be gained to see how well represented the parameters in the dataset are. If 
the parameter is well covered, it is a reasonable expectation that the event 
detection algorithm will produce useful information. From the results shown in 
table 9.1, we can see that the pressure measures are all at least above 80%, 
including those of particular interest: mean intra-cranial pressure (ICPm), cerebral 
perfusion pressure (CPP) and systolic blood pressure (BPs). 
9.1.2. EUSIG-event definitions 
Following from the description of EUSIG definitions of ICP, CPP and SBP events 
(table 9.2), ten threshold definitions are used to cover the range of clinically 
relevant definitions. 
Parameter Threshold values 
(mmHg) 
Direction Event Hold-Down (mins) 
ICP 10, 15, 20, 25, 30 Up 5, 10, 15, 20 
CPP 50, 60, 70 Down 5, 10, 15, 20 
SBP 100, 110 Down 5, 10, 15, 20 
Table 9.2: Definitions of raised ICP, lowered CPP and lowered SBP events 
Similarly, four values are applied representing the differences in hold-down and 
clear hold-down times: 5, 10, 15 and 20 mins. Therefore, there are a total of 40 (= 
10 * 4) ways that a physiological monitoring event can be detected in a dataset. 
9.1.3. EUSIG-event counts 
The event detection algorithm has been applied to the 40 definitions of EUSIG 
events. Tables 9.3-9.5 and figures 9.1-9.3 show the count of individual events for 
each EUSIG definition across all 262 patients (with all profiles now stored in the 
treatment profile database after processing). 
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Threshold value 
(mmHg) 
Hold-down value Count 
10 20 2585 (abs) 
15 20 2797 (abs) 
20 20 1631 (abs) 
25 20 643 (abs) 
30 20 280 (abs) 
10 15 +732 
15 15 +991 
20 15 +686 
25 15 +318 
30 15 +132 
10 10 +1408 
15 10 +1799 
20 10 +1452 
25 10 +714 
30 10 +316 
10 5 +3697 
15 5 +5130 
20 5 +4213 
25 5 +2266 
30 5 +1088 
Table 9.3: Event count for each ICP EUSIG definition (x20). The first five definitions are an 
absolute count, whilst the following fifteen give the additional count, as the hold-down values are 
subsets of each other. 
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Figure 9.1: Event count distribution for ICP 
Threshold value 
(mmHg) 
Hold-down value Count 
50 20 537 (abs) 
60 20 1874 (abs) 
70 20 3048 (abs) 
50 15 +252 
60 15 +670 
70 15 +1080 
50 10 +534 
60 10 +1491 
70 10 +2085 
50 5 +1759 
60 5 +4261 
70 5 +6278 
Table 9.4: Event count for each CPP EUSIG definition (x12). The first three definitions are an 
absolute count, whilst the following nine give the additional count, as the hold-down values are 
subsets of each other. 
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Figure 9.2: Event count distribution for CPP 
 
Threshold value 
(mmHg) 
Hold-down value Count 
100 20 512 (abs) 
110 20 1371 (abs) 
100 15 +193 
110 15 +450 
100 10 +384 
110 10 +935 
100 5 +1334 
110 5 +2677 
Table 9.5: Event count for each SBP EUSIG definition (x12). The first two definitions are an 
absolute count, whilst the following six give the additional count, as the hold-down values are 
subsets of each other. 
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Figure 9.3: Event count distribution for SBP 
Figures 9.1 to 9.3 show these event count results for ICP, CPP and SBP as bar 
charts. The column number in each chart is the total for that parameter (e.g. ICP 
has 20 corresponding to the five threshold definitions multiplied by the four hold-
down values). The interpretation of the cyclical shape for every set of hold-down 
definitions is as follows: as the hold-down value for that particular definition 
increases, the number of EUSIG-events captured goes down (e.g. a EUSIG-event 
with a hold-down value of 20 minutes will be less common than one with a 5-
minute hold-down). However, slightly less intuitively, the individual numbers vary 
according to definition: e.g. the most populous number of events in ICP, in each 
hold-down definition cycle, come from having a monitoring threshold of > 15 
mmHg. This represents a minima inflection point, discussed further in section 9.5 
(additional information from treatment associations).  
From this initial evaluation of event count numbers, the EUSIG-event pattern has 
clear representation in the Brain-IT dataset and can be used as a basis for assessing 
a wider picture of clinical management. The next step is to attempt to apply the 
association of treatment annotations to these event counts to generate an event 
log. 
9.2. Generation of an event log 
To generate the full event log that can then be turned into a process model, 
requires the association of treatment annotations with physiological events. 
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Referring back to section 5.1 and the relative definitions of the word "event": the 
convention in this thesis is to use "EUSIG-event" to refer to the pattern in the 
physiological output described by a threshold, a hold-down and a clear hold-down; 
whilst "event" (singular) refers to a EUSIG-event and an associated treatment. 
Multiple instances of this latter definition are chained together to form the full 
patient event log described in this sub-section.  
The treatment labels in the Brain-IT dataset follow the well-defined categories in 
that data schema and can be associated with the EUSIG-events subject to the 
considerations listed in section 5.1.3 (i.e. multiple treatments and multiple 
overlapping event time-windows being treated as one). The event log generated 
from this process is then available to be converted into a process model.  
9.2.1. Treatment categories 
Table 9.6 shows the treatment categories, and overall count of individual 
annotations, that have been identified by the Brain-IT consortium as being critical 
to identify information relevant to the management of ICP, CPP and SBP. 
Treatment category Count 
Ventilation 474 
Sedation 1796 
Analgesia 1732 
Paralysis 1790 
Volume expansion 3063 
Inotropes 860 
Anti-hypertensives 86 
Anti-pyretics 1294 
Hypothermia 99 
Steroids 68 
Cerebral vasoconstriction 24 
Osmotic therapy 1773 
Cerebrospinal fluid (CSF) drainage 661 
Head elevation 676 
Barbiturates 136 
Other 4603 
Table 9.6: Overall treatment category count (total = 19135) 
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9.2.2. Treatment association and event log 
To show the representation of instances of treatment/event associations, table 9.7 
shows an example of the count of events with associated treatments expressed as 
an absolute number count and a percentage of overall events for that definition 
(see table 9.8 for the absolute ICP event number). The definition selected is the 
ICP threshold value of 15 mmHg, for a hold-down time of 5 mins. 
Time-window 
(mins) 
Count 
(absolute) 
Count (%) 
15 1822 17.2 
30 1982 18.7 
45 2197 20.8 
60 2246 21.3 
Table 9.7: Number of events with associated treatments depending on the time-window definition 
chosen 
Figure 9.4 shows this variation across the five definitions of ICP threshold 
monitoring, with a constant hold-down time of 5 minutes. 
 
Figure 9.4: ICP associated treatment count, varied by time-window 
Overall there are 19135 annotated treatments in the dataset. Table 9.8 shows the 
absolute number of patients and events that have associated treatments, and the 
percentage relative to the total number of both (patients and events) for the same 
definition as above (ICP > 15 mmHg for hold-down of 5 minutes). This validation 
check shows that whilst the pattern is a good representation of EUSIG-events, it 
does not necessarily cover the entire patient cohort, and could be improved to 
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capture greater accuracy (see the discussion later in this chapter and in chapter 11 
on the quality and frequency of treatment annotations). 
Patients (absolute) Events (absolute) Patients (% of total) Events (% of total) 
187 1822 71.3 17.2 
Table 9.8: Number of patients and EUSIG-events with associated treatments expressed as absolute 
and percentage of total of each for a definition of ICP > 15 mmHg for a hold-down value of 5 
minutes and a time-window of 15 minutes 
This figure of 17.2% is low, though it should be highlighted here that there is 
believed to be a bug in the data processing, the impact of which is to halve the 
actual number of treatment associations, meaning the true value is closer to 34%. 
(See Appendix F for details.) 
To convert this association information into an event log, the EUSIG-event and 
associated treatment instances are collated per-patient and represented as shown 
in figure 9.5 as an example for patient 15138374. 
 
Figure 9.5: Snippet of the event log for patient 15138374 
9.3. Process model comparison – individual output 
As described in chapter 6, the event log can now be converted to a process model 
and evaluated for guideline adherence. 
9.3.1. Minute-by-minute, aggregate and statistical spread of non-adherence 
The following five patients have been selected to indicate information relating to 
different classes of non-adherence that have appeared during the dataset 
assessment. They have been selected from the patients that had treatment 
associations (and hence varied adherence information) and display different 
characteristics that exemplify the possible outcomes from this framework. Within 
those parameters and that patient subset, they are structurally representative of 
the variation shown by the framework over the whole dataset. 
The timeline captions indicate the reasons for the pattern of non-adherence for 
that event (e.g. “treatment missing”, “dosage too high”, etc). As before, each 
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patient has an accompanying table showing the aggregate (total) non-adherence 
duration and level, as well as an interquartile range table showing the statistical 
spread of the various instances of non-adherence (one feature repeated visually as 
an example box-plot diagram). Table 9.9 shows the EUSIG-event definitions used 
for these examples. 
Feature Value 
EUSIG definition ICPm with threshold of 15 mmHg 
Hold-down 5 mins 
Time-window 15 mins 
Table 9.9: EUSIG definition details that the following five examples are sourced from 
9.3.1.1. Patient 4026626 
For this patient, when the Analgesia has been applied the non-adherence distance shows 
2%, which is very adherent to the guideline (treatment present, recommended for this 
context and not over dosage). Once the time-window period has passed, the event 
continues but a recent treatment is now missing, therefore the non-adherence jumps back 
to the “default” level of 36.2%. 
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Figure 9.6: Patient 4026626, event 1 
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Figure 9.7: Total output for patient 4026626 
 
Figure 9.8: Interquartile range table for patient 4026626 
 
Figure 9.9: Box-plot visualisation of interquartile ranges of Non-adherence aspect 
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9.3.1.2. Patient 15138374 
In this case the adherence level begins at 8.6% due to earlier annotation still being recorded, 
the window goes back to default for one minute (36.2%) then drops again due to the 
Volume Expansion treatment. 
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Figure 9.10: Patient 15138374, event 0 
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Figure 9.11: Total table for patient 15138374 
 
Figure 9.12: Interquartile range table for patient 15138374 
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Figure 9.13: Interquartile range for Duration for patient 15138374 
 
9.3.1.3. Patient 26138262 
This patient shows a recurrent administration of sedation/analgesia in one patient. The 
stepped non-adherence score is due to the combined issues of going outside a time-window 
and reaching a “too high” dose. 
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Figure 9.14: Patient 26138262 – shows a recurrent administration of sedation/analgesia in one 
patient 
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Figure 9.15: Total table for patient 26138262 
 
 
Figure 9.16: Interquartile range table for patient 26138262 
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Figure 9.17: Box-plot visualisation of the A metric (Duration / Non-adherence) for patient 
26138262 
 
9.3.1.4. Patient 4026152 
This patient has a type aspect featuring as the ICP guideline is being assessed and the 
patient does not have a mass lesion or diffuse injury recorded (all others do). 
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Figure 9.18: Patient 4026152, event 19 
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Figure 9.19: Total table for patient 4026152 
 
Figure 9.20: Interquartile range table for patient 4026152 
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Figure 9.21: Box-plot visualisation of the B metric (Duration * Non-adherence) for patient 4026152 
 
9.3.1.5. Patient 64816161 
This patient was chosen as they had verifiable “too high” administrations of a particular 
treatment category (Analgesia). However, these did not register on the framework, possibly 
because the administration occurred outside a reaction time window. 
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Figure 9.22: Patient 64816161, event 0 
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Figure 9.23: Total table for patient 64816161 
 
Figure 9.24: Interquartile range table for patient 64816161 
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Figure 9.25: Box-plot visualisation of the Non-adherence aspect for patient 64816161 
The five patients show various classes of non-adherence. Most have a large time 
period where treatment annotations haven’t been associated with corresponding 
EUSIG-events (see section 9.3.2). This large presence of default time periods can 
be seen in the highly skewed interquartile ranges (see the box-plots in figures 71, 
74 and 87). However, the multiplicative nature of the A and B metrics causes the 
distribution of values to be much more evenly spread. 
Some patient records are very adherent in places, for instance patient 4026626 
shows a distance of only 2% within a specified time window as the treatment 
annotation is present, recommended and not (yet) over a considered dosage limit. 
Patient 26138262 shows non-adherence due to dosage limits being breached. 
Patient 64816161 should show similar dosage output but doesn’t due to the 
(suspected) reason that this has occurred outside the time window. Patient 
4026152 shows a contribution of type, as they do not have a mass lesion or diffuse 
injury, which is an assessed component of the ICP guideline. The instance shown in 
patient 15138374 shows a spike due to the presence of a treatment, the time-
window expiring, then another treatment immediately bringing the adherence 
distance down again. 
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9.3.2. “Default” instances of non-adherence 
Three classes of time period can be applied to this analysis of non-adherence: 
 Time period where a clinical reaction is not required 
 Time period where a clinical reaction is required but not provided 
 Time period where a clinical reaction is required and is provided 
A result that has emerged from the listing of non-adherence instances for a large 
dataset such as Brain-IT, was that for every patient, there would be a long period 
of a single level of non-adherence. This has been referred to as the “default” 
instance for a patient and is likely represented by the second category (clinical 
reaction required, but not provided). A possible clinical interpretation of this is 
that there are often periods where a clinician must gauge a patient’s status during 
a EUSIG-event, before administering a treatment (taking time to make a clinical 
judgement rather than immediately following the guideline). It is also likely to be 
due to instances where a clinical prognosis is so poor that all interventions or none 
(palliative care) are enacted (Dr Chris Hawthorne, University of Glasgow, 31st July 
2018, pers.comm). A third – and very likely – reason is that the annotations have 
not been recorded, an estimation of the error that this phenomenon introduces 
was the purpose of the validation step taken in section 8.2. 
An example of this can be seen in figures 88 and 89 (for patient 15138374).  
 
Figure 9.26: The total table for patient 15138374 with the “default” state highlighted 
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Figure 9.27: The total table for patient 15138374 with the “default” state removed 
This information can be useful in itself to understand the nature of guideline 
adherence (e.g. do different management strategies have different “wait and see” 
times, and if so, does this impact on the patient outcome). However, a secondary 
step to this is to remove this “default” instance, and thereby understand what 
variation contributes to a non-adherence score, when in the more “active” time 
periods of clinical management. 
Figures 9.26 and 9.27, show one patient with this default state retained (figure 
9.26) and the state removed (figure 9.27). The variation of non-adherence reasons 
is evidently different in these two cases, which gives potentially more detailed 
information about the reasons/levels for non-adherence during the patient stay 
(figure 9.28). This feature of being able to view the spread of non-adherence 
instances with and without the “default” instance showing is built into the web 
application as a “view toggle”. 
 
Figure 9.28: Interquartile range table for patient 15138374, but with default state removed 
Figures 9.29 to 9.36 show the difference between all four aspects for this patient 
(15138374) when the default state is retained (figures 9.29 to 9.32) or removed 
(figures 9.33 to 9.36). 
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Figure 9.29: Interquartile range for Non-adherence aspect for patient 15138374 (default state 
retained) 
 
Figure 9.30: Interquartile range for Duration aspect for patient 15138374 (default state retained) 
 
Figure 9.31: Interquartile range for (Duration / Non-adherence) aspect for patient 15138374 
(default state retained) 
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Figure 9.32: Interquartile range for (Duration * Non-adherence) aspect for patient 15138374 
(default state retained) 
 
Figure 9.33: Interquartile range for Non-adherence for patient 15138374 with default state 
removed 
 
Figure 9.34: Interquartile range for Duration for patient 15138374 with default state removed 
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Figure 9.35: Interquartile range for (Duration / Non-adherence) for patient 15138374 with default 
state removed 
 
Figure 9.36: Interquartile range for (Duration * Non-adherence) for patient 15138374 with default 
state removed 
9.3.3. Variation in reasons for non-adherence 
The variation in reasons for non-adherence, is shown for all five patients in figures 
9.37 to 9.41. This lists all the instances occurring in a single patient stay and 
visualises the contribution of the reasons to the overall non-adherence level. 
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Figure 9.37: Contributing reasons to the variation in 4026626 
 
Figure 9.38: Contributing reasons to the variation in 15138374 
 
Figure 9.39: Contributing reasons to the variation in 26138262 
213 
 
 
Figure 9.40: Contributing reasons to the variation in 402615 
 
Figure 9.41: Contributing reasons to the variation in 64816161 
This feature allows the full qualitative composition of the overall quantitative 
score to be shown (or expressed another way: the trail of reasons for this non-
adherence). 
9.3.4. Overall clinical severity of non-adherence 
Finally, the clinical severity of the non-adherence instances, by combining 
duration and distance, is evaluated and presented using the risk-analysis grids 
(figures 9.42 to 9.46), which are the mean of the combinatorial metrics A (duration 
/ distance) and B (duration * distance). The resulting quadrants are: bottom-left 
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(green) is least severe, top-right (red) most severe, and the opposing two (blue) 
are mid-range severity. 
 
Figure 9.42: Severity chart for patient 4026626 
215 
 
 
Figure 9.43: Severity chart for patient 15138374 
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Figure 9.44: Severity chart for patient 26138262 
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Figure 9.45: Severity chart for patient 4026152 
218 
 
 
Figure 9.46: Severity chart for patient 64816161 
All five of the severity charts generated by these Brain-IT examples, give severity 
indicators that occupy the top-left (mid-range) quadrant. The interpretation is 
that despite variations in the adherence information, in aggregate the instances 
are providing approximately similar output. The likelihood is that this common 
output is due to a similar volume of treatment annotations within the dataset (as 
discussed in section 9.2, the association of EUSIG-event and treatments are not 
numerous), so the output is dominated by the “treatment missing” non-adherence 
reason. 
9.4. Additional dataset information 
Two points of additional interest were derived from the Brain-IT dataset. First was 
the impact of laying the time-window over the physiological/treatment 
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information, in terms of the events counted. Second was the derivation of the 
distribution of treatments 
9.4.1. Impact of treatment association time-window on event counts 
Additional to the event log, the association of a treatment with an event provides 
a modifying parameter to the overall event number count. An inference that can 
be made is that this modification indicates a “preferred” event definition that 
clinicians are more likely to react to. The effects of this modification can be most 
clearly seen in the bar chart that represents the number of events with an 
associated treatment per definition per hold-down value, with a time-window of 
30 minutes, shown in figure 9.47, when compared to the unmodified count in 
figure 9.1 (section 9.1.3). 
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Figure 9.47: Number of ICP events that have treatment associations when a time window of 30 
minutes is applied 
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The graph shape in figure 9.47 is evidently different from the event count numbers 
in isolation in figure 9.1. It is now the definition of ICP > 20 mmHg with hold-down 
of 5 minutes that appears to be most numerous, rather than ICP > 15 mmHg, which 
would suggest that this definition input is triggering a larger number of clinical 
responses (as administered treatments). A further clinical interpretation of these 
graphs can be seen in the shape of the distribution as the time-window increases 
towards the asymptote of infinite time. According to the association algorithm 
presented in section 5.1.4 the number of events with treatment associations will 
approach the total event number as the time-window approaches infinity (i.e. with 
a sufficiently large time-window, every event will have an associated treatment). 
Figure 9.48 demonstrates this progression of the distribution shape of the ICP 
events with treatment associations as they move through the other three time-
window definitions (10, 15 and 20 minutes). The result is that definition #2 
gradually predominates again. 
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Figure 9.48: The three other time-window definitions (20, 15 and 10 mins) for ICP event and 
treatment association, with event count on vertical axis and ICP definition/time window on 
horizontal (labels removed for space). As the time-window increases (top to bottom), the 
distribution shape reverts back to that of the event count without treatment association. 
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9.4.2. Treatment distribution 
For every combination of EUSIG definition and treatment association time-window, 
a composition of the treatment categories included in the list can be constructed. 
This allows a “map” of predominating treatment protocols to be constructed which 
could be, for instance, later used as a refinement on the specific treatments 
outlined in a guideline. Figure 9.49 shows the treatment distribution for an ICP 
threshold of > 20 mmHg with a hold-down value of 5 minutes and a time-window 
for association of 30 minutes (selected due to its predominance discussed in 
section 9.2.3). The top three treatments applied in this instance are paralysis 
(18.2%), sedation (17.2%) and osmotic therapy (16.2%), from an absolute number of 
582 events with treatment associations. 
 
 
Figure 9.49: Treatment distribution for an ICP threshold > 20 mmHg with a hold-down value of 5 
minutes and a time-window of association of 30 minutes 
9.4.3. Centre-specific information 
Similarly, using the unique centre reference identifier in the dataset, the same 
contributing information can be used to create a treatment composition for each 
individual centre. For example, the top three treatments for the centre in 
Uppsala, Sweden were paralysis (32.9%), analgesia (13.4%) and a joint third place 
(11.4%) for ventilation, volume expansion and sedation, from an absolute number 
of 373 events with treatment associations (figure 9.50). 
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Figure 9.50: Treatment distribution from one centre (with highest coverage: Uppsala, Sweden) for 
an ICP threshold of > 20 mmHg with a hold-down value of 5 minutes and a time-window of 
association of 30 minutes 
9.5. Discussion 
Overall, the physiological data of the Brain-IT dataset is comprehensive and the 
EUSIG event pattern can be readily extracted. However, the annotation frequency 
and density in the dataset overall is low, leading to low association numbers with 
EUSIG events (and all other assertions made must also be qualified with this 
consideration). This is mainly due to the time of data collection (mid 2000’s) 
where the available technology was manual inputs to PDA Palm Pilots. Modern ICU 
technologies, such as Philips ICCA show a much higher density of treatment 
annotations, so a higher association number, and therefore more accurate 
representation of clinical management can be assessed. This potentially relates to 
the overall issues confronting the TBI medical community, as the increase in 
treatment annotations can be used to increase the power of studies and trials. 
However, despite this low resolution, clear indications of the adherence output 
can be found within the dataset, highlighted by the patient examples in this 
chapter (e.g. treatment presence, dosage, type differences). This suggests that, 
though requiring refinement, the framework does provide viable output for 
measuring guideline adherence. 
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10. Application of framework to non-specialist ICU dataset: 
MIMIC III 
Chapter summary 
The MIMIC III dataset was analysed using the adherence framework. The purpose 
of this was to explore whether a non-specialist ICU dataset could show guideline 
adherence output to a similar degree as datasets that have a specialist focus, such 
as Brain-IT. 
The dataset had different extraction challenges than Brain-IT. To extract TBI-
specific injuries, a survey of the ICD9 codes relating to brain injury had to be 
performed. The semantic and heterogeneous nature of the repository made the 
output of this process unpredictable (e.g. using wildcard matching for drug 
names). However, data was extracted using four physiological codes (two each for 
ICP and CPP), and three ICD9 codes describing brain injury. From this, 100 
subjects were identified, and their physiological output traced. Of this 100, seven 
had viable treatment annotations (other than blank or null inputs) and event 
identification and treatment association were performed for these seven patients. 
Due to the low-resolution of the dataset (end-hour averaged physiological values), 
a different approach for event identification and treatment association was also 
required. In this case, an event was considered to be active if the end-hour data-
point was above the appropriate EUSIG threshold, and a treatment that occurred 
within an hour of this was considered to be associated (c.f. the EUSIG definitions 
and association windows described in chapter 6). 
Some guideline adherence information was captured but the association figures 
were very low. Combined with the low-resolution of the physiological data, the 
confidence in results and representation was not high. 
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The MIMIC III dataset is a collection of non-specialist ICU data collected from 2001 
to 2012 across different intensive care units in the United States (Saeed, 2007). 
The purpose of the collection is a comprehensive repository of de-identified ICU 
data specifically for secondary studies. 
The application to this research was the use of a non-specialist dataset to obtain 
guideline adherence output in an environment where ICP/CPP management, and 
specialist management of brain injury, is not (necessarily) the primary focus. The 
generalisation of this process to other datasets will give feedback to the general 
viability of the framework. 
10.1. Dataset description 
The data is provided in a set of zipped ASCII text files, exported from a central 
database, with most data being timestamped key-value pairs, which are 
interpreted using a dictionary lookup of ICD9 codes. The data itself is protected 
against identification, using standard measures such as the use of an anonymous 
identifier (individual patient records can be distinguished, but the record itself 
cannot be traced back to a real identity). A further protection implemented by 
MIMIC is the application of anonymised timestamps – again the individual data 
points can be associated together for the purposes of analysis but are set at a time 
in the future (e.g. “01-04-2157” is a standard timestamp in the physiological 
readings). 
A major feature of this dataset is that it is very low resolution – each physiological 
data-point is an end-hour averaged value. This has an impact on the certainty of 
association of treatment with event and makes a standard EUSIG event more 
difficult to extract. 
The labels used have a wide range of free-text variations on the full ICD9 
dictionary and apply to all the labels of everything occurring in an ICU. Standard 
physiological terms, such as “ICP” and “CPP” are relatively well defined, but other 
terms such as “craniospinal fluid” have many different abbreviations and reference 
terms (e.g. “CSF”, “CS fluid”, etc). This makes categorisation – particularly of 
relevant treatment annotations – challenging. 
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10.2. Method 
The method to extract guideline adherence information from this dataset was 
similar to the Brain-IT method, but the low-resolution nature of the MIMIC dataset, 
required two different features: 
 The definition of an active EUSIG pressure event required a single point to 
be above the threshold (as this implies that the average value over an hour 
has already been above said threshold). Therefore, in terms of processing, 
this became hold-down and clear hold-down values of one minute. Clearly, 
this does not reflect reality but merely marked a non-zero point in the 
timeline. 
 A treatment was considered associated with that event if it occured at any 
point in the hour following that event time-point. And in this case 
therefore, the time-window was set to 1 hour. 
All the rest of the processing after using these definitions continued in the same 
way as when processing the Brain-IT dataset. However, of course some information 
was lost due to the low-resolution temporal data, and this would have an impact 
on the certainty of the adherence output. 
10.3. ICD9 codes and patient numbers 
The diagnosis definition file (D_ICD_DIAGNOSES) was queried to extract the 
relevant ICD9 code. This was done by returning the code associated with any 
diagnosis description that contains the word “brain”. Three codes were extracted 
that showed significant results in terms of patient numbers (i.e. greater than two): 
 “Traumatic brain hem NEC” = 85300 
 “Screen-traumtc brain inj” = V8001 
 “Hx traumatc brain injury” = V1552 
 
There were many physiological codes to choose from in the MIMIC III dataset but 
the relevant ones used here were two each for both ICP and CPP, as extracted 
from the item definition file (D_ITEMS): 
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 “CPP” = 92, 227066 
 “ICP” = 226, 2205765 
 
Table 10.1 shows the number of subject IDs that were extracted using the three 
ICD9 codes identified in section 10.3.1. This was done by searching the subject 
diagnoses files (DIAGNOSES_ICD) for those three codes. 
ICD9 code Patient number 
85300 45 
V8001 55 
V1552 0 
Table 10.1: Number of subject IDs (individual patients) with brain injury ICD codes 
The biggest file in the MIMIC III dataset (CHARTEVENTS) was then queried using 
these 100 subject IDs, in order to establish a physiological trace reading for each 
patient. This file had to be pre-processed in order to be usable, which was done by 
“chunking” the extracted CSV output into 264 files (an approximate working file 
size, which could be viewed in Notepad or MS Excel) containing 1 million lines each 
(a line corresponds to a single physiological data-point for a patient). 
Once this processing was complete, each of the 264 files was in turn analysed for 
the presence of the 100 subject IDs sourced from above. Overall this resulted in 
physiological output of 1835 entries, filtered down using the four ICP/CPP codes 
listed above. 
10.4. EUSIG-event detection 
As before, the first stage of evaluation of this dataset is to detect physiological 
EUSIG (Edinburgh University Secondary Insult Grade) events. In contrast to the 
Brain-IT database, coverage cannot be assessed in this dataset as the physiological 
data is extracted from a set of append-only text files, so no enclosing schema gives 
information about the available space. 
10.4.1. EUSIG-event definitions 
Following from the description of EUSIG definitions of ICP and CPP events (table 
10.2), 8 threshold definitions are used to cover the range of clinically relevant 
definitions. 
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Parameter Threshold values 
(mmHg) 
Direction Event Hold-Down (hrs) 
ICP 10, 15, 20, 25, 30 Up 1 
CPP 50, 60, 70 Down 1 
Table 10.2: Definitions of raised ICP and lowered CPP events in terms of threshold values 
As mentioned previously, in contrast to the Brain-IT dataset, there is only one 
(artificial) definition for the hold-down value in this dataset. Therefore, there are 
8 ways (one per threshold definition) that a physiological monitoring event can be 
detected in a dataset. 
10.4.2. EUSIG-event counts 
The event detection algorithm was applied to the 8 definitions of EUSIG events. 
Tables 10.3 and 10.4 shows the count of individual events for each EUSIG definition 
across the 7 patients with viable annotations (with all profiles now stored in the 
treatment profile database after processing). 
 
Threshold value 
(mmHg) 
Hold-down value 
(hrs) 
Count 
10 1 373 
15 1 179 
20 1 96 
25 1 64 
30 1 43 
Table 10.3: Event count for each ICP EUSIG definition 
 
Threshold value 
(mmHg) 
Hold-down value Count 
50 1 3 
60 1 5 
70 1 6 
Table 10.4: Event count for each CPP EUSIG definition 
The number of CPP events recorded was evidently low compared to the count of 
ICP events. It is uncertain if this is of significance other than the capture process 
of ICP had been markedly better in this particular patient sample. Also, the 
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decreasing number of ICP events as the thresholds increase was in contrast to the 
Brain-IT dataset, which had a peak at the 15 mmHg definition. 
10.5. Generation of an event log 
As before with Brain-IT, to generate the full event log that can then be turned into 
a process model, required the association of treatment annotations with 
physiological events. Referring back to section 5.1 and the relative definitions of 
the word "event": the convention in this thesis is to use "EUSIG-event" to refer to 
the pattern in the physiological output described by a threshold, a hold-down and 
a clear hold-down; whilst "event" (singular) refers to a EUSIG-event and an 
associated treatment. Multiple instances of this latter definition are chained 
together to form the full patient event log described in this sub-section. 
10.5.1. Treatment categories 
The list of treatment annotations was extracted using wildcard string-matching (or 
“regular expression matching”) with the Brain-IT category names as input patterns. 
This list was found in the item definition file (D_ITEMS) and was then applied to 
the non-physiological (or “episodic”) event files: INPUTEVENTS, OUTPUTEVENTS 
and MICROBIOLOGYEVENTS. 
Table 10.5 shows the treatment categories available for association in the MIMIC 
dataset. It also shows the overall count of individual annotations in each category 
in the dataset. 
Treatment category Count 
Tidal Volume (Set) 120 
Anti-Embolism [Device] 1058 
Tidal Volume (Obser) 122 
Minute Volume(Obser) 185 
Anti-Embolism [Status] 1054 
Minute Volume (Set) 29 
Stroke Volume 24 
Tidal Volume (Spont) 91 
Dilantin 22 
Table 10.5: Overall treatment category count (total = 2705) 
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10.5.2. Treatment association and event log 
To show the representation of instances of treatment/event associations, table 
10.6 shows an example of the count of events with associated treatments 
expressed as an absolute number count and a percentage of overall events for the 
single 1-hour definition possible (see table 10.3 for the absolute ICP event 
number). The definition selected is the ICP threshold value of 10 mmHg, for a 
hold-down time of 1 hour (as defined for the MIMIC dataset). 
Time-window 
(hours) 
Count 
(absolute) 
Count (%) 
1 55 7.3 
Table 10.6: Number of events with associated treatments for a 1-hour time-window (only option 
available in MIMIC dataset) 
10.6. Process model comparison - individual output 
The following two patients were selected to indicate information relating to 
different classes of non-adherence that had appeared during the dataset 
assessment. They were selected from the patients that had treatment associations 
(and hence varied adherence information) and displayed different characteristics 
that exemplified the possible outcomes from this framework. Within those 
parameters and that patient subset, they were structurally representative of the 
variation shown by the framework over the whole dataset. 
The timeline captions indicate the reasons for the pattern of non-adherence for 
that event (e.g. “treatment missing”, “dosage too high”, etc). As before, each 
patient has an accompanying table showing the aggregate (total) non-adherence 
duration and level, as well as an interquartile range table showing the statistical 
spread of the various instances of non-adherence (one feature repeated visually as 
an example box-plot diagram). Table 10.7 shows the EUSIG-event definitions used 
for these examples. 
Feature Value 
EUSIG definition ICPm with threshold of 10 mmHg 
Hold-down 1 min 
Time-window 60 mins 
Table 10.7: EUSIG definition details that the following two examples are sourced from 
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10.6.1. Patient 16265 
 
Figure 10.1: Timeline of adherence for patient 16265 
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Figure 10.2: Instances of non-adherence for patient 16265 
 
Figure 10.3: Interquartile range of adherence for patient 16265 
 
 
Figure 10.4: Boxplot visualisation of adherence spread for patient 16265 
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Figure 10.5: Reasons contributing to non-adherence for patient 16265 
 
Figure 10.6: Severity chart for patient 16265 
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10.6.2. Patient 18849 
 
Figure 10.7: Timeline of adherence for patient 18849 
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Figure 10.8: Instances of non-adherence for patient 18849 
 
Figure 10.9: Interquartile range of adherence for patient 18849 
 
Figure 10.10: Boxplot visualisation of adherence spread for patient 18849 
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Figure 10.11: Reasons contributing to non-adherence for patient 18849 
 
Figure 10.12: Severity chart for patient 18849 
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10.7. Discussion 
The MIMIC dataset poses difficult challenges in terms of data extraction and 
processing. The low-resolution nature of the physiological data and the difficulty in 
categorising treatment annotations, make the accuracy of any adherence output 
very difficult to establish. Of particular note are the low association percentages 
in table 10.6 (7.3%) and the difficulties in rendering the end-hour summary 
information on a windowed timeline (as the treatments and physiological data 
stack one upon the other). 
However, as with Brain-IT some adherence information was able to be extracted. 
With further work it may give more accurate output, but advances in 
understanding adherence would be much more readily achieved by using richer 
datasets such as Philips ICCA. 
The original reason for using the MIMIC dataset was to find out if the framework 
could be used on a general ICU dataset. The answer to this is that it can, but with 
many qualifications and low accuracy. These issues are likely due to the nature of 
the MIMIC dataset, rather than its representation of a general ICU dataset. 
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11. Discussion 
11.1. Aims of the thesis 
In this research work, a novel technological method was developed to 
quantitatively feedback information about adherence to the Brain Trauma 
Foundation (BTF) guidelines in a given cohort of ICU patients. The following three 
hypotheses were formulated: 
1. In high-resolution time-series clinical data, one can extract clinically-valid 
treatment processes for ICP/CPP management in TBI patients 
2. Having extracted treatment processes, one is able to develop an algorithm to 
compare those against other treatment processes to establish the degree of 
similarity between them 
3. One can develop a computerised tool that readily quantifies and displays to 
clinical staff a metric of actual ICP/CPP management protocol adherence 
In summary, the findings of this research were: 
1. A process for the management of ICP and CPP can be derived from the analysis 
of physiological and treatment data in many ICU datasets. This can be seen 
from the output of the unit tests (section 8.1), Philips ICCA (section 8.3), Brain-
IT (chapter 9) and MIMIC III (chapter 10) datasets. However, a common issue, 
especially in the large-scale datasets was the low number of event/treatment 
associations, which directly affected the confidence in the adherence output. 
This led to the identification of the need for rich and accurate treatment 
annotations, an estimate of which was attempted through the timing evaluation 
(section 8.2) 
 
2. The process model derived from physiological and treatment data, can be 
compared against other processes of a similar nature, which in this case are the 
BTF guidelines represented in Business Process Model Notation (BPMN). Both 
sets of models can be compared using the method proposed in (Dijkman, Dumas 
and Garcia-Banuelos, 2009) – a calculation of distance between process models. 
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3. The output of this comparison can be constructed into a clinically accessible 
tool – in this case a web-enabled application. The application allows adherence 
information to be obtained from clinical management processes. However, a 
statistical relationship with patient outcome was unable to be detected. 
11.2. Interpretation of results 
11.2.1. Evaluation 
11.2.1.1. Unit testing 
The goal of the unit testing was to make sure that the system performed as 
expected, when given predictable inputs. The use-cases covered general cases 
contributing to guideline adherence including: whether a treatment was 
present/not-present, or if a dosage too high/within bounds. And individual cases 
relating to the BTF guidelines included: different patient ages (BPs), mass 
lesion/diffuse injury present (ICP), and type conflict between pressors and fluids 
(CPP). Test patient physiological data was used, with treatment annotations 
artificially applied to create these use-cases. The results showed that all use-cases 
covered by the BTF guidelines did indeed produce adherence output and captured 
clinical management processes. 
The main issue in this section was the first appearance of the “default” adherence 
level which occurs when a EUSIG-event occurs and has no associated treatment. 
This issue re-occurs in all stages of evaluation, has a strong influence on the 
overall measurement of adherence, and is largely only solved by the rich and 
accurate input of annotations to the dataset. 
11.2.1.2. Treatment annotation timings 
Using the unique feature of the CSO dataset – a physiological and treatment 
dataset, annotated by a “live observer” that was able to watch and confirm 
physical actions taken in the ICU – an estimation of the difference between “live” 
and “non-live” timings of annotations was attempted. 
The results showed that when observed in real-time (the “live observer”), the 
accuracy of timing does correspond well to the physical output of the physiological 
data at the bedside. Unfortunately, the comparison against the non-live dataset 
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was inconclusive, with no matching annotations at all in the non-live dataset, it is 
possible that the discrepancy between manual recording of annotations in a 
regular ward shift, and the physiological output is so dense, that (correctly) none 
appeared in this small analysis. However, other reasons such as the type of event 
observed or the approach to noting those types of event in the ward may be 
contributing factors. 
If repeated, a different set of events would be tracked and attempted to be 
matched, and a consultation with the ward staff would allow an understanding of 
which events are priorities in order to more accurately gauge the timing. However, 
the “no matching events” result from this study could be a key finding in itself in 
this regard. The events were never annotated, therefore timing overall is 
inaccurate, which has large repercussions for the performance of the framework in 
a real ICU setting. 
11.2.1.3. Domain expert information 
The system was evaluated against the input of three ICU patients that had 
accompanying patient notes, compiled and distributed by domain experts. The 
data was processed and adherence output retrieved and compared against the 
patient notes. 
The adherence output generated from the three patients highlighted several issues 
with the system: 
 The drug categorisation issue (mentioned above) affected the quantitative 
output, as this would be registered as type conflict when compared against 
the guideline model. 
 The adherence output responds poorly to refractory pressure events 
(constant increase with no positive resolution). This is mainly due to the 
time-window application issue (mentioned in 11.3.1.1). 
 Though the outputs derived from this initial error in processing of refractory 
events, it also highlighted the issues encountered when variation is low (i.e. 
only one adherence instance is present). The spread of instances is highly 
skewed – which is a correct, if unusual, representation - and the severity 
chart indicates “most severe”, though it has reached this conclusion through 
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an incorrect pathway (believing that there have been no annotations, rather 
than the refractory nature of the patient context). This issue relates to the 
use of a single time-window when assessing treatment annotations (see 
section 11.3.2). 
 When a clinical context of intentional non-treatment is encountered 
(patient #3 had regular transient ICP pressure events which appeared to 
synchronise with the rise and fall of ETCO2 levels), the system also fails to 
incorporate this into its adherence evaluation. In this case a notion of 
baseline context should be incorporated, though it is uncertain how this 
would be manifest in the technology. 
11.2.1.4. Patient outcome 
The logistic regression against patient outcome showed no statistically significant 
effect against 6-month patient outcome (as measured by the extended Glasgow 
Outcome Score). This was not unexpected as the numerical values associated with 
the guideline adherence information require calibration and clinical consensus, as 
well as the Brain-IT dataset only providing around 17% of EUSIG events with 
associated treatments (though see Appendix F for the reasoning that this number 
should be roughly double at 34%). 
Whilst a relationship of adherence output with patient outcome would have been 
ideal, the wider context is that this framework captures a clinical management 
process that is useful for audit purposes, regardless of patient outcome. It is also 
just one example of a protocol, and though obviously patient outcome is the most 
important, there may be other end-points that the adherence information does 
have a significant correlation with. 
Finally, in the case of TBI, one of the major reasons for the lack of high-power and 
clinically significant findings is the lack of correlation with patient outcome. As 
mentioned in chapter 3, studies such as BEST-TRIP (Chesnut et al., 2012) have 
indicated that ICP monitoring has no treatment effect on the overall patient 
outcome. Though this is disputed in the expert community, in this context, the 
lack of correlation between adherence output and outcome is not necessarily an 
indicator of failure. 
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11.2.2. Large-scale datasets 
The framework was applied to two large-scale datasets – Brain-IT and MIMIC III – 
which gave a variety of results that exemplified the individual adherence output 
that could be derived, and aggregate information about adherence over both 
cohorts. 
11.2.2.1. Brain-IT 
Overall, the individual guideline adherence output derived from the Brain-IT 
dataset is useful but must be considered in the context of low association 
numbers. The physiological data is comprehensive and the EUSIG event pattern can 
be readily extracted. However, the annotation frequency and density in the 
dataset overall is low, leading to low association numbers with EUSIG events (and 
all other assertions made must also be qualified with this consideration)18. 
This is mainly due to the time of data collection (mid 2000’s) where the available 
technology was manual inputs to PDA Palm Pilots. Modern ICU technologies, such 
as Philips ICCA show a much higher density of treatment annotations, so a higher 
association number, and therefore a more accurate representation of clinical 
management can be assessed. This potentially relates to the overall issues 
confronting the TBI medical community, as the increase in treatment annotations 
can be used to increase the power of studies and trials. 
However, despite this low resolution, clear indications of the adherence output 
can be found within the dataset, highlighted by the patient examples in this 
chapter (e.g. treatment presence, dosage, type differences). This suggests that, 
though requiring refinement, the framework does provide viable output for 
measuring guideline adherence over this dataset. 
11.2.2.2. MIMIC III 
The MIMIC III results were an exercise in applying the same strictures of EUSIG 
definitions and treatment associations over a very low-resolution dataset. With 
some liberties taken in the definition of a EUSIG event (hold-down of one minute 
representing a whole hour of an assumed event) it was possible to chart 
                                                     
18 There is a known issue with the processing of these associations – detailed in appendix F.1 – which suggests 
that actually this reported association number (17%) is roughly half of what it actually should be (34%). 
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physiological output (at a resolution of one reading per hour) and to associate 
some treatment events, with several TBI patients that had been found in the 
general ICU population. 
The adherence information that this provided again did capture some management 
processes but was unlikely to provide powerful insight into the nature and duration 
of non-adherence to the guidelines, as the resolution of the information was just 
too low. In an age of increasing awareness of digital-privacy it is commendable 
that the MIMIC team implemented the averaging of physiological data and the 
transposition of timestamps, but these also conspired to reduce the effectiveness 
of clinical insight that could be drawn from the data. 
However, it was possible to obtain some results. Instances of non-adherence were 
able to be compiled and a final severity chart was produced, as shown in the 
example patients in chapter 10. The achievement of the framework to work with 
almost any dataset is demonstrated here, though the best results are obtained 
with highly sampled physiological data and high density of treatment annotations. 
In this work so far, the Philips ICCA system provides that benchmark. 
11.3. Evaluation 
The following strengths and weaknesses have been identified in this thesis. 
11.3.1. Strengths 
As identified in the literature review (chapter 3), the system has been developed 
to provide immediate, detailed and independent feedback on adherence at a level 
of clinical management. The vision for this application would be to fit into audit 
procedures, such as weekly meeting to assess compliance (e.g. a technological TBI 
version of the Surviving Sepsis campaign) or to assist with the review and further 
development of the guidelines themselves. This level of clinical management is 
more detailed than the typical inputs to a clinical study and allow a quick 
assessment of adherence in the live ICU context. 
The presentation styles chosen – individual view-charts, interquartile range 
representation, aggregate information, and clinical severity risk analysis charts – 
were all carefully chosen as to maximise the utility of the information, in a way 
that informs a clinician as rapidly as possible about a patient status relative to the 
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guideline considered. The trace of non-adherence reasons provides a qualitative 
detail to the overall quantitative non-adherence, so information – whilst hidden for 
easier viewing – can still be “unpacked” and reviewed if required. These 
considerations were taken from the combination of concepts brought from the 
business process management domain and from observing what already worked in a 
clinical context for the sepsis guideline adherence meetings. The use of the 
severity chart also allows the quantitative results to be expressed as summary 
measures for an overall assessment of impact of the guideline adherence. 
A key philosophy in the development of this system was that minimal knowledge 
should be used to identify the patterns of clinical management. Additional 
contextual requirements could be added “piece-wise” to the knowledge base as 
necessary, which would be an obvious first step in future work. A major benefit of 
this approach is that individual insights on adherence can be made in isolation, 
which can then be combined and built upon, rather than attempting to identify 
signal from competing sources of noise of other components. This goes some way – 
though is not a complete solution – to the issue of comorbidities, which guidelines 
are notorious for not capturing well. 
This approach also has the advantage of occupying a clinical work-flow “silently” 
by using all the data that is already available (rather than either technical 
developers or domain experts contributing more information to imbue semantic 
meaning). The knowledge used is the already-agreed standards of repositories that 
are already in use (i.e. the database schemas supporting Philips ICCA, Brain-IT, 
MIMIC III, etc). 
11.3.2. Limitations 
The largest clinical issues raised as motivation for this thesis was the lack of high-
powered TBI studies available. It is hoped that a vision of how to build a real-time 
feedback tool to help with this problem would be useful. However, an underlying 
factor would be the accuracy of the component parts. This is a major and common 
issue in the development of many clinical technologies, and often manifests in the 
issue of clinical interpretation being lost in the opacity of the supporting 
technology and calculations (e.g. the process model distance calculations outlined 
in chapter 6). Further validation and refinement of the calculation method and the 
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quantitative weightings would be required to increase faith in the accuracy of the 
framework developed in this research work. Until this was achieved and rigorously 
demonstrated, the technology will experience large barriers to adoption. 
A central feature of the framework is the presence or absence of a treatment 
annotation proximate to the EUSIG events detected. The main Brain-IT dataset 
provided enough richness of annotations to infer various non-adherence instances. 
However, the overall percentage of associated events (approximately 17%) could 
be vastly improved. The ICCA dataset provided a much higher density of 
associations between treatment annotations and EUSIG-events (approximately 80% 
in the three-patient sample). A reasonable inference is that the ability to capture 
treatment annotations has improved since the dates of collection between these 
two datasets (2006 to 2018). 
However, the evaluation of timing accuracy shows that in a typical ICU dataset, 
even though the density of these treatments is high, they may still be inaccurate, 
and much work still needs to be done to guarantee the accuracy of these 
annotation timings. Unfortunately, this variable is also a key component to the 
accuracy of the guideline adherence output and must be evaluated or qualified 
whenever the system is used. 
Another central feature of this framework is the application of business process 
techniques and models to the clinical domain, in a manner that is not traditional 
(e.g. rather than administrative processes, the techniques are applied to the 
actual clinical management). These tend to be approaches familiar to the 
informational world of IT, logistics administration, project management, etc, and 
the primary goal is always the search for efficiencies of process. 
The two most obvious presentations of this cross-domain application are the main 
method of the research (expression of clinical processes as BPMN), but also the use 
of a risk analysis chart to express clinical severity and impact on outcome when 
two values are interpreted in combination. Though this feature is potentially 
useful for expressing clinical outcome of multi-factors in broad strokes, it also runs 
the risk of over-simplifying complex medical situations. A balance on how to 
present this should be found through feedback with clinical users. 
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Two important technical limitations were discovered during the course of 
evaluating the framework in chapter 8: the failure of the system to effectively 
deal with refractory EUSIG events – presenting as one catastrophic event in patient 
#2 in the Philips ICCA sample set – and periods of high physiological volatility, 
which relates to the issues raised in chapter 6 about how to associate multiple 
treatments with multiple EUSIG events. 
The first could be addressed by the use of multiple time-windows. Currently, a 
single time-window is overlaid on the output since the start of a single event. 
However, a more effective solution may be a combination of one time-window at 
the beginning of the event, then a second moving time-window, which would be 
evaluated each minute, would likely give enough contextual temporal information 
to capture single large events, and the more regular patterns (with clear 
resolution) which make up the bulk of the events assessed in this work. Careful 
consideration on how to communicate this concept to the end user would be 
required, as in the practical experience of this work, the concept of a single time-
window is possibly still not widely understood amongst the clinical community (as 
it is also a construct brought from the information theory community). 
The second issue has been avoided in this work through the assumption of a one-
to-one relationship between event and treatment, and the datasets used so far 
have been of low enough density for this assumption to hold true. However, as has 
been noted several times the key to better performance of this framework is the 
high density of treatment annotations, therefore it is likely this issue will be 
encountered. Possible solutions include the attempt to capture the explicit target 
of the treatment (not always available but sometimes – such as in Brain-IT – or can 
be inferred from patient notes, such as with the Philips ICCA system). 
A final limitation of the system is inherent in the nature of guidelines themselves. 
As detailed in (Greenhalgh et al., 2014) and repeated in many conference 
presentations on the nature of technology and guidelines, they are inefficient at 
coping with comorbidities. In this thesis, this has been represented most clearly in 
the evaluation of the domain expert information with the Philips ICCA dataset (e.g. 
the transient episodes of ICP events, which the system failed to account for as it 
was not aware of the ETCO2 outputs and correlation between the two). This 
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comorbidity problem was considered from the beginning of this research work and 
a mitigation was provided in the form of only focusing on three guidelines which 
had features well suited to the technical problem space (quantitative elements 
with well-defined flow processes). However, future work would include – likely in 
the form of enhanced domain context – knowledge of general guideline 
repositories. 
11.4. Other considerations 
There were several findings and discussion points raised through the course of this 
research, relating to the adherence framework. These have been grouped into 
themes that are discussed individually in this sub-section. 
11.4.1. Contextual domain knowledge 
As mentioned previously, a central part of this thesis is the ability to make these 
inferences about non-adherence given the minimum knowledge possible. The 
intention was to add contextual information in a piece-wise fashion, rather than 
describe everything and attempt to strip away unnecessary “noise”. This allows 
the ability to clearly address each separate use-case of the BTF guidelines in turn 
and overlay the resulting output. But when context is important (e.g. such as 
understanding the patient load of pressors when attempting to follow the CPP 
guideline) this approach requires addition of knowledge. 
In this case, an approach using an ICU ontology was attempted (mentioned briefly 
in chapter 5, and described in full in appendix B, which constituted a short 
conference paper in its own right19). The difficulties involved were largely 
influenced by the steep learning requirements of ontology implementation, but the 
main structural issue was one that has been covered in section 3.4.3, namely the 
desire to “describe everything” that exists in an ICU. 
When presented with the BTF guideline as a BPMN diagram (the solution later 
chosen), a neurosurgical specialist noted that there was a wider context that the 
diagram was missing. The use of an ontology would go some way to approaching 
this – encoding the contextual parameters required. But again, careful introduction 
of only the minimum necessary would be required. 
                                                     
19 Computer-Based Medical Systems (CBMS), 2012 in Rome, Italy 
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11.4.2. Technical utility 
One re-usable technical outcome of this work is the establishment of what has 
been called the “treatment profiles” database. The full schema as presented in 
section 5.2, provides a host of information such as guideline numbering and 
treatment annotations for a particular dataset. However, one of the main uses, is 
the extraction of EUSIG pattern information from a particular dataset.  
This synthesised information is useful in its own regard (i.e. the same physiological 
dataset can be viewed using different parameters of the EUSIG definition – 
threshold, hold-down length, etc), but when combined with the “EventDetection” 
code, with minor edits to the code interface (depending on whether the physio 
stream is represented as wave-form, minute-by-minute, etc) any time-varying 
physiological dataset can be analysed and stored to add to this repository. There is 
great potential for use of this code and repository for future studies, as 
information about ideal thresholds change or require investigation (e.g. for the 
establishment of CPPopt levels). 
A project that could conceivably help in this regard is the CENTER-TBI initiative, 
which is believed to collect a lot of high-resolution physiological data and rich 
treatment annotations. 
11.4.3. Weightings and input values 
The main source of quantitative information in this framework comes from the 
application of quantitative values to reasons for non-adherence. These were 
estimated based on minor feedback from clinicians and an assessment of the 
relative importance of the component reasons. As these constitute the main 
components of the quantitative non-adherence output, they will require re-
evaluation and refinement for better accuracy. 
One approach to understand and refine these values would be to chart them 
against the different patterns of guideline adherence output and attempt to find 
optimal minima representing a favoured value. 
11.4.4. Detection of clinical behaviour pattern 
An unexpected outcome of the initial audit of the Brain-IT dataset was the ability 
to observe a preferred clinical reaction when assessing counts of events reacted to 
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as part of a clinical management process. The original chart of counts across 
several EUSIG definitions was modified when different time-windows were overlaid 
and the remaining events with associations were counted. The most numerous 
definition in the original count was 15 mmHg, which shifted to 20 mmHg when the 
time-window was applied (with a constant hold-down of 5 minutes). This suggested 
that events on a crossing threshold of 20 mmHg elicited the most frequent clinical 
management responses. As the time-window was extended from 15 minutes to 1 
hour, the pattern gradually returned to the original un-associated version. 
It can be concluded from this that even before considering adherence to guidelines 
the act of associating treatments to EUSIG-events can provide valuable information 
about clinical management processes. 
11.5. Context 
11.5.1. Technical 
From a technical standpoint, the work is unique in its combined approach to 
measuring distance between process models, combining this with information from 
two sources of a different nature (ICU and text guidelines), and implementing this 
to provide clinical utility. Further review of literature additional to that reviewed 
in chapter 3, suggest that the state-of-the-art remains as it was in the fields 
reviewed that are closest to this work. 
In the field of knowledge representation, the latest work by Montani is at (Montani 
et al., 2015) and whilst having an extra module, is virtually the same work as 
presented a year earlier to the AIME conference. Since the work conducted in 
(Dijkman, Dumas and García-Bañuelos, 2009), which is referenced throughout this 
thesis, he has conducted several further iterations on the work of measuring 
distances between process models. One of these (Dijkman et al., 2012) specifically 
attempts to improve on the work conducted in the 2009 paper, and the other 
provides a short overview of the various methods available in addition to the one 
he outlined previously (Dijkman et al., 2013). 
In terms of other work involving clinical guideline formalisms, and their 
combination with apps, the MobiGuide project – the leading project in this space - 
concluded in 2016. As also mentioned in chapter 3, this was patient-centred and 
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focused on the aspect of patient-centred adherence – using “wearable technology” 
to improve adherence, making use of the features of smart-phones and apps, as 
covered in section 3.4.2. The latest publication from this group is at (Peleg, 
Shahar, Quaglini, Fux, et al., 2017b) and whilst novel in the combination of 
formalisms and physical technology, does not concern the same area of clinical 
management as this thesis. 
11.5.2. Clinical 
The project most closely aligned to this work in the clinical sphere is the EU-
funded CENTER-TBI project. Many publications have been made by this group over 
the lifetime to date of the project, with a particular focus on Living Systematic 
Reviews (LSRs). They cover several areas, such as the need for combining human 
and machine effort (suggestions for approach) (Thomas et al., 2017), and 
recommendations for the curation and development of Living Guidelines (Akl et 
al., 2017).  
These publications largely detail the issues and challenges experienced so far 
rather than outlining a full implementation of procedure. Adherence to guidelines 
in the TBI space are well covered in particular, as the focus of the PhD thesis of 
Maryse Cnossen (Cnossen, 2016c). However, these are also manual in approach and 
do not provide the technological solution as presented in this thesis. 
Most instructive in the clinical space has been the recent review of the sixth InTBIr 
conference in October 2017 (InTBIr, 2017) (a worldwide collaboration of major TBI 
projects) This reflected upon the progress of many of the leading TBI initiatives 
world-wide, with particular interest from the point of view of this thesis, on the 
progress of data development by CENTER-TBI and TRACK-TBI (McMahon et al., 
2014). 
In particular, challenges expressed by the CENTER-TBI team on the difficulties in 
curating wide-ranging data from the many patients (approximately 5400 as of the 
conference date), indicate that the repository has been designed with a desire to 
“capture everything”, and from the large number of partners involved, across 
many countries, leads to unmanageable heterogeneity in the datasets. Control was 
attempted on this from the beginning of the project using the Common Data 
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Elements (CDEs) inherited from the IMPACT studies (Marmarou et al., 2007), but it 
is likely these were not specified at a low enough level, and the same data issues 
now occur. 
As such, data curation meetings and recommendations have now been formulated 
in response to the challenge of controlling this heterogeneity (InTBIr, 2017). An 
ideal synergy of the work of this thesis – attempted to no avail during the course of 
the research – would be to apply the framework to the appropriate subset of the 
heterogeneous data (physiological output and treatment annotations, which can be 
standardised relatively easily) and attempt to extract adherence output from a 
well-annotated dataset. 
Finally, in the same meeting, a representative of the Brain Trauma Foundation 
noted that on the development of TBI guidelines there is a lot of progress on 
literature identification/synthesis and evidence-based recommendations, but not 
on the development of protocols and algorithms which would assist technologically 
in the revision and development of guidelines. The framework developed in this 
thesis would be almost a perfect fit for this vision, and an immediate future step 
for the continuation of this research will be to contact the BTF and demonstrate 
the application and how it works with their developed guidelines. 
11.6. Future work 
There are a variety of avenues of research and refinement that can be pursued as 
a result of this research work.  
Tasks that should be immediately addressed include the technical limitations 
discovered during the evaluation phases of the work, including: 
 Feedback on usability, interface and clinical efficacy of the application from 
clinical users 
 Improved sensitivity to refractory EUSIG events 
 Improved processing of multiple treatments and events 
 Refinement on the weighting values chosen to calibrate the adherence 
output 
 Refinement of the threshold values of the severity charts 
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In terms of contextual application, it would be ideal to apply the framework to a 
subset of the CENTER-TBI dataset and to approach the Brain Trauma Foundation to 
demonstrate as a possible application of technological algorithms to the feedback 
and development of TBI guidelines. 
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12. Conclusions 
This thesis presents research into the use of process models to represent clinical 
guidelines and to calculate a distance between these and real ICU data, as a 
measure of guideline adherence. The methods are applied to the Traumatic Brain 
Injury domain, specifically the threshold monitoring guidelines for SBP, ICP and 
CPP as formulated by the Brain Trauma Foundation (BTF). The work presents the 
following original contributions to research: 
Technical 
 The application of process models to neuro-intensive data 
 The expression of the Brain Trauma Foundation guidelines as process models 
 The application of process model distance calculations to neuro-intensive 
data (and their use as a guideline adherence measure) 
 A novel method of presentation of guideline adherence results 
 A novel technological framework: the conversion of text guidelines and 
clinical data into comparable objects, the implementation of distance 
calculations to run the comparisons, the implementation of novel 
presentation techniques 
Clinical 
 A technological solution to provide direct and detailed information on 
guideline adherence and clinical management processes of ICP and CPP in 
neurological ICU data 
12.1. The research 
Business Process Model Notation (BPMN) was used to represent the process models 
of both the text guidelines and the physiological and treatment ICU data. A 
method of calculating distances between process models was then used to 
compare the two. This framework was then implemented into a web-enabled 
application to present adherence information on any ICU dataset. 
The three hypotheses formulated for this work were: 
1. In high-resolution time-series clinical data, one can extract clinically-valid 
treatment processes for ICP/CPP management in TBI patients 
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2. Having extracted treatment processes, one is able to develop a method to 
compare these against other treatment processes to establish the degree of 
similarity between them 
 
3. One can develop a computerised tool that readily quantifies and displays to 
clinical staff a metric of actual ICP/CPP management protocol adherence 
12.2. Methodology 
The main technological concept in this thesis was that of process models – a 
construct used in corporate and business domains to model time-varying processes 
and identify efficiencies. The process models were used to measure the adherence 
of clinicians to specific TBI guidelines (ICP/CPP/BP monitoring thresholds) using 
physiological and treatment data from bedside machines in neurological ICUs 
(EUSIG pressure events and corresponding treatment annotations).  
Similarly, the relevant guideline texts from the Brain Trauma Foundation (BTF) 
were represented using Business Process Model Notation (BPMN) so that a 
comparable process model could be constructed. Then building on previous 
comparison work between process models, a “distance” between the two models 
was evaluated and presented as a quantitative metric of adherence, along with the 
qualitative components making up this metric.  
Finally, this model construction and comparison was developed into a web-enabled 
application that can readily feed-back the non-adherence measurements in a 
clinical environment for any given cohort of patients that have standard 
physiological and treatment output. 
Four evaluations were completed:  
1) Evaluation of the application’s functions 
2) Evaluation of the typical timing accuracy of treatment annotations 
3) Evaluation against domain expert patient notes 
4) Evaluation of adherence output against patient outcome 
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The framework was then applied to two large-scale patient cohorts, one 
neurological specialist dataset (Brain-IT) and the other a general collection of non-
specialist ICU data (MIMIC III). 
Adherence “distance” and duration was presented in a variety of ways to 
communicate as effectively and efficiently as possible how clinical management is 
affected by guideline adherence. These included minute-by-minute windowing 
output (single number each minute, with component reasons viewable if desired), 
list per-patient of all non-adherence instances (also with component reasons) and 
a summary view using inter-quartile range tables and box-plots (to understand the 
spread of non-adherence durations). 
A key philosophy of the thesis was to minimise the use of subjective judgement 
information about adherence wherever possible. This was largely achieved but was 
unavoidable in components such as a clinical “weighting” multiplier added to the 
reasons for non-adherence. 
12.3. Key results 
The evaluation of the system showed that adherence output was reliably captured 
when tested in isolation with data that provided expected outcomes. However, a 
key point that became apparent was the sensitivity to the accuracy of treatment 
annotations, in particular their timing, shown by the large “default” adherence 
instances. 
Therefore, a follow-up evaluation was conducted to investigate the typical timing 
accuracy of an ICU dataset with a “live observer”. This study showed that timing 
could indeed be variable and depended on factors such as the typical ward 
approach (or culture) towards annotations in general. 
To ascertain further insight to the system performance in a real clinical setting, 
the third evaluation assessed the adherence output against contextual patient 
notes provided by domain experts. This highlighted adherence output of interest 
(e.g. repeat dosages administered), and also provided feedback on issues that 
required addressing (e.g. the system was insensitive to refractory EUSIG events). It 
also showed more varied adherence output as a result of the higher density of 
annotations of the Philips ICCA system.  
257 
 
The final evaluation used a logistic regression to investigate if there was a 
relationship between the adherence output and 6-month patient outcome 
(captured in the Brain-IT dataset). However, there was no statistically significant 
relationship observed, once the known indicators for TBI had been accounted for.  
All of these evaluations provided insight to the strengths and limitations of the 
system when deployed into a real clinical setting. Though issues were highlighted, 
the system was capturing clinical management processes satisfactorily enough to 
proceed to be applied to the two large-scale datasets (Brain-IT and MIMIC III). 
A range of observations on guideline adherence were made in both datasets. A 
variety of non-adherence patterns could be ascertained and presented in the five 
methods outlined in the implementation (timeline, instance table, interquartile 
range of instances, box-plots and severity charts). The coverage of EUSIG events 
with adherence information in Brain-IT was around 17% (with the caveat that a 
processing bug suggests the actual figure should have been around 34%), which is 
low relative to the overall number of events. The MIMIC III dataset had low-
resolution physiological data (end-hour averaged) and even lower association 
values (7%). Therefore, both datasets had issues in terms of coverage and quality. 
However, even with these limitations examples of many guideline adherence 
patterns were indicated. With modern data capture methods, such as Philips ICCA, 
these figures indicating representation would likely be much higher. 
In conclusion, the answers to the three original hypotheses were:  
1) A treatment process for the management of ICP and CPP can indeed be 
derived from the analysis of physiological and treatment data 
2) This process can be compared against other process of similar nature (in 
this, the BTF guideline represented in BPMN) 
3) The output of this comparison can be constructed into a clinically accessible 
tool – in this case a web-enabled application 
12.4. Future research 
Immediate future work on this research would include: 
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 Feedback on usability, interface and clinical efficacy of the application from 
clinical users 
 Improved sensitivity to refractory EUSIG events 
 Improved processing of multiple treatments and events 
 Refinement on the weighting values chosen to calibrate the adherence 
output 
 Refinement of the threshold values of the severity charts 
In terms of contextual applications, it would be ideal to apply the framework to a 
subset of the CENTER-TBI dataset and to approach the Brain Trauma Foundation to 
demonstrate the work as a possible application of technological 
algorithms/protocols to aid with the development of TBI guidelines. 
12.5. Summary 
The clinical goals of this research were to investigate possible technological 
solutions to aid with the challenge of low-power TBI studies, in particular trying to 
leverage the proximity of data to the ICU source. From a broader perspective, a 
long-term goal would be the generalisation of the framework to include other 
clinical domains and management goals beyond the specific management of 
ICP/CPP in TBI. 
To recap, it is believed that this technology is unique and provides an original 
contribution of providing detailed and information on guideline adherence in the 
clinical management of ICP and CPP in a neurological ICU. It applies process 
models to neuro-intensive data, expresses the BTF guidelines as process models, 
applies a distance calculation between process models in the neuro-intensive 
domain, presents guideline adherence information in a novel way, and combines 
all the above technology into one unique framework. 
It is hoped that this research and resulting technology represents a new, novel and 
effective way to capture clinical guideline adherence information in an ICU. 
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Appendices 
A. Literature Review Methods 
The strategy for reviewing literature for this thesis is outlined in this section. 
A.1. Research Questions 
The main review of literature covered the following research areas: 
 Review novel and established tools which encourage and/or monitor 
adherence to clinical guidelines (technological and non-tech) 
 Review common issues encountered when trying to improve adherence to 
clinical guidelines (general and TBI-specific) 
A.2. Eligibility Criteria 
 Studies published in English between 1994 and 201820 
 Studies which had a clinical implementation and/or evaluation 
A.3. Exclusion Criteria 
 Studies which were not peer-reviewed (except theses) 
 Poster abstracts 
 Studies which did not include clinical guidelines 
A.4. Search terms with dates 
Whilst a general and less systematic search continued throughout the course of the 
research, the following were periods particularly devoted to organised literature 
searching, so provide the most relevant reference points. 
 
February 2012 (then re-run in June 2016) 
 “Computerised/Computerized clinical guidelines” 
 “Computer-Interpretable Clinical/Medical Guidelines” 
 “Clinical workflows” 
 “Workflow Patterns” 
 “Evidence-Based Medical/Clinical Guidelines” 
                                                     
20 Though some older papers were referenced, such as (Shortliffe, 1987) published in 1987. 
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 “Decision Support Systems/DSS/Clinical Decision Support Systems/CDSS” 
 “Clinical Guideline Adherence” 
 
February 2013 
 "Clinical management variation studies" [+neuro, +icu, +tbi] 
 "TBI RCT reliability studies" [+ expanded acronyms] 
 "TBI physiological data" [+ expanded acronyms] 
 "TBI clinical management" 
 “adherence to BTF guidelines” 
 “deviation from BTF guidelines” 
 “why do clinicians not follow the BTF guidelines” 
 "physiological data analysis icu" 
 "interpreting ICU data" 
 "capturing ICU data" 
 "capturing and interpreting ICU data TBI" 
 "statistical analysis of icu data tbi" 
 "time series variation icu data tbi" 
 “TBI data of low/high quality resolution” 
 "Therapy intensity level tbi" 
 "clinical management variability studies icu" 
 "clinical management variability studies icu tbi" 
 "quantifying icu clinical management" 
 "minimising tbi management variability" 
 "variation in TBI management" 
 
February 2014 
 "adherence to medical guidelines" 
 "clinician adherence to medical guidelines" 
 "physician adherence to medical guidelines" 
 "medical guideline adherence improvement" 
 "clinical decision support tools" 
 "icu clinical decision support tools" 
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 "icu clinical decision support tools traumatic brain injury" 
A.5. Search strategy 
Search fields for keywords in the title and abstract of papers were returned. 
Metadata was recorded using the Mendeley Reference Manager software 
(www.mendeley.com). Lists and digests of papers based on pre-entered keywords 
and search behaviour on Google Scholar were also directly received by email 
weekly. Of the included papers, reference searches for further related papers was 
then conducted. 
 
Total paper number in Mendeley = 317 
Total paper number referenced in thesis (including books and websites) = 137 
A.6. Sources 
A.6.1. Search Engines & Digital Libraries 
 Google Scholar 
 ACM Digital Library 
 IEEE Xplore Digital Library 
 Springer Link 
 Science Direct 
 Pubmed 
A.6.2. Journals 
 Artificial Intelligence in Medicine 
 Journal of Clinical Monitoring & Computing 
 BMC Medical Informatics and Decision Making 
 Journal of the American Medical Informatics Association 
 Journal of Biomedical Informatics 
 Health Informatics Journal 
 Methods of Information in Medicine 
 Journal of Medical Systems 
 The New England Journal of Medicine 
 The Medical Journal of Australia 
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 The Lancet 
 Journal of Neurotrauma 
 Journal of Neurosurgery 
 The Journal of Trauma: Injury, Infection and Critical Care 
 Journal of the American Medical Association 
 Critical Care Medicine 
 Acta Neurochirurgica 
A.7. Most current literature 
A final appraisal of literature was conducted in September 2018 to check on the 
most up-to-date developments in projects relevant to the research work. This was 
primarily focused on the CENTER-TBI project, in particular the PhD of Marie 
Cnossen (which specifically concerned TBI guidelines), and the latest InTBIr 
meeting (Oct 2017). 
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B. Knowledge representation through domain ontologies 
One of the initial avenues of research work in this thesis was to explore the use of 
ontologies to achieve the aims of the thesis. This culminated in a short paper that 
was accepted for publication to the CBMS (Computer-Based Medical Systems) 
conference proceedings, presented in Rome in 2012, an excerpt of which is 
presented in this section. 
B.1. System architecture 
The AMITIE system (Automated Medical Intervention and Treatment Inference 
Engine) has been developed to identify abnormal physiological events and 
automatically infer subsequent medical interventions from time series 
physiological and treatment data. Figure B.1 provides a high-level overview of the 
system. 
 
Figure B.1: High-level overview of the AMITIE system 
The patient data is explored for instances of abnormal physiological readings. Once 
identified, the data is further examined to find related interventions given to the 
patient. In some cases, the interventions are easy to identify as they have been 
specifically recorded in the patient data-set, with an explicit target noted. 
However, as described above interventions often have to be inferred. To enable an 
intervention to be inferred, detailed information can be obtained from domain 
ontologies. Information such as the known physiological effects of the intervention 
and other contextual information (e.g. contraindications of a drug) can help to 
determine whether it is likely that the patient has received the intervention for 
the abnormal reading. For example, consider a series of abnormally raised 
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intracranial pressure readings which then return to normal. If the data-set is 
examined and no intervention is recorded, it may be reasonable to infer from the 
observation of the patient’s temperature decreasing, that the procedure 
‘therapeutic cooling’ has been administered. 
In the AMITIE system, a set of ontologies are used to model the domain. An 
ontology “defines a set of representational primitives with which to model a 
domain of knowledge or discourse.” (Gruber, 2008) AMITIE’s knowledge base 
consists of three OWL (W3 – OWL, 2011) domain ontologies which model the 
medical domain, patient data and human physiology. This knowledge base has 
been reused from previous work on the EIRA system (Moss, 2010). The following 
high-level algorithm summarises the functionality of the AMITIE system: 
1. Identify an abnormal physiological event (E) 
a. Characterize E into whether it has returned to a baseline (“normal”) value or 
not.  
b. If it has, it is assumed that the patient has been treated and the time period 
(TP) of E is determined. 
c. Examine TP for instances of annotated interventions 
i. If intervention (I) is noted in data-set: suggest that I has been given in 
response to E. 
ii. Else, infer non-annotated intervention: 
iii. Identify known physiological effects of possible interventions for E. 
iv. Examine TP for evidence of any of these effects. 
v. If possible intervention (Ip) is found:  
vi. suggest Ip has been given in response to E 
vii. Else, suggest that patient returned to baseline value without intervention. 
 
Issues of negation and ranking have not yet been handled. This algorithm also 
assumes a one-to-one relationship between event and physiological output. 
However, it is likely that combinations and emergent factors make this relationship 
more complex. 
283 
 
B.2. Implementation 
The AMITIE system software is written using the JENA API (Apache – JENA, 2011) 
[incubator.apache.org/jena/]. To obtain the information from the ontology, a set 
of SPARQL queries have been implemented. These allow for a separation of the 
inference process from the application code (for later re-use in other medical 
contexts). They have the following functions and features: 
1) The first query obtains all the physiological data above a certain threshold: 
SELECT ?timepoint ?physiovalue   
WHERE {?x <http://www.owl-ontologies.com/amitie.owl#hasTime>?timepoint .  
[...] 
?reading <http://www.owl-ontologies.com/amitie.owl#readingParameter>  
<http://www.owl-ontologies.com/amitie.owl#"[physiolabel]"> .  
FILTER (?physiovalue > "[physioThreshold]"}.}  
Of the variables in the query, “physiolabel” refers to the physiological parameter 
that is being queried (e.g. heart rate) and “physioThreshold” refers to the value 
above which an abnormal event is deemed to have occurred (e.g. ICP readings 
above 20 mmHg are generally considered to require treatment). 
2) The second query obtains all the treatments that are annotated in the data-set 
within the time period of a single event. 
3) The information required to infer interventions, for when a treatment is not 
annotated in the data-set, is extracted from the ontology using five queries that 
interrogate the following features to see if they are present (as they are significant 
in the event signature):  
 High_Feature  
 Low_Feature  
 Increase_Parameter_Change 
 Decrease_Parameter_Change  
 Constant_Parameter 
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4) The final query obtains other physiological data that may relate to the abnormal 
event in question but has not been retrieved in the original query. The layout is 
similar to the first query but is constrained by time series rather than threshold 
physiological values. 
B.3. Results 
Using this combination of domain knowledge and patient data, the resulting 
management of a patient’s abnormal event is determined to either be an 
annotated treatment, a non-annotated treatment, or the patient’s vital sign has 
returned to normal without any clinical intervention. Table B.1 shows the results 
of the AMITIE system run against three patients selected from the Brain-IT 
database. 
Patient ID No. of ICP 
events 
Annotated 
Treatments 
for each ICP 
event 
Inferred 
Treatments for 
each ICP event 
15026161 25 0 Ventilation and 
cerebral 
vasoconstriction 
15127262 209 0 Ventilation and 
cerebral 
vasoconstriction 
15137626 77 0 Ventilation, 
induced 
hypothermia and 
cerebral 
vasoconstriction 
Table B.1: AMITIE results 
B.4. Discussion 
Ultimately, this research avenue was abandoned due to similar issues as those 
quoted in section 3.4.3. (outlining the use of clinical guideline formalisms and 
ontologies). These included: the over-specification of surrounding context 
information, only a small sub-section of which was directly relevant to the 
guideline evaluation (the EUSIG parameter definitions); the difficulty in re-
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purposing an ontology for secondary usage; and over-engineering of the solution, 
which required a large overhead in new technologies that were ultimately 
unnecessary – for instance, the SPARQL query language over regular Standard 
Query Language (SQL) to query data repositories, and the use of the Protégé 
ontology editor over a regular text editor. 
Another issue was that the inference engine presented in this paper (AMITIE) 
claimed to do the detection and association of physiological events and 
treatments. At a very basic level this was correct, but the implementation of this 
inference was weak and ultimately required the more robust method 
implementation that can be found in chapters 4-6 of the thesis. 
Though the primary use of ontologies was abandoned, this initial work was 
instructive in highlighting the features required for the eventual solution. Though 
the BPMN notation was ultimately chosen to represent the BTF guidelines (see 
chapter 4), an ontology with more contextual domain knowledge of an ICU would 
be a possible alternative.  
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C. Brain Trauma Foundation Guidelines 
The guidelines followed for this thesis are outlined in full here. They are 
comprised of Table 3 (“Thresholds”) in (Carney et al., 2016), which is the 4th 
edition update of the guidelines. 
C.1. Brain Trauma Foundation guidelines - 4th Edition 
C.1.1. Blood pressure thresholds 
Level III 
 “Maintaining SBP at >=100 mm Hg for patients 50 to 69 years old or at 
>=110 mm Hg or above for patients 15 to 49 or >70 years old may be 
considered to decrease mortality and improve outcomes.” 
C.1.2. Intracranial pressure thresholds 
Level IIB 
 “Treating ICP >22 mm Hg is recommended because values above this level 
are associated with increased mortality.” 
Level III 
 “A combination of ICP values and clinical and brain CT findings may be used 
to make management decisions.” 
C.1.3. Cerebral perfusion pressure thresholds 
Level IIB 
 “The recommended target CPP value for survival and favorable outcomes is 
between 60 and 70 mm Hg. Whether 60 or 70 mm Hg is the minimum 
optimal CPP threshold is unclear and may depend upon the auto-regulatory 
status of the patient.” 
Level III 
 “Avoiding aggressive attempts to maintain CPP >70 mmHg with fluids and 
pressors may be considered because of the risk of adult respiratory failure” 
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C.2. Brain Trauma Foundation guidelines - 3rd Edition 
A revision of these guidelines occurred in August 2016 (Carney et al., 2016), during 
the course of this research work.  
Examples of the transition between the 3rd and 4th editions (the 3rd being published 
in 2007) are shown below. 
C.2.1. Blood pressure thresholds 
Level II 
 “Blood pressure should be monitored and hypotension (systolic blood 
pressure < 90 mmHg) avoided.” 
Level III 
 “Oxygenation should be monitored and hypoxia (PaO2 < 60 mmHg or O2 
saturation < 90%) avoided.” 
The differences between these recommendations and those which appear in the 4th 
edition are quite large: references to hypotension and oxygenation have been 
removed and replaced with a single consideration of patient age. 
C.2.2. Intracranial pressure thresholds 
Level II 
 “Treatment should be initiated with intracranial pressure (ICP) thresholds 
above 20 mmHg.” 
Level III 
 “A combination of ICP values, and clinical and brain CT findings, should be 
used to determine the need for treatment” 
The only difference between these recommendations and those which appear in 
the 4th edition is with the monitoring threshold: 20 mmHg in the 3rd edition; 22 
mmHg in the latest. 
C.2.3. Cerebral perfusion pressure thresholds 
Level II 
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 “Aggressive attempts to maintain cerebral perfusion pressure (CPP) above 
70 mm Hg with fluids and pressors should be avoided because of the risk of 
adult respiratory distress syndrome (ARDS)” 
Level III 
 “CPP of <50 mm Hg should be avoided” 
 “The CPP value to target lies within the range of 50-70 mm Hg. Patients 
with intact pressure autoregulation tolerate higher CPP values” 
 “Ancillary monitoring of cerebral parameters that include blood flow, 
oxygenation, or metabolism facilitates CPP management” 
For CPP, the differences are structural as well as in the content: the lower limit of 
the target value of CPP has changed (50 mmHg in the 3rd, 60 mmHg in the 4th). The 
certainty of the recommendations have changed places (the considerations of ARDS 
is level 3 in the 4th edition, where it was level 2 in the 3rd, and vice versa with the 
CPP target information), along with a new sub-category of “IIb” introduced in the 
4th edition. 
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D. Automated process mining 
This section details the work invested in attempting to automatically – as opposed 
to manually – derive process models from the neurological ICU data in this research 
work. The following excerpt is from a paper that was submitted (unsuccessfully) to 
the CBMS (Computer-Based Medical Systems) conference in Sao Paolo, 2015. It 
details the main methods used which were the conversion of the physiological and 
treatment data to XES format (XES-Standard, 2015), and the use of the PrOM 
framework (Dongen, 2005) to generate a process model using simple heuristic 
filtering and the “alpha-algorithm” process miner. 
D.1. Conversion of XES standard 
The XES standard (eXtensible Event Stream) is an XML representation of event logs 
that provides a generalized format from which process models can be extracted. 
Represented by the authors as being simple, flexible, extensible and expressive, 
the basic structure includes a log, made up of traces, which are in turn made up of 
events. All entities can have attributes of primitive types familiar to programmers 
(e.g. string, int, boolean, etc), which can be nested within each other and can 
have varying scope (e.g. within a trace, within a log, global, etc).  
To convert the raw EUSIG information taken from the ICU data stream into XES, 
the event information is translated to the appropriate extension definitions, with 
the mapping as shown in table D.1. This is done programmatically, using the event 
and treatment information from (STELL, MOSS and Piper, 2014) as the input, and 
an XML file using the XES templates provided by the ProM authors as the output. 
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EUSIG Feature Example XES Attribute 
Event start Timestamp lifecycle: 
transition 
Event end Timestamp lifecycle: 
transition 
Event type ‘ICP’ concept: name 
Event threshold ‘Raised over 
threshold’ 
concept: instance 
Treatment start Timestamp lifecycle: 
transition 
Treatment end Timestamp lifecycle: 
transition 
Treatment target ‘ICP’ concept: name 
Treatment type ‘Analgesics’ concept: instance 
Table D.1: Mapping of data-set features from the Brain-IT data-set to the features as specified in 
the XES standard 
Additional to these, two event classifiers are defined in the header of the XES file. 
Labelled as ‘MXML Legacy Classifier’ (using templates from the ProM authors) this 
classifier counts all objects that match on the ‘concept: name’ and ‘lifecycle: 
transition’ attributes. Another classifier – ‘Event name’ – matches on ‘concept: 
name’ only. Using these classifiers and the mappings from table D.1, a full log-file 
is built up of events, which are part of traces drawn from the 262 individual Brain-
IT patient information streams. This creates the full “Brain-IT XES log-file”. 
D.2. Generation of process model 
The ProM framework allows an event log file to be imported, filtered and 
analyzed. The framework has three major components: workspace, actions and 
views. The workspace acts as the home file directory allowing import and browsing 
of event log files. The actions section allows selection of a list of “miner” plugins 
that can be run to filter and analyze the event log. The views section shows the 
output of all analysis in tabular and visualized format. 
In this work, the event log generated by the XES event log file is filtered using the 
“Simple Heuristics” plugin. This filters out events that are irrelevant to the 
process that is being analyzed or those that have been picked up from the previous 
conversion incorrectly (for instance any treatment label that has been assigned to 
291 
 
the target due to a transposition in the original database columns). Types of start, 
end, and all other event and treatment classes are explicitly selected. After this 
filter has been run the number of processes, cases, events (with classes and 
types), and originators will be tabulated. 
Once this data-set is filtered, the log is mined for a process model using the alpha-
algorithm. The alpha-algorithm creates a work-flow net from a work-flow log by 
examining the causal relationships between tasks within that work-flow (full 
details of this process can be found in (van der Aalst, Weijters and Maruster, 
2004)). 
D.3. Results 
In general, the process model outputs show a standard relationship between start 
and end tags for ICP and CPP events throughout all traces (as expected). The 
interactions of interest are the treatment responses to physiological events. 
Covering the 13 main treatment categories (listed in the output graphs of (STELL, 
MOSS and Piper, 2014)), the listing of occurrences allows the strength of the 
relationships between treatment and physiological events to be evaluated for 
particular centre traces, individual patient traces, or for the overall trace of the 
262 Brain-IT patients. 
Table 2 shows an example centre event log which has had the simple heuristic 
filter applied. When filtered on all of the treatment information, the list showed 
that the two most frequently occurring treatments were volume expansion and 
paralysis (accounting for 80% of all instances within the log, the rest being made 
up of the other 13 treatment categories). 
 
Table D.2: Distribution of events and treatments throughout Brain-IT trace log after filtering with 
simple heuristics 
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Using these four classes in the filtered event log, a petri-net diagram was then 
generated using the alpha algorithm plugin (figure 1). The nodes and arrows 
indicate the direction of dependency in time of each entity. For instance, ICP start 
and CPP start always lead to ICP complete and CPP complete, respectively (which 
is intuitive as only well-defined physiological events with start and end tags are 
included).  
 
 
 
 
Figure D.1: Petri-net of processes derived from the Brain-IT data-set using the alpha-algorithm on 
an example center (Vilnius) 
In terms of the dependencies of the treatments on the ICP/CPP events, volume 
expansion occurs in response to ICP start/complete (which indicates that the 
treatments are given in response to both the start and completion of an event, 
depending on the clinical circumstances). Volume expansion also occurs in 
response to CPP event triggers. But according to the event log paralysis only occurs 
in response to CPP events, not ICP. 
A possible medical explanation for this is that paralysis would be applied to ICP 
events in isolation rather than CPP (paralysis is applied when a patient “fights” a 
ventilator, their CO2 processing increases, which causes their ICP to rise 
simultaneously). However, this process model suggests that the treatment is being 
applied by measuring the CPP instead. Further study to validate this finding would 
indicate whether this process model does actually show whether they have 
deviated from the consensus treatment practice for such events. 
D.4. Discussion 
Ultimately, this work did not produce viable process models, most likely due to the 
use of heuristics and simple process miner algorithms, both of which are not 
generally tolerant of “noisy” real-world data. The avenue of research was 
abandoned as the amount of manual constraints applied to the inputs and outputs 
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of the processing – in order to produce process models that represented 
recognisable processes in an ICU – suggested that a manual method (chapter 4) 
would be just as effective and was also more transparent (rather than depending 
upon “black box” tools). The trade-offs between both methods in terms of errors 
and uncertainties (see end of section 5.2) also suggested that either option was a 
viable path. 
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E. Mathematical representation of graph-edit algorithms 
In this thesis the algorithm used for comparison of process models is an exhaustive 
one, checking all available possibilities between all states, which is possible due to 
the constrained nature of the problem space (the categories available for all nodes 
and edges are low in number by design). This is in contrast to the open problem 
formulated for all process model solutions in (Dijkman, Dumas and García-
Bañuelos, 2009), leading to the designation of that issue as an “NP-complete 
problem” – one which is of sufficient complexity that finding solutions with proofs 
that can be verified in polynomial time (i.e. a reasonable time-scale) is not 
considered likely. The four algorithms they used are reproduced here for future 
reference, as they may yet be applicable to the research space. 
E.1. Greedy 
“The algorithm starts by marking all possible pairs of nodes from the two graphs 
as open pairs. In each iteration, the algorithm selects an open pair that most 
increases the similarity induced by the mapping and adds this pair to the 
mapping. The selected pair consists of two nodes. Since each node can only be 
mapped once, the algorithm removes from the set of open pairs, all pairs in which 
one of the selected nodes appears. The algorithm iterates until there is no open 
pair left that can increase the similarity induced by the mapping”. 
E.2. Exhaustive with pruning 
“The algorithm recursively explores all possible mappings, but when the recursion 
tree reaches a certain size, the algorithm prunes it to keep only the mappings 
with the highest similarity. In the extreme case, the algorithm is thus 
exponential, but the pruning parameters will control its complexity. The 
algorithm starts by initializing the set of unfinished mappings to an empty 
mapping, with all nodes from the two graphs mapped as ‘free’ to be mapped. It 
repeatedly prunes the set of unfinished mappings and performs a step in which 
finished mappings are added to the set of finished mappings and unfinished 
mappings are extended with an additional pair of nodes. It repeats this until 
there are no more unfinished mappings. It then returns the finished mapping with 
the highest similarity score.” 
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E.3. Process heuristic 
“This algorithm is a variation of the exhaustive algorithm. It also builds a 
recursion tree of possible mappings, but it starts by mapping the source nodes of 
the business process graphs, then mapping nodes that immediately follow the 
source nodes, etc. Since it is plausible that nodes closer to the start of a process 
should be mapped to nodes closer to the start of the other process (and 
conversely), this should yield a higher-quality pruning. Indeed, the algorithm is 
more likely to prune mappings with node pairs that are further apart in terms of 
their distance to the starts of their processes.” 
E.4. A-star search 
“This algorithm is based on the well-known A-star heuristic search, which has 
been applied to the problem of graph matching in (Messmer, 1996). In each step, 
the algorithm selects the existing partial mapping map with the maximal graph 
edit similarity. The algorithm then takes a node n1 from graph G1 that has not 
yet been mapped and creates a mapping between this node and every node n2 of 
G2 such that n2 does not already appear in map. Let us say that m such nodes n2 
exist. The algorithm then creates m new mappings, by adding (n1, n2) to map. In 
addition, one mapping is created where (n1, ?) is added to map (? is a “dummy” 
node). This latter pair represents the case where node n1 has been deleted. This 
step is repeated until all nodes from G1 are mapped. It can be proven that the 
result is an optimal mapping.” 
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F. Known issues 
The following issues were discovered during the course of writing this thesis. The 
first was unable to be fixed before the date of submission, the second and third 
were considered after feedback from examiners at the viva. 
F.1. Time formatting issue 
Dataset: Brain-IT (chapter 9 – dataset analysis) 
Nature: the issue involves the incorrect parsing of date/timestamps. The 
formatter used was converting 24-hour readings to a 12-hour clock. 
Impact: Low/Moderate 
50% of EUSIG pressure events in the dataset have their timing offset by 12 hours. 
The event counts remain accurate, but the number of treatment associations will 
likely be reported as approximately 50% lower than is actually the case. This 
affects the consideration of how valid the adherence measurements from the 
Brain-IT dataset are (i.e. how many useful instances of adherence reporting, which 
depend on those treatment associations, are present). Currently around 17% in the 
Brain-IT dataset have associations. This error suggests that, once fixed, the 
number should be closer to 34%. 
Resolution: re-run the event detection program for the Brain-IT dataset with the 
formatter fixed, re-compile the indexing for the treatment profiles database, then 
re-run the counts of event/treatment associations. 
F.2 Severity chart issue 
Dataset: all 
Nature: It has been considered that the transformation of the guideline output to 
metric A (duration / non-adherence) is unnecessary, and the severity of duration 
combined with non-adherence would be best expressed only with metric B 
(duration * non-adherence). Requiring modification to the two-dimensional 
severity charts. 
Impact: Moderate 
The rationale for this change is as follows: 
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 If both duration and non-adherence are high, then the output has high 
severity 
 If both duration and non-adherence are low, then the output has low 
severity 
 If either factor has a disproportionate influence on metric B then this will 
affect the severity accordingly. 
This would be a reasonable clinical analogue for assessing severity as expressed by 
non-adherence to guidelines, and it is considered that entity A does not influence 
this output at all. 
A separate but related consideration is that the severity charts themselves would 
have most utility in a bedside ICU setting, and not in a retrospective audit 
situation, as in this latter case, time would be available to go into the more subtle 
and nuanced depth for the reasons for non-adherence (i.e. clinicians can make 
their own mind up about the case’s severity). 
Resolution: express the severity as a linear scale rather than a two-dimensional 
chart. 
F.3 Description of “default” instance value 
Dataset: all 
Nature: a recalculation of the factors that make up the structural difference 
between two process models, resulted in distance score reporting as 37.8% instead 
of 36.2%. 
Impact: Low 
Wherever the value of 36.2% is encountered in the thesis, this should be 37.8%. 
The clinical/informational effect is negligible. 
Resolution: apply the amended weighting factors to the code and re-process. 
